https://gowlingwlg.com/ecaapi/fr-fr/rss/resource?sector=Sciences+de+la+vieRessources de Gowling WLG - Produit RSSb853516f-1f4d-437a-9cb1-aff976cda93fhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2024/employment-law-changes-2024The Government has advanced employment law reforms, including expanded trade union rights, stronger industrial action protections, updated tips guidance and new right to work obligations from October 2026. Employers should also monitor developments on the Fair Work Agency, gender pay reporting and contract changes.Tue, 11 Aug 2026 00:00:00 Z3dda3cd1-2d9b-42fa-88bf-f464fd1d7d74https://gowlingwlg.com/fr-FR/insights-resources/articles/2026/the-future-of-ai-regulation-in-healthcare-what-the-mhraThe MHRA's call for evidence and AI sandbox signal a more agile approach to healthcare AI regulation, emphasising lifecycle oversight, transparency and accountability. Organisations should strengthen governance, monitoring and evidence generation now to prepare for the UK's evolving regulatory framework.Mon, 20 Jul 2026 00:00:00 Z8d72c88d-8ca5-45f9-b060-735d440f7184https://gowlingwlg.com/fr-FR/insights-resources/articles/2026/pharmascience-v-janssen-supreme-courtThe Supreme Court of Canada’s first patent decision since 2017 provides new guidance on when methods of medical treatment may be patentable.Fri, 17 Jul 2026 00:00:00 Z30dd4909-bd48-46b9-b845-0b219699d7bchttps://gowlingwlg.com/fr-FR/insights-resources/articles/2026/patentability-and-the-supreme-courtA highly anticipated Supreme Court of Canada decision could bring new clarity to how Canadian patent law treats methods of medical treatment.Thu, 02 Jul 2026 00:00:00 Z39317f16-8055-4ff3-8093-405eeeafc997https://gowlingwlg.com/fr-FR/insights-resources/reports/2026/risky-businessGeopolitical volatility is no longer a background risk for business leaders. It is shaping strategy, investment and governance decisions in real time. Our latest report explores why resilience is becoming a defining leadership capability, and what organisations must do to move beyond reactive risk management in an era of permanent volatility.Fri, 05 Jun 2026 00:00:00 Zc7efa8e2-f1a5-4597-9e9c-5db1ed9ade41https://gowlingwlg.com/fr-fr/insights-resources/articles/2026/from-neurodata-to-the-no-fakes-actThe Nurture Originals, Foster Art, and Keep Entertainment Safe Act of 2026 (the so-called NO FAKES Act) creates a federal intellectual property right in an individual's voice and visual likeness. The new development signals that the idea of treating personal human data as a protectable asset is gaining legislative worldwide traction.Tue, 02 Jun 2026 00:00:00 Z33cebdb0-aefe-4723-b5a0-55c2c4b44702https://gowlingwlg.com/fr-FR/insights-resources/articles/2026/health-canada-issues-revised-biosimilar-guidance-reducing-clinical-evidence-requirementsHealth Canada has issued a new Guidance Document pertaining to biosimilar drug submissions. The new Guidance significantly reduces the supporting clinical safety and efficacy data that biosimilar applicants are required to submit as part of a new drug submission. It also removes the previous requirement for biosimilar manufacturers to provide a detailed rationale justifying approval for each indication being sought.Tue, 26 May 2026 00:00:00 Z1cba1f60-553a-4c6a-955e-5afa9d8b519chttps://gowlingwlg.com/fr-FR/insights-resources/articles/2026/uk-clinical-trials-regulations-2025The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025, effective 28 April 2026, mark the most significant reform of United Kingdom clinical trials in over 20 years, driving innovation, improving patient access, and introducing major changes to trial design, approvals, transparency and compliance.Mon, 18 May 2026 00:00:00 Z45deb591-1899-46dd-998f-c2067bb9568bhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2026/new-pmac-model-clausesThe UPC’s Patent Mediation and Arbitration Centre has published model ADR clauses, completing its framework. The development shows why drafting now matters for enforcement, leverage and outcomes under the UPC for patent‑critical SEP and FRAND agreements. Find out more.Tue, 05 May 2026 00:00:00 Z57736a3d-bd57-4bcc-b17d-dbd2654e299bhttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2026/capital-markets-team-advises-cavendish-on-10-million-fundraise-for-ixicoOur Capital Markets team has advised Cavendish on a successful £10 million fundraise by IXICO plc, comprising a placing, subscription and retail offer.Tue, 28 Apr 2026 00:00:00 Z683624be-5cc6-4fae-8453-b78db546dcebhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2026/china-spc-signals-stronger-judicial-action-against-systematic-bad-faith-trademark-filingsChina’s Supreme People’s Court has confirmed that repeated, coordinated bad‑faith trademark registrations can constitute unfair competition. The decision strengthens civil litigation under the Anti‑Unfair Competition Law, shifting enforcement from reactive administrative action to proactive deterrence for brand owners. Find out more.Thu, 23 Apr 2026 00:00:00 Z9d09a15f-6caa-4931-b902-0853c1da0123https://gowlingwlg.com/fr-FR/insights-resources/articles/2026/protecting-pharmaceutical-and-medical-device-patents-in-saudi-arabiaSaudi Arabia’s fast-growing pharma market under Vision 2030 creates real opportunity, but patents alone won’t stop generics. Rights holders must also register products and notify the Saudi Food and Drug Authority. Get the protection strategy right before launch.Tue, 21 Apr 2026 00:00:00 Z492c3296-2a2e-4d84-b2ad-3141354239c3https://gowlingwlg.com/fr-FR/insights-resources/articles/2026/big-picture-for-business-2026-q1-snapshotQ1 2026 has reshaped the business outlook. Geopolitical tensions, trade disruption and energy supply shocks are weighing on growth and inflation expectations, while interest rate cuts recede. At the same time, accelerating AI investment is reshaping markets and strategy.Mon, 20 Apr 2026 00:00:00 Z80449212-a361-4866-aee4-f8b2b5ccaa72https://gowlingwlg.com/fr-FR/insights-resources/articles/2026/the-neverending-licence-that-ended-court-of-appeal-clarifies-licence-termination-rightsCan an IP licence last forever? The Court of Appeal confirms "indefinite" doesn’t mean "perpetual". Zaha Hadid Limited v Zaha Hadid Foundation offers key drafting lessons for licensors and licensees.Tue, 31 Mar 2026 00:00:00 Z81f30dd0-0812-4d81-83dd-6cffe0037806https://gowlingwlg.com/fr-FR/insights-resources/articles/2026/changing-life-sciences-patent-landscapeLife sciences has transformed and the patent landscape is transforming with it. The question the industry must confront is whether the licensing models inherited from an earlier era can still deliver life-saving innovation to patients efficiently, or if something new is required?Wed, 25 Mar 2026 00:00:00 Z1225288e-7c1b-4133-b235-0db7dcb92f71https://gowlingwlg.com/fr-FR/insights-resources/articles/2026/built-for-humans-challenged-by-aiWho owns AI‑created brands, and does IP law still work when AI buys for us? Discover the answers at INTA 2026 with global experts and new data.Thu, 05 Mar 2026 00:00:00 Z154240c7-677d-4e10-adc9-47b139d21ef8https://gowlingwlg.com/fr-FR/insights-resources/articles/2026/redomiciliation-a-uae-perspectiveRedomiciliation to the UAE offers new flexibility for companies seeking operational, tax and regulatory advantages. From legal considerations to employee impacts, businesses must plan carefully. Read the full article to explore the seven key questions every company should assess.Fri, 06 Feb 2026 00:00:00 Z51d1cceb-3592-45eb-97e2-ca786b2e42abhttps://gowlingwlg.com/fr-fr/insights-resources/articles/2026/legal-foundations-for-early-stage-life-sciences-companiesEarly‑stage life sciences companies face unique legal, regulatory, and commercial challenges driven by high capital requirements, long development timelines, complex regulation, and the central importance of intellectual property. Decisions made at incorporation—including corporate structure, share classes, and governance arrangements—can have long‑term implications for fundraising, tax efficiency, founder control, and exit options.Wed, 04 Feb 2026 00:00:00 Za0b64b5c-d229-4568-9bdb-e6f7a12d4560https://gowlingwlg.com/fr-FR/insights-resources/client-work/2026/capital-markets-team-advises-on-3-million-placing-and-subscription-for-genincode-plcOur Financial Services and Capital Markets team advised Cavendish, Oberon and TPI on GENinCode’s £3.9 million placing and subscription, marking our third fundraising for the company and supporting its US commercialisation, and UK and EU expansion plans.Wed, 04 Feb 2026 00:00:00 Zc856c7df-e1f0-4fcd-9de2-11f72207899ahttps://gowlingwlg.com/fr-fr/insights-resources/articles/2026/life-sciences-ca-2025-year-in-reviewWhat shaped Canada’s life sciences sector in 2025? Check out our snapshot of the key court decisions, regulatory guidance, and patent developments.Tue, 27 Jan 2026 00:00:00 Zcc4c9fc4-4d24-4a3d-8f8b-1f79ec0a244ehttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2025/life-sciences-team-advises-nanexa-on-a-multi-million-us-dollar-licence-and-option-agreementOur Life Sciences team has advised Nanexa on a licence and option agreement with Moderna for the development of PharmaShell ®-based products to advance the delivery of injectable therapies. The deal sees Nanexa receive a US$3m upfront payment, plus up to US$500m in potential milestone payments and a tiered single-digit royalty on product sales.Mon, 15 Dec 2025 00:00:00 Z3bfe55d8-a5da-46ae-b830-dafb50891763https://gowlingwlg.com/fr-FR/insights-resources/articles/2025/how-to-assess-patentable-subject-matter-eligibilityOn the heels of the Supreme Court of Canada’s (“SCC”) hearing in Pharmascience Inc. v. Janssen Inc., et al. regarding subject matter eligibility of methods of medical treatment, the Federal Court issued a subject matter eligibility decision in Dusome v. Canada (Attorney General).Tue, 09 Dec 2025 00:00:00 Zd67f081d-9fce-4e99-99e9-6574154a117fhttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2025/upc-case-win-for-molecular-instrumentsOur Life Sciences UPC Litigation team is proud to announce that, together with teams at patent attorney firm Boult and Dutch lawyers at De Brauw Blackstone Westbroek, they have secured a victory for US company Molecular Instruments in a patent litigation case before the Unified Patent Court (UPC), Local Division of the Hague.Thu, 04 Dec 2025 00:00:00 Z415a1823-66d2-4760-b232-18c9df64be4dhttps://gowlingwlg.com/fr-fr/insights-resources/articles/2025/updates-announced-to-the-uk-us-trade-deal-see-greater-support-for-the-pharmaceutical-sectorIn May, the UK became the first to announce a significant trade deal with the US, providing greater stability for many of its exporting industries. As further details now come through, there is positive news for the UK pharmaceutical and life sciences sectors in a new deal on the trade of pharmaceutical products into the US.Wed, 03 Dec 2025 00:00:00 Z1ecee06f-f71c-4ca2-a557-6724f462e273https://gowlingwlg.com/fr-FR/insights-resources/articles/2025/femtech-in-canada-guide-to-patents-trademarks-and-ip-strategyFemtech—technology and innovation focused on women’s health—has rapidly grown from a niche sector into a central pillar of the modern healthcare economy. As the market expands, strategic intellectual property protection is essential, with patents and trademarks creating defensible moats that safeguard innovation, build consumer trust, and support long-term commercial success.Tue, 18 Nov 2025 00:00:00 Z45454061-6812-48de-bf44-2749a5f37c40https://gowlingwlg.com/fr-fr/insights-resources/articles/2025/general-counsel-as-a-ceos-most-trusted-allyThe CEO-GC relationship is vital for navigating ambiguity and risk. GCs must build trust, understand the business deeply, and advise beyond legal matters. We explore how this dynamic strengthens leadership, decision-making, and governance across the organisation.Wed, 29 Oct 2025 00:00:00 Z5b794496-842d-4317-b9ea-f1bcd0ddd245https://gowlingwlg.com/fr-FR/insights-resources/articles/2025/ai-in-health-and-care-key-legal-risks-to-navigate-in-managing-data-privacyMedical technology is advancing rapidly, but AI and data privacy risks remain. We explore best practices to help MedTech manufacturers and healthcare providers address key challenges and legal complexities in the health and care sector.Tue, 14 Oct 2025 00:00:00 Zfa27054a-5fb9-4b6a-98e5-66bd172ebcf1https://gowlingwlg.com/fr-FR/insights-resources/articles/2025/understanding-eccta-what-is-the-reasonable-procedures-defence-and-how-does-it-affect-your-contractsAs of 1 September 2025, large UK companies face criminal liability under ECCTA for failing to prevent fraud by associated persons. Unlimited fines apply unless “reasonable procedures” exist. We explore how contract wording supports compliance, risk assessment, and government guidance.Thu, 09 Oct 2025 00:00:00 Z99eb48b2-50c0-4fa3-ae5e-e1b291f29894https://gowlingwlg.com/fr-FR/insights-resources/articles/2025/uk-high-court-defines-licence-fee-damages-in-merck-v-msd-trademark-disputeThe High Court's decision in Merck KGaA v MSD offers key guidance on assessing damages in trade mark and contract disputes, especially involving global brand use. The ruling shapes future litigation strategies and valuation approaches for IP rights.Mon, 06 Oct 2025 00:00:00 Z24de14c2-584b-4541-9c70-d491952cbfcchttps://gowlingwlg.com/fr-FR/insights-resources/articles/2025/crispr-patent-landscapeIn this article we summarize the current state of the CRISPR patent landscape, including major disputes and proceedings in key jurisdictions, and more.Wed, 24 Sep 2025 00:00:00 Z8fcef619-d091-4b38-9eb2-dc03840f1329https://gowlingwlg.com/fr-FR/insights-resources/articles/2025/neurodata-in-the-algorithmic-ageIn today's algorithmic age, neurodata is no longer just a medical curiosity—it has become a critical resource powering personalized medicine, adaptive technologies, and even targeted advertising.Wed, 24 Sep 2025 00:00:00 Zb826b25d-5ee3-4ec0-bb56-459c9066abfbhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2025/ip-ownership-of-the-human-cell-atlasLet’s unpack the legal implications of this ambitious international project.Fri, 15 Aug 2025 00:00:00 Z6d01df53-1f60-4c97-afc0-c0d493a4f885https://gowlingwlg.com/fr-FR/insights-resources/client-work/2025/life-sciences-team-advises-biontech-on-non-exclusive-licenseOur Life Sciences team has advised BioNTech on its agreement, with its partner Pfizer, to obtain a non-exclusive licence for mRNA-based COVID-19 and/or influenza products and resolve certain patent litigation with CureVac and GSK.Mon, 11 Aug 2025 00:00:00 Zdb6494e0-1c96-4360-b2bf-08743eb6e124https://gowlingwlg.com/fr-fr/insights-resources/articles/2025/what-are-the-contract-essentials-for-china-related-life-sciences-collaboration-agreementsAs pharmaceutical and biotechnology companies explore Chinese partnerships, robust contracts are essential. Our life sciences experts outline key considerations in collaboration and IP licensing agreements with Chinese parties, highlighting crucial differences in these kinds of collaborations and what to address during contract drafting.Mon, 28 Jul 2025 00:00:00 Zcfc4f290-f371-481f-9a80-d5dd2824e773https://gowlingwlg.com/fr-FR/insights-resources/articles/2025/supporting-growth-the-uks-plan-to-unlock-the-potential-of-life-sciencesLife sciences is one of eight high-growth sectors identified in the UK's Industrial Strategy as central to driving innovation and growth. With the Life Sciences Sector Pan now published, there is greater clarity on the framework being put in place to deliver on the ambition to make the UK the leading life sciences economy in Europe by 2030. Our sector experts explore the details.Thu, 24 Jul 2025 00:00:00 Z7497155d-8b53-40a9-8dd4-7ecdb457e6dchttps://gowlingwlg.com/fr-FR/insights-resources/articles/2025/upcoming-hearing-patentability-methodsThe Supreme Court is set to hear arguments in Pharmascience v Janssen, a decision involving the validity of patents claiming "methods of medical treatment."Tue, 15 Jul 2025 00:00:00 Zcb632d3c-e14b-4c19-8269-49be91c067dbhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2025/tech-trade-and-talent-modern-industrial-strategy-launched-to-future-proof-uk-economyThe UK’s 10-year Modern Industrial Strategy sets a bold path for growth, innovation, and investment. With sector-wide reforms and legal foundations in place, it aims to future-proof the economy and position the UK as a global leader. Explore our comprehensive summary of the Strategy and what this means for businesses.Wed, 25 Jun 2025 00:00:00 Z9f6b3bb3-21a0-4837-b4d1-ead401b2f1b5https://gowlingwlg.com/fr-FR/insights-resources/articles/2025/supporting-growth-what-does-the-uks-industrial-strategy-mean-for-life-sciencesThe UK’s new Industrial Strategy aims to position the country among the top three global life sciences economies by 2030, focusing on regional growth, international competitiveness, and innovation through targeted reforms and investment in key sector clusters.Tue, 24 Jun 2025 00:00:00 Zc0f2235b-2e20-4a8a-93c5-f384418fb275https://gowlingwlg.com/fr-FR/insights-resources/articles/2025/health-canada-phase-iii-trial-requirementHealth Canada is proposing to eliminate the phase III trial requirement for most biosimilar drug submissions. Learn what’s changing — and how to weigh in before Sep. 8.Fri, 13 Jun 2025 00:00:00 Z7fc95ad7-289b-4706-bd54-64df21f4bc4ahttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2025/gowling-wlg-advises-afynia-on-us$5m-seed-roundOn December 23, 2024, Canadian biotech company Afynia Laboratories completed a US$5 million seed funding round to support the commercialization of its microRNA-based blood test for endometriosis. The round was led by Bio-Rad Laboratories, a global clinical diagnostics manufacturer listed on the New York Stock Exchange, with participation from additional investors in the healthcare and life sciences sectors.Tue, 03 Jun 2025 00:00:00 Zc064f433-401b-4988-86ba-98505a207139https://gowlingwlg.com/fr-FR/insights-resources/articles/2025/navigating-virtual-patent-marking-in-chinaVirtual patent marking in China is complex due to the lack of explicit regulations. Companies must comply with general patent laws, detailing patent categories and numbers in Chinese to ensure proper protection and showcasing of intellectual property.Tue, 27 May 2025 00:00:00 Zce3aaa8c-9f7b-428c-9e81-ce833f1290c1https://gowlingwlg.com/fr-FR/insights-resources/articles/2025/licensing-partnerships-in-the-life-sciencesExplore the trends shaping licensing partnerships—from patent cliffs and AI breakthroughs to the surge in China-based licensing activity.Wed, 30 Apr 2025 00:00:00 Zbbc6e883-60a4-4e71-91a1-be33aeee164bhttps://gowlingwlg.com/fr-fr/insights-resources/articles/2025/uk-government-consults-business-on-responses-to-us-tariffsThe UK Government is consulting businesses on its response to the tariffs introduced by the Trump administration.Wed, 09 Apr 2025 00:00:00 Zef063a2d-545d-4e4a-b2c9-46dc5ec21c28https://gowlingwlg.com/fr-FR/insights-resources/articles/2025/from-ad-law-to-influencersThis year's INTA Annual Meeting is once again almost upon us. The event is now global benchmark on the IP industry calendar. This year's no different with more than 10,000 delegates set to descend on the San Diego Convention Center, for five days of meetings, presentations and networking.Tue, 08 Apr 2025 00:00:00 Z44524a07-f75e-480b-8cba-842d2b881687https://gowlingwlg.com/fr-FR/insights-resources/articles/2025/quantum-computing-legal-issues-the-risks-and-opportunitiesQuantum computing is a fundamental topic to all businesses across the globe. While it may not be present in the average office, it's already in cloud technology and central processing hubs. We take a look at the opportunities and risks of quantum computing.Wed, 02 Apr 2025 00:00:00 Ze1737b62-b9b4-4a03-b415-4ce33912152chttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2025/life-sciences-team-advises-oxford-biotherapeutics-on-strategic-$1-billion-partnership-with-rocheOur UK Life Sciences team has successfully advised client Oxford BioTherapeutics on a $1 billion agreement with Roche, a global leader in pharmaceuticals and diagnostics.Wed, 02 Apr 2025 00:00:00 Ze5cd7560-6131-4329-8ab7-473a53ba2792https://gowlingwlg.com/fr-FR/insights-resources/articles/2025/sr-and-ed-tax-incentiveThe Fall Economic Statement 2024, released on December 16, 2024, provided significant updates to the SR&ED regime.Wed, 26 Feb 2025 00:00:00 Z43605e81-4a62-46a1-a8f7-ab55fc45b2f4https://gowlingwlg.com/fr-fr/insights-resources/articles/2025/what-does-the-upcs-dusseldorf-courts-long-arm-mean-for-global-patent-disputesWe explore the Fujifilm v Kodak case, as the UPC Düsseldorf court's recent decision to rule on a UK patent, despite the UK not being part of the UPC system, highlights the court's jurisdictional reach and its implications for global patent disputes.Mon, 24 Feb 2025 00:00:00 Z14856e20-aa9e-4887-8715-7a87c5bff9dchttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2025/capital-markets-team-advises-on-fundraise-by-belluscura-plcOur Capital Markets team has advised Dowgate Capital, Allenby Capital and SPARK Advisory Partners on a placing of new shares by Belluscura plc (AIM: BELL), a UK medical device company.Mon, 24 Feb 2025 00:00:00 Z74bff0de-a210-4e58-b930-dc130380b122https://gowlingwlg.com/fr-fr/insights-resources/client-work/2025/our-financial-services-and-capital-markets-team-has-advised-cavendish-capital-markets-genincodeOur Financial Services and Capital Markets team has advised Cavendish Capital Markets Limited (acting as nominated adviser and joint bookrunner) and Oberon Capital, a trading name of Oberon Investments Limited (acting as joint bookrunner) on a conditional fundraising by AIM-traded GENinCode plc.Mon, 17 Feb 2025 00:00:00 Zf1f036ff-2375-4e6d-bbd0-857a4ff3f80ehttps://gowlingwlg.com/fr-FR/insights-resources/articles/2025/life-sciences-in-canada-2024-year-in-reviewWed, 12 Feb 2025 00:00:00 Z6cd8e497-1ec6-4d6a-977b-ba0f365df648https://gowlingwlg.com/fr-FR/insights-resources/articles/2025/canada-supply-chain-update-no-2Cette mise à jour est le deuxième volet d’une série axée sur la conformité à la Loi sur les chaînes d’approvisionnement.Tue, 11 Feb 2025 00:00:00 Z92cd9fb2-83c5-4abb-9774-ddf437721c96https://gowlingwlg.com/fr-fr/insights-resources/articles/2025/beware-overreach-by-eu-courts-in-foreign-patent-disputesWhy should companies be wary of overreach by EU courts in foreign patent disputes? We explore the BSH v Electrolux and Fujifilm v Kodak cases that raise critical questions about the jurisdiction of courts of EU Member States and the UPC.Thu, 30 Jan 2025 00:00:00 Zd4ff421c-d769-4b89-bd44-98982068adb3https://gowlingwlg.com/fr-FR/insights-resources/client-work/2025/capital-markets-team-advises-on-an-equity-fundraise-for-oxford-biodynamics-plcOur Capital Markets team has advised OAK Securities (a trading name of Merlin Partners LLP) on a secondary fundraising (Placing, Subscriptions and WRAP Offer of ordinary shares) which has raised £7.35 million for AIM-listed company, Oxford BioDynamics plc, with the fundraising due to be completed on 3/4 February 2025 (subject to shareholder approval).Wed, 29 Jan 2025 00:00:00 Z27ca84b9-669c-477c-a38f-3cacbf291c6ahttps://gowlingwlg.com/fr-fr/insights-resources/articles/2025/beyond-the-standard-patent-termBeginning January 1, 2025, patent term adjustment is available to protect patent owners from diminished patent terms in Canada.Thu, 09 Jan 2025 00:00:00 Z21e1accd-4132-4389-a92e-e4fd26674184https://gowlingwlg.com/fr-FR/insights-resources/articles/2024/when-can-patent-filing-and-enforcement-strategies-breach-eu-competition-lawCan patent filing and enforcement strategies breach EU competition law? Our latest insight discusses Teva's €462 million fine for abusing its dominant market position in the sale of Copaxone, and highlights how manipulating patent rules and disparaging competitors can violate Article 102 TFEU.Mon, 18 Nov 2024 00:00:00 Z022390e6-f878-4d2d-bd8c-0b5e3e769892https://gowlingwlg.com/fr-FR/insights-resources/client-work/2024/ecm-team-advises-ondine-biomedical-inc-on-funding-for-us-phase-3-clinical-trialOur Equity Capital Markets team has advised RBC Capital Markets and Singer Capital Markets on Canadian life sciences company Ondine Biomedical's fundraising to secure approximately C$16.2 million (£9.0 million), for its upcoming Phase 3 clinical trial to help advance infection control.Thu, 07 Nov 2024 00:00:00 Z43155990-9f31-4254-9eca-362389131f2bhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2024/sick-visits-to-conspicuously-ill-employeesIs your team battling an outbreak of insincere sick calls? Workplaces are seeing an increase in employees calling into work sick when they're not actually unwell, leading to a disrupt in productivity. Our latest insight details the effects of these dishonest calls, and the steps employers can take to minimise misleading sick leave.Mon, 04 Nov 2024 00:00:00 Z0af72e9f-37d1-4b44-9014-772d1dd035d9https://gowlingwlg.com/fr-FR/insights-resources/articles/2024/why-good-counsel-matters-when-dealing-with-nuclear-medicine-mattersCurious about the world of medical isotopes and how they are crucial to modern healthcare? We detail how medical isotopes are used in nuclear medicine to support diagnostics and treatment, the complex regulatory challenges that surround it and how we can best support clients on a nuclear medicine matter.Wed, 16 Oct 2024 00:00:00 Zff381398-6a6b-41e5-ad4f-5e24d283f36dhttps://gowlingwlg.com/fr-fr/insights-resources/articles/2024/interim-relief-applications-in-judicial-review-casesThe Court of Appeal in R (RRR Manufacturing Pty Ltd) v British Standards Institution [2024] EWCA Civ 530 upheld BSI's appeal against a lower court order that restrained it from withdrawing or suspending a medical device certificate and required it to renew the certificate until the conclusion of an associated judicial review claim. Our latest article looks at the background of the appeal that was upheld on all grounds, and the relevant principles for interim relief laid down under American Cyanamid Co v Ethicon Limited [1975] AC 396.Mon, 29 Jul 2024 00:00:00 Z927e6ac1-9fab-4670-866c-109e381b29f2https://gowlingwlg.com/fr-fr/insights-resources/articles/2024/transparency-in-litigation-part-threeIn the final article of our three-part series on transparency in litigation, we take a look at transparency issues from the perspective of the courts of France.Thu, 25 Jul 2024 00:00:00 Zed0f3b50-249c-4408-9e35-eccc9f431feahttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2024/life-sciences-team-advises-astrazeneca-and-pinetreeOur Life Sciences team has advised AstraZeneca on an exclusive option and global license agreement with biotechnology company Pinetree Therapeutics for a preclinical EGFR degrader candidate.Thu, 25 Jul 2024 00:00:00 Z9140b0f7-875a-4201-979e-c1e81e668669https://gowlingwlg.com/fr-FR/insights-resources/articles/2024/transparency-in-litigation-part-twoIn part two of our series on transparency in litigation, we take a look at the litigation documents that non-parties can obtain in the courts of England and Wales, and the principles underlying document requests.Thu, 18 Jul 2024 00:00:00 Z0a5db28a-191e-43e3-a118-b9a1a2e95a9ahttps://gowlingwlg.com/fr-fr/insights-resources/articles/2024/transparency-in-litigationIn our three-part series 'Transparency in Litigation' we take a look at the documents that non-parties can obtain in the Unified Patent Court (part one), the courts of England & Wales (part two) and the French courts, with a deep dive into the principles underlying requests for documents (part three). Read the first article here.Fri, 12 Jul 2024 00:00:00 Z2f66f635-f8cb-47bb-8cb3-1241d5b9d2achttps://gowlingwlg.com/fr-FR/insights-resources/reports/2024/sustainability-report-2023Our new Sustainability report 'Let's take a closer look – accepting responsibility', looks at sharing activities and progress across our core ESG programmes, as well as future plans.Wed, 19 Jun 2024 00:00:00 Z2c2433c2-c71d-4b02-bc71-d6af4334080dhttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2024/acto-acquires-4th-down-solutionsOn June 11, 2024, ACTO Technologies Inc. announced its acquisition of 4th Down Solutions, a leading provider of innovative mobile technology and data-driven learning solutions for biopharmaceutical companies, headquartered in Chicago, Illinois.Tue, 11 Jun 2024 00:00:00 Za2951cc6-d36b-4da0-9a27-429465783c63https://gowlingwlg.com/fr-fr/insights-resources/articles/2024/new-rules-for-deducting-patent-costsBudget 2024 introduced new rules for the immediate 100 per cent deduction of capital acquisition costs of certain capital assets, including patents.Wed, 29 May 2024 00:00:00 Zaa4c27d8-a150-444d-a759-6b8c67cce2c5https://gowlingwlg.com/fr-fr/insights-resources/articles/2024/canada-proposed-patent-box-regimeIn January 2024, the Department of Finance released a consultation paper on a proposed patent box regime, aiming to tax income from certain intellectual properties (IP) at preferential rates lower than the current federal rate.Tue, 28 May 2024 00:00:00 Z8eb3fc98-bbf3-46e9-b3a8-dc97103423ffhttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2024/labworks-acquired-by-hodess-cleanroomsOn April 17, 2024, Massachusetts-based Hodess Cleanrooms, a leader in the cleanroom construction and advanced technology industry, announced that it had acquired Labworks International Inc. of Woodbridge, Ontario.Wed, 17 Apr 2024 00:00:00 Zb4386ebb-63cf-44e3-b8a0-529c6be23454https://gowlingwlg.com/fr-FR/insights-resources/client-work/2024/dechra-veterinary-acquires-stem-animal-healthLe 15 avril 2024, Dechra Veterinary Products, Inc. (« Dechra ») a conclu l'achat de toutes les actions émises et en circulation de STEM Animal Health Inc. auprès de Kane Biotech Inc. et d'Ecuphar NV (une filiale d'Animalcare Group PLC).Mon, 15 Apr 2024 00:00:00 Z97beb504-500b-4ed0-99f0-559f243a7563https://gowlingwlg.com/fr-fr/insights-resources/articles/2024/trade-secret-tactics-10-strategies-counselLes secrets commerciaux jouent un rôle primordial dans l'écosystème de l’innovation. Compte tenu de la vitesse à laquelle elle modifie les technologies récentes, les rendant redondantes voire obsolètes, il peut s'avérer inapproprié ou peu rentable de s'appuyer uniquement sur la protection par brevet pour protéger sa propriété intellectuelle.Tue, 26 Mar 2024 00:00:00 Z813b0691-1547-4ec1-9d4e-3488fa97c569https://gowlingwlg.com/fr-FR/insights-resources/client-work/2024/gowling-wlg-advises-eloxx-pharmaceuticalsGowling WLG's award-winning Life Sciences team has advised Eloxx Pharmaceuticals on an exclusive licence agreement with Spanish pharmaceutical company Almirall for a drug to treat rare skin conditions and other diseases caused by gene mutations.Tue, 19 Mar 2024 00:00:00 Z40a69ed1-9550-448c-8c4a-539e6fca1fd5https://gowlingwlg.com/fr-FR/insights-resources/client-work/2024/oxford-biodynamics-advised-on-equity-fundraiseOur Capital Markets team is advising Shore Capital (Nomad and joint broker), Northland Capital Partners (trading as Baden Hill) and WG Partners (both also as joint brokers) on a Placing, Subscriptions and PrimaryBid Offer raising £9.9 million for AIM-listed Oxford BioDynamics plc (OBD), announced by OBD on 13 March 2024.Mon, 18 Mar 2024 00:00:00 Z49436825-9dcb-4bab-9ab2-cba8ea3a2f38https://gowlingwlg.com/fr-FR/insights-resources/client-work/2024/innocan-closes-non-brokered-private-placementOn March 14, 2024, Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) announced that it had closed its previously announced non-brokered private placement offering of units of the company for aggregate gross proceeds of $1,988,210.Thu, 14 Mar 2024 00:00:00 Z94622cf9-cf74-4c3d-a046-e8230d639acchttps://gowlingwlg.com/fr-fr/insights-resources/articles/2024/the-whole-truth-and-nothing-but-the-truthIn France a saisie is the instrument par excellence needed for when proving infringement. Although highly effective, it is strictly regulated due to its invasive nature and the fact that the procedure for obtaining it is in principle non-adversarial. In France, in addition to an ad hoc legal framework, case law, and particularly the Cour de cassation (French Supreme Court) has, over the years, laid down obligations that the applicant is required to comply with.Wed, 13 Mar 2024 00:00:00 Z870552e3-3a7a-4661-8084-fea9cf8fc905https://gowlingwlg.com/fr-fr/insights-resources/articles/2024/patentability-of-methods-of-medical-treatmentMethods of medical treatment are considered to be an exception to patentable subject matter in Canada. However, it is acknowledged that the exception has no explicit statutory basis, and the supporting jurisprudence is both unclear and contradictory.Fri, 23 Feb 2024 00:00:00 Z2f841df9-2318-41d2-8a0d-f3019d7227dehttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2024/camh-redevelopment-project-reaches-financial-closeOn February 20, 2024, Infrastructure Ontario (IO) and the Centre for Addiction and Mental Health (CAMH) awarded a fixed-price contract of $1.33 billion to PCL Partnerships to design, build and finance the CAMH Phase 1D Redevelopment project.Tue, 20 Feb 2024 00:00:00 Z7fbc0f61-11a0-4c20-b9bd-a1be3c60b72ahttps://gowlingwlg.com/fr-fr/insights-resources/articles/2024/cjeu-assessed-compliance-with-eu-lawTitulaires de brevets, exécuter une mesure provisoire vous expose à devoir indemniser la partie adverse en cas d'annulation de votre titre. Bien évaluer sa validité préalablement est donc essentiel. Notre nouvel article revient sur la décision rendue en la matière par la Cour de justice de l'Union européenne le 11 janvier 2024, sur son incidence en France et en Allemagne, et sur la façon dont cette problématique est traitée au Canada, au Royaume-Uni, et en Chine.Mon, 12 Feb 2024 00:00:00 Zed612fbf-3338-4a51-aec1-354c13903c81https://gowlingwlg.com/fr-FR/insights-resources/client-work/2024/trillium-health-partners-project-reaches-financialOn February 8, 2024, Infrastructure Ontario (IO) and Trillium Health Partners (THP) awarded a fixed-priced contract of $1.3 billion to EllisDon Corporation to Build and Finance the redevelopment project of The Future Home of The Gilgan Family Queensway Health Centre in Etobicoke, Ontario.Thu, 08 Feb 2024 00:00:00 Zca8a8849-c18a-4d2d-8289-6b8a98f5f23fhttps://gowlingwlg.com/fr-fr/insights-resources/articles/2024/supply-chain-transparency-reporting-begins-canadaLa Loi canadienne sur la lutte contre le travail forcé et le travail des enfants dans les chaînes d’approvisionnement (Loi « S-211 ») est entrée en vigueur le 1er janvier 2024.Wed, 31 Jan 2024 00:00:00 Z1a46ace0-758c-4f18-a9da-98bedaa2094chttps://gowlingwlg.com/fr-FR/insights-resources/articles/2024/new-costs-cap-under-the-shorter-trial-schemeFor patent and registered design right cases in England and Wales, a new costs cap has been introduced under the Shorter Trials Scheme procedure in the High Court's Patents Court. What does the change mean and how will it impact cost recovery? Here we provide a summary of the key points to note and the wider implications of this change in terms of the options for resolving disputes through the courts.Wed, 31 Jan 2024 00:00:00 Z53e1f35d-1543-463e-8ffc-421cca96c316https://gowlingwlg.com/fr-FR/insights-resources/articles/2024/2023-year-in-review-life-sciences-in-canadaThe Canadian life sciences sector saw several notable developments in 2023. This article summarizes a number of the more remarkable court decisions, as well as other life sciences-related developments from 2023.Thu, 18 Jan 2024 21:00:00 Za3d0cdb1-d07a-4a73-8782-978397a59ee7https://gowlingwlg.com/fr-FR/insights-resources/articles/2024/decision-in-allergan-v-juno-2023-fc-1686Allergan and Abbvie brought this action under the PM(NOC) Regulations, seeking to prevent the issuance of a Notice of Compliance for Juno Pharmaceuticals' generic version of Allergan’s LUMIGAN RC product.Thu, 18 Jan 2024 20:02:00 Za6a04992-433f-4849-b5e2-6a0133fdf579https://gowlingwlg.com/fr-FR/insights-resources/articles/2024/federal-court-clarifies-humira-decisionIn this review, we summarize key points from the Federal Court’s lengthy decision in AbbVie Corporation and Abbvie Biotechnology Ltd v JAMP Pharma Corporation, 2023 FC 1520 (“HUMIRA”).Thu, 18 Jan 2024 19:59:00 Zfa2f51ca-fb8b-46f0-a0f8-5fa4d7959090https://gowlingwlg.com/fr-fr/insights-resources/articles/2024/new-voluntary-scheme-for-branded-medicines-pricingAt the start of the year, the new Voluntary Scheme for Branded Medicines Pricing, Access and Growth (the VPAG) came into force. In this article we take a look at the case of British Generic Manufacturers Association Ltd v Secretary of State for Health and Social Care, which led to the implementation of the VPAG.Mon, 15 Jan 2024 00:00:00 Z63fa5223-bbf8-4d78-9cb3-6db010b5dfc6https://gowlingwlg.com/fr-FR/insights-resources/client-work/2024/nurexone-biologic-inc-closes-private-placementOn January 5, 2024, NurExone Biologic Inc. (formerly, EnerSpar Corp.) (“NurExone”) (TSXV: NRX) announced that it closed a private placement financing through the issuance of 7,091,993 units of the company for gross proceeds of $1,985,758.04.Fri, 05 Jan 2024 00:00:00 Z971ddd34-0385-4525-933a-aae9ba0d8878https://gowlingwlg.com/fr-FR/insights-resources/articles/2024/patent-applications-must-identify-human-inventorsUK Supreme Court rules in Thaler case: a patent application must identify a human inventor. The judgment leaves open for later cases the possibility of patents for inventions made by humans involving the use of AI. Our legal experts explore this topic in our latest insight.Wed, 03 Jan 2024 10:54:00 Z2d9340d9-b186-4d04-bf2b-1c0138ca5d7ehttps://gowlingwlg.com/fr-FR/insights-resources/articles/2023/upc-and-the-definition-of-same-partiesThe Unified Patent Court's (UPC's) decision in a recent case has raised a significant point in relation to the definition of 'same parties' in the context of parallel revocation and infringement claims. Our IP experts do a deep dive and consider what it means for future claims brought before the UPC.Wed, 20 Dec 2023 08:26:00 Zbf434b2b-e2a8-493a-8bf2-43d5cdf147a6https://gowlingwlg.com/fr-fr/insights-resources/articles/2023/court-of-appeal-diverges-from-cjeuIn this article, we explore the recent landmark judgment delivered by the Court of Appeal of England and Wales, which diverged from the case law of the Court of Justice of the EU on an aspect of trademark law, specifically the 'acquiescence' defence to trademark infringement.Wed, 13 Dec 2023 00:00:00 Z9334b1f3-9fde-4de2-a89a-3d492a44fdf3https://gowlingwlg.com/fr-FR/insights-resources/client-work/2023/hsbc-uk-bank-plc-funding-pharmacies-acquisitionThe Banking and Finance team has supported HSBC UK Bank plc on its funding of pharmacy business Jhoots' acquisition of 36 community pharmacies. With the sites covering a large swathe of the UK, the acquisition was made feasible by a bespoke funding package provided by the bank.Mon, 04 Dec 2023 11:13:00 Zd4ccafe5-7301-4811-b8aa-69f948aa4f7chttps://gowlingwlg.com/fr-FR/insights-resources/articles/2023/rational-reaction-to-emotional-perceptionThe UK Intellectual Property Office (IPO) has changed its patenting guidelines for AI inventions. Two recent announcements from the IPO have shed some light on the issue, but questions remain. We take a look at what the IPO said and what it will do.Mon, 04 Dec 2023 00:00:00 Zea825db5-8827-49f9-a76f-8a94cf3a20d0https://gowlingwlg.com/fr-fr/insights-resources/articles/2023/get-ready-for-patents-for-aiCan you get a patent for AI? The UK High Court has recently issued its first judgment on this topic, Emotional Perception AI v Comptroller-General of Patents [2023] EWHC 2948 (Ch) and has said 'yes'. In this article, we discuss the eligibility, implications and key takeaways.Mon, 27 Nov 2023 00:00:00 Zf1d1d107-19d1-4528-8b94-2f4e6d476206https://gowlingwlg.com/fr-FR/insights-resources/client-work/2023/khiron-closes-sale-of-its-european-businessOn November 17, 2023, Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) ("Khiron") announced that it had completed the sale of its European subsidiaries, being Khiron Europe GmbH, Zerenia Clinics Limited, PharmaDrug Production GmbH, Khiron Life Sciences UK Limited and Khiron Life Sciences Spain SL to 2518542 Alberta Ltd., a company controlled by Avonlea-Drewry Holdings Inc., for an aggregate base purchase price of $3,000,000.Fri, 17 Nov 2023 00:00:00 Z1b19a2a0-7a35-44c4-ad2e-4837f7d97e03https://gowlingwlg.com/fr-FR/insights-resources/articles/2023/trade-secrets-non-competes-ndasAs one method of safeguarding trade secrets and shielding them from misappropriation, companies often use non-competes and non-disclosure agreements (NDAs). The problem, however, is that such agreements may not always be legally enforceable, thus falling short of delivering the intended protection.Fri, 10 Nov 2023 13:50:00 Z7e4f5bfb-bde7-4f08-98ea-a358caa9b68dhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2023/prescribers-of-cannabis-based-medicinal-productsNHS England published a summary of key guidance and advice on cannabis-based products for medicinal use (CBPMs) to support prescribers of such products. In this article, we examine the main takeaways provided by NHS England, as well as provide additional regulatory insight into the background status of cannabis and CBPMs.Wed, 01 Nov 2023 08:35:00 Zcd9de36d-8472-4802-b42d-79130cdd445chttps://gowlingwlg.com/fr-fr/insights-resources/articles/2023/new-trade-secrets-directive-in-germanyThe Act relating to safeguarding trade secrets (GeschGehG) entered into force on 26 April 2019 and fundamentally changed the protection of trade secrets in Germany. Find out key details about the Act and its wider impact in our article.Tue, 24 Oct 2023 14:01:00 Z5b2e7839-0170-4277-9bf8-0bed4db71a99https://gowlingwlg.com/fr-FR/insights-resources/client-work/2023/cybin-completes-acquisition-of-small-pharmaOn October 23, 2023, Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin") acquired Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) ("Small Pharma") by way of a plan of arrangement under the Business Corporations Act (British Columbia).Mon, 23 Oct 2023 00:00:00 Z560fdcd0-fcf7-4ba0-b8df-02137f56d8d5https://gowlingwlg.com/fr-FR/insights-resources/client-work/2023/innocan-pharma-closes-brokered-life-offeringOn October 20, 2023 Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) announced that it had closed the second and final tranche of its previously announced private placement offering of units. In total, Innocan issued an aggregate of 5,425,608 units under the offering for aggregate gross proceeds of $1,627,682.40.Fri, 20 Oct 2023 00:00:00 Z1b7044a8-161c-4f25-9899-38d4526283a8https://gowlingwlg.com/fr-FR/insights-resources/client-work/2023/itm-and-cnl-announce-launch-of-joint-ventureOn October 18, 2023, ITM Isotope Technologies Munich SE ("ITM"), a leading radiopharmaceutical biotech company, and Canadian Nuclear Laboratories ("CNL"), which manages and operates the national laboratory at Chalk River, Ontario on behalf of Atomic Energy of Canada Limited ("AECL"), announced the launch of Actineer™ Inc., a new joint venture company between CNL and ITM for the industrial scale production of Actinium-225 (225Ac).Wed, 18 Oct 2023 00:00:00 Z69c73497-ad60-450b-b162-4e58979a9d1dhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2023/recording-assignments-with-the-epoThe European Patent Office has confirmed its return to requiring handwritten signatures for the assignment of legal documents. Our intellectual property lawyers discuss the background to the decision and what organisations need to consider when making future applications to the EPO.Thu, 12 Oct 2023 00:00:00 Zd90bcc61-4369-449b-bbf8-6c59de18c56ahttps://gowlingwlg.com/fr-FR/insights-resources/articles/2023/distinction-confidential-information-know-howQu’est-ce qu’un savoir-faire? Qu’est-ce qu’un secret commercial? Un savoir-faire est-il toujours un secret commercial? Tous les savoir-faire sont-ils confidentiels?Tue, 12 Sep 2023 12:07:00 Z2e0c023d-8e9b-4d96-aede-ddf6530d47cahttps://gowlingwlg.com/fr-FR/insights-resources/articles/2023/how-reula-will-impact-ip-law-in-the-ukThe Retained EU Law (Revocation and Reform) Act 2023 (REULA) is now on the statute books. As has been reported widely, it revokes, at the end of 2023, a long list of retained direct and subordinate legislation derived from EU legislation. This will impact intellectual property law in the UK as the UK separates further from the EU.Mon, 04 Sep 2023 11:13:00 Zb987d3c4-8d34-4306-a89a-917151452b4chttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2023/shore-capital-baden-hill-advised-on-fundraisingOur corporate team has advised Shore Capital (Nomad and joint broker) and Baden Hill (joint broker) on an equity fundraising (Placing, Subscriptions and a Primary Bid offer) which raised £6.15 million for AIM-listed company, Oxford BioDynamics plc, with the fundraising being completed on 21 and 22 August 2023 (following shareholder approval). Our corporate team previously acted for Shore Capital and Baden Hill on a £9.3 million equity fundraising for the same company in October 2022.Tue, 22 Aug 2023 00:00:00 Z06bddb4f-7146-419d-a99b-781535568e23https://gowlingwlg.com/fr-FR/insights-resources/articles/2023/judicial-review-of-patent-register-eligibilityIn a recent decision of the Federal Court, Janssen Inc v The Minister of Health, the Court determined that Health Canada's refusal to list one of Janssen's patents on the Patent Register was reasonable.Fri, 04 Aug 2023 14:50:00 Z5bf6a0d4-efca-46b0-9325-1a35d27e812dhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2023/federal-court-affirms-osip-decisionThe Federal Court in Janssen Inc. v. Canada (Health), 2023 FC 870 dismissed Janssen’s application for judicial review of the decision of the Office of Submissions and Intellectual Property to not list Canadian Patent No. 3,113,837 on the Patent Register.Fri, 04 Aug 2023 14:47:00 Z55264a3d-b215-4968-932c-07f9e283c3fehttps://gowlingwlg.com/fr-fr/insights-resources/articles/2023/pmprb-updating-interim-guidanceOn June 20, 2023 the Patented Medicine Prices Review Board (PMPRB) invited stakeholders to comment on its proposed amendment for conducting interim price reviews on New Medicines per the Interim Guidance.Fri, 04 Aug 2023 14:44:00 Z5ae1325c-f104-4fc9-b135-8048e680ff8bhttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2023/eden-research-plc-successful-fundraiseOur Capital Markets team has advised AIM quoted biopesticides product and technology company, Eden Research, in relation to its secondary capital fundraising of up to £11 million through a firm placing, conditional placing, subscription and retail offer, with Cenkos Securities plc acting as bookrunner and broker.Thu, 03 Aug 2023 00:00:00 Z7f194f2c-9176-4fa3-9550-80423d10b97fhttps://gowlingwlg.com/fr-fr/insights-resources/articles/2023/what-does-material-breach-and-cure-meanIn this final article in our Life Sciences Contract Disputes series, we look at how material breach and cure are interpreted by the courts/arbitrators under English law.Mon, 03 Jul 2023 00:00:00 Z1e5358d9-3270-474b-ba30-e22caa0e49cbhttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2023/ironwood-and-vectivbio-announce-completionLe 29 juin 2023, Ironwood Pharmaceuticals, Inc. (« Ironwood ») (Nasdaq : IRWD) et VectivBio Holding AG (« VectivBio ») (Nasdaq : VECT) ont annoncé la conclusion de l'OPA réussie d'Ironwood visant l'achat des actions ordinaires en circulation de VectivBio au prix de 17,00 $ l'action en espèces.Thu, 29 Jun 2023 00:00:00 Z34a39450-06e9-4463-bfe4-aa2b21ea06e7https://gowlingwlg.com/fr-fr/insights-resources/articles/2023/what-does-commercially-reasonable-efforts-meanIn this third article in our Life Sciences Contract Disputes series, we look at how commercially reasonable efforts is interpreted by the courts and what you can do to define it and improve its meaning in your contracts.Mon, 26 Jun 2023 00:00:00 Zffc91912-8733-4121-b217-8c4774a813edhttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2023/life-sciences-team-advises-on-deal-for-astrazenecaOur Life Sciences team has advised long-standing client AstraZeneca on a collaboration and license agreement with biopharmaceutical company Quell Therapeutics. The deal will facilitate the development of engineered T-regulator cell therapies for treating certain autoimmune diseases.Tue, 20 Jun 2023 08:17:00 Zc8e6b90c-96c9-4ec7-912c-518f3576db84https://gowlingwlg.com/fr-FR/insights-resources/articles/2023/resolving-disputes-in-life-sciences-contractsIn the second article in our 'Life sciences contract disputes toolkit', we identify some of the common areas where disputes can arise, how risks can be mitigated and what to consider if you do find yourself in a breach position.Mon, 19 Jun 2023 00:00:00 Z4502e5cd-509b-434e-b437-e2ca832ea257https://gowlingwlg.com/fr-FR/insights-resources/articles/2023/avoiding-disputes-from-key-financial-clausesDeals and collaborations in the life sciences sector come with big numbers attached. Which is why it's crucial to avoid conflicts during the contractual process. In this first article in our new 'Life sciences contract disputes toolkit', we outline key points to consider when drafting the terms of your agreements and how you can avoid contract disputes.Mon, 12 Jun 2023 00:00:00 Z3930b06b-1dcc-49d9-8cb8-cafe3106f66ehttps://gowlingwlg.com/fr-FR/insights-resources/guides/2023/data-unlocked-how-data-sharing-can-unlock-valueOur Data Unlocked series sets out what businesses need to know about data, legal structures, ethics and standards, integration and architecture in order to share data safely and successfully.Wed, 31 May 2023 00:00:00 Zf8754a0a-cf31-4afe-8d06-cff95ee19bbdhttps://gowlingwlg.com/fr-fr/insights-resources/articles/2023/claim-reduction-strategies-canadaEn octobre 2022, des modifications apportées aux Règles sur les brevets au Canada comportaient l'établissement de taxes sur les revendications excédentaires dans les cas où une demande de brevet s'accompagne de plus de 20 revendications. Par conséquent, il y a lieu de se montrer plus stratégique en limitant les revendications dans les demandes de brevet soumises à l'Office de la propriété intellectuelle du Canada (OPIC).Tue, 30 May 2023 00:00:00 Zd606a892-ac37-490e-81ae-0a3b06184b06https://gowlingwlg.com/fr-fr/insights-resources/articles/2023/should-you-consider-using-trade-secretsWith a significant rise in the importance and prominence of branding, brand owners typically seek to protect and distinguish themselves from others by utilising a raft of IP rights, ranging from patents to copyright. But is there still a place for trade secrets in your brand's protection portfolio, and do they still give brands that competitive edge in the market? Or are trade secrets an outdated concept that hold little relevance today?Fri, 21 Apr 2023 10:59:00 Z46efb9e2-2412-4582-a62c-fc96537cee29https://gowlingwlg.com/fr-FR/insights-resources/articles/2023/dismisses-claim-for-section-8-damageThe Ontario Superior Court of Justice has dismissed a claim for damages brought by Apotex under section 8 of the Patented Medicines Regulations.Mon, 17 Apr 2023 00:00:00 Zb926573d-4e69-42be-b1d6-c6dae0badc01https://gowlingwlg.com/fr-fr/insights-resources/articles/2023/press-releases-located-by-patent-appeal-boardThe Patent Appeal Board (the "PAB") recently released two decisions relating to patent applications claiming compositions comprising the insomnia drug doxepin and uses thereofWed, 29 Mar 2023 00:00:00 Zaee0185d-8588-42b1-a598-507d28f009c9https://gowlingwlg.com/fr-FR/insights-resources/white-papers/2023/annual-patent-review-paper-2022Our annual review of UK patent judgments in 2022 comprehensively reviews the patent decisions of the courts of England and Wales, with comment and opinion on the big issues arising.Wed, 08 Feb 2023 12:07:00 Z2ee8334c-f6b9-451d-a2cc-9271db027c3dhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2023/uk-and-uae-approach-to-patent-enforcementIn this article we look at some of the procedural differences between patent litigation in the UK and the UAE. First, we remind readers of the process for obtaining patent rights and utility models in the UAE.Mon, 30 Jan 2023 08:44:00 Z974233a7-b726-446d-8864-67e3e626f6b4https://gowlingwlg.com/fr-fr/insights-resources/articles/2023/trade-secret-protection-in-sea-and-chinaThis article briefly discusses the legal framework and case studies for trade secret protection in South-East Asia and China, as well as to provide a list of practical tips for companies to protect and manage their trade secrets.Wed, 18 Jan 2023 00:00:00 Z69d24411-d5e3-4300-93e5-fe649a4104e3https://gowlingwlg.com/fr-FR/insights-resources/articles/2023/life-sciences-in-canada-2022-year-in-reviewLes tribunaux canadiens ont rendu de nombreuses décisions dans le secteur des sciences de la vie en 2022. Le présent article résume les plus notables en plus de présenter d'autres développements récents de 2022 en la matière.Mon, 16 Jan 2023 18:40:00 Zf0c07a1c-27b4-48e4-b3ce-14baf77a2b36https://gowlingwlg.com/fr-FR/insights-resources/client-work/2023/nanexa-advised-on-sek-46-1-million-agreementLawyers in our Life Sciences team have advised new Swedish-based client Nanexa on a material transfer and feasibility study agreement with global pharmaceutical company Novo Nordisk A/S.Wed, 11 Jan 2023 00:00:00 Z0d6cd5b7-4bb6-4c0b-982f-fa7ac64e788ehttps://gowlingwlg.com/fr-FR/insights-resources/reports/2023/the-big-picture-for-business-2023Our Big Picture For Business 2023 looks at five macro trends shaping the economic outlook, the global growth map and a 'playbook for uncertainty' for businesses to thrive in the year ahead.Fri, 06 Jan 2023 00:00:00 Z9caacd4f-6609-44a6-bebd-a49ca7d98db8https://gowlingwlg.com/fr-FR/insights-resources/client-work/2022/sosei-heptares-global-agreement-with-eli-lillyOur Life Sciences team has advised long-standing client Sosei Heptares on a collaboration and license agreement with Eli Lilly to develop new treatments in diabetes and metabolic diseases.Wed, 21 Dec 2022 10:14:00 Z5021bc95-d1af-4be6-b1ff-aada6a31df6ehttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2022/cenkos-fundraising-for-skinbiotherapeuticsThe Public Companies and Capital Markets team at Gowling WLG has advised Cenkos Securities (Cenkos) on a conditional fundraising by AIM-traded SkinBioTherapeutics.Wed, 21 Dec 2022 00:00:00 Z945ccdcd-58af-4052-afbf-030d72010a4ahttps://gowlingwlg.com/fr-FR/insights-resources/articles/2022/pre-emption-group-updated-statement-of-principlesThe Pre-Emption Group recently issued an updated Statement of Principles, and also template shareholder resolutions, for UK listed companies to deal with their shareholder authorities to disapply pre-emption rights. We set out the key revisions in this insight.Wed, 07 Dec 2022 09:06:00 Z077ba475-634d-4ca6-ae01-6fbc6ccaff23https://gowlingwlg.com/fr-FR/insights-resources/articles/2022/scc-upholds-usd644-million-award-for-patent-infringementIn an 8 to 1 decision (2022 SCC 43), the Supreme Court of Canada has upheld the largest monetary award ever by a Canadian court for patent infringement: $644 million in favour of Dow Chemical for Nova Chemicals' infringement of Dow's patent. In so doing, the Supreme Court provided fresh guidance and a preferred framework for conducting an accounting of profits.Fri, 18 Nov 2022 20:30:00 Z0cab7b81-9de0-489d-97f4-9c621514b234https://gowlingwlg.com/fr-FR/insights-resources/client-work/2022/license-agreement-for-oxford-biotherapeuticsOur Life Sciences team has advised Oxford BioTherapeutics on a global commercial licence agreement with a biotech company to advance the development of a novel, pre-clinical immuno-oncology antibody.Tue, 25 Oct 2022 00:00:00 Zbefe3712-2c2c-4b91-b2eb-f6094f4551b9https://gowlingwlg.com/fr-FR/insights-resources/articles/2022/how-far-can-the-upc-reachLa JUB a récemment proposé une modification du Règlement. Dans cet article, notre équipe de propriété intellectuelle examine ces changements et leurs implications.Fri, 21 Oct 2022 00:00:00 Z78dca8ff-abbb-45e4-ac76-3d52c0e6b7dbhttps://gowlingwlg.com/fr-FR/insights-resources/reports/2022/tomorrow-s-world-a-snapshotWe explore how Gen Z is driving organisational change from an ESG perspective.Fri, 14 Oct 2022 08:28:00 Zcde2bbf6-696a-4657-91d4-7ff833f29b71https://gowlingwlg.com/fr-FR/insights-resources/articles/2022/pmprb-releases-new-draft-guidelinesOn October 6, 2022, the PMPRB released new draft guidelines to give effect to the July 2022 amendments to the Patented Medicines Regulations set forth by Health Canada. Stakeholders will have a 60-day period (up until December 5, 2022) to submit written feedback. All submissions will be made available to the public.Wed, 12 Oct 2022 00:00:00 Zefa13785-6d84-4a54-aaad-fe2af14f1ce9https://gowlingwlg.com/fr-FR/insights-resources/client-work/2022/equity-fundraising-for-oxford-biodynamics-plcOur Corporate team has advised Shore Capital and Baden Hill on a Placing to raise £9.1 million and an Open Offer to raise a further £2.9 million for AIM-listed company, Oxford BioDynamics plc.Tue, 11 Oct 2022 00:00:00 Z430bd747-402f-41f3-b527-aba48e17baadhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2022/how-generation-z-is-driving-changeESG trends, and organisational responses to it, are increasingly being shaped by shifting societal attitudes including a lack of consumer trust. Most importantly, this shift in attitude is being driven by young people, or 'Gen Z'. In this article, we outline some key actions for businesses to consider as Gen Z both enters the workforce and becomes our largest group of consumers.Tue, 04 Oct 2022 00:00:00 Z52942777-3029-4ae2-9eae-526de0cd99b0https://gowlingwlg.com/fr-FR/insights-resources/articles/2022/five-years-of-csps-what-have-we-learnedSeptembre 2022 marque le cinquième anniversaire du régime canadien des certificats de protection supplémentaire (CPS). Le mois coïncide également avec le dépôt de la 100e demande de CPS. Ces jalons atteints, nous pouvons nous pencher sur la manière dont les CPS sont utilisés au Canada.Fri, 23 Sep 2022 00:00:00 Zcc8a23ef-8a37-40ca-94df-c175f1534a37https://gowlingwlg.com/fr-FR/insights-resources/on-demand-webinars/2022/be-a-leader-in-digital-transformationLa numérisation transforme le monde, un pays, un secteur et une entreprise à la fois. Mais tous les secteurs et pays ne changent pas à la même vitesse. Le déploiement de nouvelles technologies en soutien au numérique, ainsi que l’impact de la pandémie de la COVID-19 ont accéléré le passage aux technologies numériques des secteurs à faible coefficient de technologie.Thu, 15 Sep 2022 19:34:00 Zaa3cf212-bbaf-4dc2-8e27-832c1be97f55https://gowlingwlg.com/fr-FR/insights-resources/articles/2022/the-cost-challengeGordon Harris' insightful article 'The Cost Challenge: How can UK courts remain competitive for patent litigation in a new era' explores the success of costs reforms instigated in the last 30 years in England and Wales.Tue, 13 Sep 2022 13:11:00 Z85c48bcb-7ff2-46a0-b25f-4fe91cb05d7bhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2022/market-it-or-lose-it-a-cautionary-taleIn AbbVie Corporation v Canada (Health), 2022 FC 1209, Justice Fothergill of the Federal Court upheld the Minister of Health's finding that innovator pharmaceutical companies must actively market their drugs in Canada in order to benefit from Canada's patent linkage regime.Tue, 30 Aug 2022 00:00:00 Zd74cb515-2cf2-4194-823d-3d5eb167e985https://gowlingwlg.com/fr-FR/insights-resources/articles/2022/ontario-court-of-appeal-dismissal-of-actionCan a generic pharmaceutical manufacturer who engages Canada's pharmaceutical linkage regime (the PM(NOC) Regulations) make a claim for treble damages or the patent holder's profits in respect of alleged market entry delays caused by the statutory scheme?Mon, 29 Aug 2022 00:00:00 Z384b6a37-4b11-4dfa-89f5-ef4314ad7ec5https://gowlingwlg.com/fr-FR/insights-resources/guides/2022/trade-secrets-guide-uk-2022-trends-developmentsUK trade secret law has been the subject of a number of significant updates. We take a look at the latest trends and developments including the rise of AI, increase in demand and the UK's implementation of the EU's trade secrets directive.Wed, 03 Aug 2022 00:00:00 Z5327db39-c471-4ed0-95cb-773430fec09fhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2022/patent-ownership-when-your-r-d-staff-departThe success of IP transactions is rooted in the IP asset in play. But what if your company suddenly discovers it no longer actually owns the right, despite it being created by employees?Tue, 02 Aug 2022 14:38:00 Zbe731487-11b7-4f80-a27f-29565a2f65a5https://gowlingwlg.com/fr-FR/insights-resources/articles/2022/be-proactive-about-ip-ownershipFor patented or patentable inventions, it is best practice to execute an agreement for a patent assignment that compensates the employee for the invention separately from their usual employment compensation.Tue, 02 Aug 2022 14:36:00 Z2ec86df4-8dd8-44f9-905c-3a8ef217402fhttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2022/khiron-completes-acquisition-of-pharmadrugOn August 2, 2022, Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC) announced that it had completed its previously announced acquisition of Pharmadrug Production GmbH from Pharmadrug Inc. (CSE:PHRX) (OTC: LMLLF).Tue, 02 Aug 2022 00:00:00 Z50cfc279-6c82-472d-be8b-737202b33659https://gowlingwlg.com/fr-FR/insights-resources/client-work/2022/real-estate-advises-jazz-pharmaceuticalsOur Real Estate team has advised Jazz Pharmaceuticals on its new 60,000 sq. ft, state-of-the-art manufacturing facility, representing an investment of over $100 million (approximately £75 million).Thu, 23 Jun 2022 00:00:00 Z6eddaa0b-a04e-4480-9eb3-630e3767c976https://gowlingwlg.com/fr-FR/insights-resources/client-work/2022/oxford-biotherapeutics-and-immunogen-collaborationOur Life Sciences team has advised Oxford BioTherapeutics on a multi-year collaboration with ImmunoGen, Inc. to advance the development of antibody-drug conjugates (ADCs) for the treatment of cancer.Mon, 20 Jun 2022 00:00:00 Za71cf256-5888-432e-9bd4-fd1638e07282https://gowlingwlg.com/fr-fr/insights-resources/articles/2022/supreme-courts-astrazeneca-decisionLa Cour suprême du Canada a transformé le paysage des litiges relatifs aux brevets en jugeant à l’unanimité que la doctrine de la promesse était sans fondement en droit canadien et n’était « pas une règle de droit valide.Mon, 13 Jun 2022 14:26:00 Z65b64332-c32f-4c8f-a505-8343d9d5c532https://gowlingwlg.com/fr-FR/insights-resources/client-work/2022/khiron-closes-overnight-brokered-offeringOn June 10, 2022, Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) (Frankfurt: A2JMZC) closed its previously announced underwritten overnight public offering of units of the company, including the exercise in full of the over-allotment option.Fri, 10 Jun 2022 00:00:00 Z20d6d7c2-9e54-44e9-a993-e324a1915385https://gowlingwlg.com/fr-FR/insights-resources/videos/2022/ip-for-life-sciences-startupsGowling WLG's Vancouver IP Group has created a three-part video series to provide early-stage life sciences companies with the resources they need to ensure their IP assets are protected in a highly competitive market.Wed, 08 Jun 2022 20:04:00 Z7295a317-3fdc-4d44-bd6d-105a3205cde0https://gowlingwlg.com/fr-FR/insights-resources/articles/2022/middle-east-based-patent-filers-are-you-preparedIn this article we summarise everything Middle East-based European patent holders need to know about the major changes to the European patent system.Wed, 01 Jun 2022 00:00:00 Zb34907ab-c601-454b-88d4-65a49a235a36https://gowlingwlg.com/fr-FR/insights-resources/client-work/2022/innocan-obtains-receipt-for-base-shelf-prospectusOn May 17, 2022, Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) ("Innocan") announced that it had filed and obtained a receipt for a final short form base shelf prospectus with the securities regulatory authorities in each of the provinces and territories of Canada.Tue, 17 May 2022 00:00:00 Z01ddcfac-9474-4b2a-a085-416b35766427https://gowlingwlg.com/fr-FR/insights-resources/client-work/2022/life-sciences-team-advises-amphista-therapeuticsOur Life Sciences team has advised Amphista Therapeutics on two multi-million pound deals to advance the company's work developing protein degrading therapeutics for treating a wide range of diseases.Wed, 04 May 2022 00:00:00 Z8b43438d-1c53-4090-bf60-ab2898b7b313https://gowlingwlg.com/fr-FR/insights-resources/client-work/2022/west-lincoln-memorial-hospital-reaches-closeOn April 29, 2022, Infrastructure Ontario (IO) and Hamilton Health Sciences (HHS) awarded a fixed-price contract of $224 million to EllisDon Infrastructure Healthcare (EDIH) to design, build and finance the West Lincoln Memorial Hospital (WLMH) Redevelopment project in Grimsby, Ontario.Fri, 29 Apr 2022 00:00:00 Z3a9d6cf8-9a00-444f-8129-bbb3e1a77324https://gowlingwlg.com/fr-fr/insights-resources/articles/2022/amendments-update-patented-medicines-regulationsLe 14 avril 2022, l'honorable Jean-Yves Duclos, ministre de la Santé, a annoncé que le gouvernement ne procéderait qu’avec une partie des modifications annoncées précédemment.Thu, 21 Apr 2022 00:00:00 Z6d01761e-9c90-4f93-a202-510a043cde06https://gowlingwlg.com/fr-FR/insights-resources/client-work/2022/life-sciences-team-advises-immedica-pharma-abOur Life Sciences team has advised Immedica Pharma AB on a deal relating to a pioneering bone marrow transplant treatment.Thu, 21 Apr 2022 00:00:00 Z15b8ae02-2101-4a8c-aec6-a45dc1ec84c9https://gowlingwlg.com/fr-fr/insights-resources/articles/2022/launch-of-ontario-s-life-sciences-strategyLe 31 mars 2022, l'Ontario a dévoilé sa stratégie en matière de sciences de la vie, Faire passer les sciences de la vie au niveau supérieur, accompagnée d'un communiqué faisant état d'un prêt de 40 M$ octroyé par Investissement Ontario. Ce prêt vise la construction d'une installation d'élaboration et de production (en sous-traitance) de thérapies cellulaires et géniques à l'échelle commerciale totalisant 580 M$, au Parc de l'innovation McMaster à Hamilton (Ontario).Thu, 14 Apr 2022 17:30:00 Z1023ea78-86ef-41b1-a667-11f8c45e6cb4https://gowlingwlg.com/fr-fr/insights-resources/articles/2022/life-sciences-in-asean-data-export-controlsIn the first of a three-part article series exploring key aspects of IP transactions in life sciences in the ASEAN countries, we examine data export controls.Thu, 14 Apr 2022 00:00:00 Z9bf0817a-3cc1-489e-9d4b-50b1c32fef41https://gowlingwlg.com/fr-FR/insights-resources/reports/2022/digital-currentsDownload our latest digitalisation report 'Digital Currents' to find out how your business can keep up with digital transformation.Thu, 07 Apr 2022 13:14:00 Zcd5d7eb2-fad9-45a0-a270-0ecb724d8502https://gowlingwlg.com/fr-FR/insights-resources/client-work/2022/precision-biomonitoring-target-of-acquisitionOn March 31, 2022, NatureMetrics acquired the environmental DNA business of Canada-based Precision Biomonitoring Inc. ("PBI"). The deal will see nine leading experts in the field of DNA-based biomonitoring joining the NatureMetrics family.Thu, 31 Mar 2022 00:00:00 Zca66a038-f24a-4e1c-83bd-f74a4eaed385https://gowlingwlg.com/fr-FR/insights-resources/articles/2022/accelerate-patent-prosecution-in-asean-regionHow can businesses accelerate patent prosecution in the ASEAN Region? In this article, our Singapore IP experts discuss the main international, regional, and national acceleration programmes in Association of Southeast Asian Nations (ASEAN) countriesThu, 24 Mar 2022 00:00:00 Zf7a549ba-2a6b-4e61-9a5d-aeb76a5e220dhttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2022/cross-practice-team-advises-thomas-white-oxfordA multi-disciplinary team has advised Thomas White Oxford Limited on a 50:50 joint venture partnership to bring forward a £700 million global life sciences district development in Oxford.Tue, 22 Mar 2022 00:00:00 Z00a58eff-319b-466e-93a2-d155873aac8dhttps://gowlingwlg.com/fr-fr/insights-resources/articles/2022/exhaustion-of-patent-and-trademark-rightsSi votre entreprise participe ou souhaite participer à l'importation au Canada de marchandises protégées par un droit de propriété intellectuelle, il vous faut comprendre les implications de la loi canadienne en ce qui a trait à « l'épuisement » du droit concerné.Wed, 09 Mar 2022 14:54:00 Z50b15b00-b4cb-4258-b84d-8d171b324d99https://gowlingwlg.com/fr-fr/insights-resources/articles/2022/exhaustion-of-patent-and-trademarks-in-franceWhat is the law on 'exhaustion' of intellectual property in France and the EU? Our global IP experts explore the development of the regime governing exhaustion in the country for patents and trademarks, and what this means for businesses.Wed, 09 Mar 2022 14:52:00 Z5a7689a4-a4e4-4b6d-8ce6-727a356593a3https://gowlingwlg.com/fr-fr/insights-resources/articles/2022/exhaustion-of-patent-trademark-rights-in-the-ukOur global IP experts explore the UK's 'exhaustion' regime for patents and trademarks, how this governs the import of genuine IP-protected goods, and what it means for businesses.Wed, 09 Mar 2022 00:00:00 Z4f471089-dded-469d-8861-4ed29b64767ehttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2022/delpharm-acquires-sandoz-facilityOn March 1, 2022, Delpharm Industrie ("Delpharm") announced that it had acquired the Sandoz Canada manufacturing plant located in Boucherville, Québec, from Novartis.Tue, 01 Mar 2022 00:00:00 Zc7cd38f8-7fd3-43c1-8a57-549f8fc70371https://gowlingwlg.com/fr-fr/insights-resources/articles/2022/two-amendments-patented-medicines-regulationsLe 18 février 2022, la Cour d'Appel du Québec a publié sa décision (2022 QCCA 240) concernant la contestation constitutionnelle des modifications portées au Règlement sur les médicaments brevetés.Tue, 22 Feb 2022 00:00:00 Z713cbf43-823b-467f-bd26-476c6b85400ahttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2022/sqi-diagnostics-completes-acquisitionOn February 14, 2022, SQI Diagnostics Inc. (SQI) (TSXV: SQD) (OTCQB: SQIDF) announced that it had completed its previously announced asset acquisition of Precision Biomonitoring Inc.'s (PBI) human diagnostic COVID-19 PCR testing business and its TripleLock™ molecular diagnostic testing technology.Mon, 14 Feb 2022 00:00:00 Z0a7f34a8-3774-4eec-b074-40b98eb380c9https://gowlingwlg.com/fr-FR/insights-resources/white-papers/2022/annual-review-of-uk-patent-judgments-2021Read our complete guide to the key patent case law emerging from the courts in the UK in 2021, in which partner Gordon Harris takes you through a blockbuster year of patent case law, noting trends and points to watch out for.Fri, 11 Feb 2022 11:08:00 Zce265dfc-bce1-4adf-8fbd-338ab10beed8https://gowlingwlg.com/fr-FR/insights-resources/articles/2022/new-uae-patent-law-what-do-you-need-to-knowThe UAE has issued Federal Law no. 11 of 2021 concerning the regulation and protection of Industrial Property Rights. In this article, we review the key changes in the Law and their implications.Thu, 03 Feb 2022 08:53:00 Ze869e1ff-c63c-4c1b-a25b-76f199b8145bhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2022/gcc-patent-office-new-working-model-confirmedThe Implementing Regulations for the GCC Patent Office's new working model were issued in November 2021. We take you through the key takeaways for the new Regulations.Tue, 01 Feb 2022 10:20:00 Z2baa75ea-1c0c-4b13-bba8-1d705cfdb0f9https://gowlingwlg.com/fr-FR/insights-resources/client-work/2022/ashfield-engage-acquires-medaxisOn January 25, 2022, Ashfield Engage, a division of UDG Healthcare plc, announced the acquisition of Montréal-based Medaxis, a patient engagement services partner for the life sciences industry, providing services to healthcare professionals and patients.Tue, 25 Jan 2022 00:00:00 Z12475dc8-12aa-4d4b-81cc-6788d0ac41a5https://gowlingwlg.com/fr-fr/insights-resources/articles/2022/invega-sustenna-patent-is-infringedCette nouvelle décision se distingue par le fait qu'il s'agit de la première décision de procès sommaire sur la contrefaçon dans une affaire pharmaceutique en vertu du Règlement sur les médicaments brevetés (avis de conformité).Mon, 24 Jan 2022 00:00:00 Z4b1e6b68-8e1a-4bfa-939f-4d49bc7b3525https://gowlingwlg.com/fr-FR/insights-resources/client-work/2022/life-sciences-team-advises-astrazenecaThe transaction will aid in the development of precision medicines against previously hard-to-target cancer proteins.Mon, 24 Jan 2022 00:00:00 Z321b62af-e677-48d2-87dd-3531143eab62https://gowlingwlg.com/fr-FR/insights-resources/client-work/2022/life-sciences-team-advises-kelso-pharmaOur Life Sciences team has advised Kelso Pharma in partnership with the healthcare specialist private equity investor, Apposite Capital on the acquisition of Stirling Anglian Pharmaceuticals Limited.Mon, 24 Jan 2022 00:00:00 Z520ab497-48b3-440f-af85-6521a33007a3https://gowlingwlg.com/fr-fr/insights-resources/articles/2022/collaboration-between-competition-bureau-and-hpfbLe 10 janvier 2022, le Bureau de la concurrence et la Direction générale des produits de santé et des aliments de Santé Canada (DGPSA) ont publié un avis conjoint à l'appui d'une nouvelle alliance intragouvernementale. Tel que le mentionne l'avis, les deux organismes reconnaissent qu'ils ont un important rôle à jouer en « s'assurant que les Canadiens ont accès à des médicaments sûrs et efficaces dont ils ont besoin ».Thu, 13 Jan 2022 00:00:00 Zc3edcb1a-3b7a-4cb6-988b-244474b04853https://gowlingwlg.com/fr-fr/insights-resources/articles/2022/epo-rejects-patent-application-in-dabus-caseIn the latest on the DABUS case, the European Patent Office has confirmed the decision of the Receiving Section that a patent application cannot succeed where the designated inventor is not a person, but an AI machine.Fri, 07 Jan 2022 09:34:00 Zd8eb3efc-7193-4142-b8f0-b9d92ed0831fhttps://gowlingwlg.com/fr-fr/insights-resources/articles/2021/the-uk-s-nsi-act-key-aspects-to-considerWhat will the new UK NSI Regime mean for investment screening on national security grounds, when it enters force on 4 January 2022? Our EU, Trade and Competition experts detail the essential considerations.Fri, 17 Dec 2021 00:00:00 Z60dec7ed-93b7-4931-a2d8-2fd965ecc103https://gowlingwlg.com/fr-FR/insights-resources/reports/2021/patent-litigation-trends-the-future-of-biologicsAs the biologics market continues to expand, patent litigation is also increasing. Our report examines what we're likely to see in the next few years in this industry and how litigators can prepare for the increase of innovation in next generation therapies.Mon, 06 Dec 2021 00:00:00 Z6f3b5c30-04ff-480d-b537-19df918085b5https://gowlingwlg.com/fr-FR/insights-resources/client-work/2021/gowling-wlg-advises-sosei-heptares-on-2-6bn-collaGowling WLG's life sciences experts have advised long-standing client Sosei Heptares on its collaboration with Neurocrine Biosciences Inc to develop novel muscarinic receptor agonist compounds.Tue, 23 Nov 2021 00:00:00 Z8fa63d9b-6a12-4380-b222-540b53eb1945https://gowlingwlg.com/fr-fr/insights-resources/articles/2021/exhaustion-of-intellectual-property-rightsIn Singapore, the question of whether an intellectual property right (such as a registered trademark or a patent) can be enforced by way of an infringement action against the sale of genuine goods placed on the market in another country and then parallel imported into Singapore, is governed by an area of law called 'exhaustion'.Thu, 18 Nov 2021 00:00:00 Z645e05f8-3594-466b-a9f6-295cac02177ahttps://gowlingwlg.com/fr-fr/insights-resources/articles/2021/exhaustion-in-the-uk-ip-law-under-reviewHow might UK law on exhaustion of IP rights change soon? And what does this mean for parallel imports into post #Brexit Britain? Our IP team detail the key points to note.Fri, 12 Nov 2021 13:42:00 Zc1057bef-4a85-478d-b936-537cfd214145https://gowlingwlg.com/fr-FR/insights-resources/on-demand-webinars/2021/role-of-ip-strategy-in-drug-developmentWith vaccine brand names still very much top-of-mind for Canadians, Gowling WLG's own Brian Kingwell and Dr. Sonia Ziesche took part in a recent online panel discussion surrounding drug development and intellectual property.Mon, 08 Nov 2021 00:00:00 Zf245fa18-f682-434f-9136-1b2c4d5a8fa0https://gowlingwlg.com/fr-FR/insights-resources/on-demand-webinars/2021/how-to-protect-ideas-in-the-life-sciences-sectorThe life sciences sector is booming! Most sectors of the economy are now becoming knowledge-based industries, and in those industries – the competition is for ideas. But how do firms protect ideas and innovations, and shield them from being stolen?Thu, 28 Oct 2021 14:13:00 Zd57023b6-02fa-4a0a-bc07-6ca105da96f5https://gowlingwlg.com/fr-fr/insights-resources/articles/2021/federal-court-health-canada-csp-regimeLa Cour fédérale a imposé un troisième revers à Santé Canada concernant l'interprétation du Règlement sur les certificats de protection supplémentaire (Règlement sur les CPS) .Wed, 20 Oct 2021 13:30:00 Za7fd5e40-10c1-4264-8961-57326c99ea37https://gowlingwlg.com/fr-fr/insights-resources/articles/2021/patent-applications-examination-avoid-claim-feesAfin d'éviter les nouvelles taxes proposées par le Canada pour les revendications excédentaires dans les demandes de brevet, les demandeurs auraient intérêt à faire leur requête d'examen avant la fin de l'année.Wed, 13 Oct 2021 12:25:00 Z25d304cd-4e9c-4255-88bf-578090563e3bhttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2021/innodem-signs-strategic-agreement-with-novartisLe 5 octobre 2021, Innodem Neurosciences (Innodem) a annoncé la signature d 'un accord de partenariat pluriannuel avec Novartis Pharmaceuticals Canada Inc.l (Novartis) afin de mener des essais cliniques révolutionnaires dans le but d'aider les personnes atteintes de sclérose en plaques (SP).Tue, 05 Oct 2021 00:00:00 Z76ee0b80-335a-4696-be5c-86af101f9bcehttps://gowlingwlg.com/fr-fr/insights-resources/client-work/2021/providence-therapeutics-enters-into-agreementOn September 13, 2021, Everest Medicines Limited (HKEX 1952.HK, "Everest") announced two separate definitive agreements with Providence Therapeutics Holdings Inc. ("Providence"), a clinical stage biotechnology company developing messenger RNA ("mRNA") therapeutics and vaccines. Everest and Providence have agreed to (i) license rights to Providence's mRNA COVID-19 vaccine candidates in Asia emerging markets, including Greater China, Southeast Asia and Pakistan, and (ii) establish a broad, strategic partnership to develop mRNA products globally leveraging Providence's cutting-edge mRNA technology platform ("mRNA Platform").Mon, 13 Sep 2021 00:00:00 Za9b6b238-b224-4305-af72-70b2774b887ehttps://gowlingwlg.com/fr-fr/insights-resources/articles/2021/china-joint-patent-infringement-hearingsIn July 2021, in Guangdong Province (Foshan City), a joint hearing took place to determine patent validity and patent infringement. This was the first time such a joint hearing had been held in Guangdong Province: Does it signal a fundamental change in China's bifurcated patent system? And is it bad news for plaintiffs, good news for defendants? Or too early to tell?Thu, 09 Sep 2021 10:55:00 Zd2e0f3d2-7ff1-489a-8796-f53b3702554ahttps://gowlingwlg.com/fr-FR/insights-resources/reports/2021/post-pandemic-the-road-to-a-true-new-normalWe look to the future and explore what businesses should be aware of post pandemic.Fri, 03 Sep 2021 13:31:00 Z78e1e7e6-b5d6-4655-9ddc-f0d7f4d36bb1https://gowlingwlg.com/fr-FR/insights-resources/articles/2021/is-an-nda-useful-when-doing-business-in-chinaOur global IP team explores the key considerations businesses should make when using NDas in China.Tue, 24 Aug 2021 00:00:00 Z9461b2ce-9506-417d-be00-b2552bd2b745https://gowlingwlg.com/fr-FR/insights-resources/articles/2021/the-great-divide-patent-law-and-antitrustIn his article 'The Great Divide? The interaction of patent law and antitrust in the pharmaceutical markets', first published in the BIO-Science Law Review, IP partner Gordon Harris looks at the position and concludes that the patent system is capable of policing itself.Thu, 12 Aug 2021 10:04:00 Za0219387-614d-4972-b936-573cb40e50cehttps://gowlingwlg.com/fr-FR/insights-resources/articles/2021/federal-court-appeal-pmprb-consumer-protectionIn an important decision released on July 29, the Federal Court of Appeal strongly criticized a decision of the Patented Medicine Prices Review Board (the Board) relating to Alexion's SOLIRIS product.Wed, 04 Aug 2021 12:47:00 Z54b47a5f-6dba-44e3-b3ea-b484cc1edef3https://gowlingwlg.com/fr-FR/insights-resources/articles/2020/brexit-trademarks-10-key-pointsFor trademarks and the law in relation to trademarks, there are some important issues caused by Brexit for businesses to be aware of.Thu, 29 Jul 2021 10:39:00 Z5dcc5b46-55ad-4b1c-9d48-5622490da842https://gowlingwlg.com/fr-FR/insights-resources/articles/2021/fca-upholds-compound-interest-cefaclor-appealIn the latest Cefaclor decision, the Federal Court of Appeal of Canada has upheld the award of compound interest as damages for the time value of money lost, where there is trial evidence to support the award.Tue, 27 Jul 2021 00:00:00 Zf338c801-e535-40cc-a6f5-291b3ada9f50https://gowlingwlg.com/fr-FR/insights-resources/articles/2021/proposed-amendments-canadian-patent-rulesLes modifications proposées aux Règles sur les brevets, que vous pouvez consulter ici, introduiraient, si elles sont mises en œuvre, des taxes sur les revendications excédentaires au-delà de 20 revendications et limiteraient le nombre d’actions officielles à trois.Fri, 09 Jul 2021 00:00:00 Z4470615f-fbcd-4ca9-94b7-f0cb3ecd60f9https://gowlingwlg.com/fr-FR/insights-resources/articles/2021/patented-medicines-regulations-delayed-jan-2022Selon le site Web du Conseil d'examen du prix des médicaments brevetés (CEPMB), la date de l'entrée en vigueur du Règlement sur les médicaments brevetés modifié (le « Règlement ») a de nouveau été reportée de six mois, soit au 1er janvier 2022.Tue, 29 Jun 2021 00:00:00 Zc3451fd0-92d2-4652-a085-d966594787f6https://gowlingwlg.com/fr-FR/insights-resources/videos/2021/patents-vs-registered-industrial-designsBefore applying for a patent or a registered industrial design (or both), it is important to understand the difference between the two.Thu, 24 Jun 2021 13:43:00 Z8466dbe4-aba7-4c62-b76d-c62ba2fb10cchttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2021/eisai-and-advanz-pharm-deal-newsGowling WLG's Life Sciences team has advised Eisai Co., Ltd. on an agreement to divest its rights for the antiepileptic agent Zonegran in Europe and other regions to Advanz Pharma.Wed, 16 Jun 2021 00:00:00 Z14b42aea-5fc7-4500-b683-4dfc4b5c51c0https://gowlingwlg.com/fr-FR/insights-resources/articles/2021/schrodinger-s-seed-drillIf the alleged disclosure takes place in the open, but there is no allegation that it was actually observed, just what actually constitutes a level of disclosure sufficient to invalidate a patent?Thu, 10 Jun 2021 00:00:00 Z6729152c-92de-44f3-a947-e6b518c78334https://gowlingwlg.com/fr-FR/insights-resources/articles/2021/canadian-patent-board-broadening-scope-claimsPar le passé, l’Office de la propriété intellectuelle du Canada (OPIC) s’est opposé à certaines formes de revendications d’« utilisation » thérapeutique au motif qu’il s’agit en fait de revendications liées aux méthodes de traitement et, par conséquent, d’un objet non admissible. Dans deux décisions récentes, la Commission d’appel des brevets (CAB) s’est prononcée en faveur des demandeurs, élargissant ainsi la portée des revendications d’« utilisation » disponibles au Canada et portant sur la posologie.Wed, 26 May 2021 12:18:00 Za89f4d08-035f-4166-bd3b-d501de80042bhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2021/pmprb-seeks-feedback-on-guideline-monitoringLe Conseil d'examen du prix des médicaments brevetés (CEPMB) a annoncé une nouvelle initiative, appelée le Plan de surveillance et d'évaluation des Lignes directrices (PSELD), au moyen de laquelle le CEPMB s'efforcera « de suivre et d'évaluer les tendances du marché pharmaceutique susceptibles d'avoir un impact sur les titulaires de brevets, ainsi que sur les consommateurs, les patients et les payeurs qu'il est chargé de protéger ».Tue, 04 May 2021 00:00:00 Z50d2511b-11e5-4df1-aa1f-c00b3f889515https://gowlingwlg.com/fr-FR/insights-resources/articles/2021/proposed-amendments-to-listing-patents-canadaDes modifications proposées récemment au Règlement modifiant le Règlement sur les médicaments brevetés (avis de conformité) visent à : 1) rendre les brevets comportant des revendications liées à une forme différente de sel d'un ingrédient médicinal approuvé admissibles à l'inscription au Registre des brevets; et 2) fournir une disposition transitoire pour accorder à une première personne une période de temps pour soumettre ou resoumettre un brevet contenant une telle revendication pour inclusion dans le Registre des brevets.Tue, 27 Apr 2021 00:00:00 Z9072842b-0292-4d95-a8c7-a32b2c8c7664https://gowlingwlg.com/fr-FR/insights-resources/articles/2021/understanding-ip-value-history-of-insulinOn the occasion of a World IP Day that is taking place in the midst of a global pandemic, and during the life saving rollout of entirely new vaccine technologies, it is worth commemorating the role that innovation has long played in improving human health.Mon, 26 Apr 2021 00:00:00 Z0381168a-1fbf-4a83-b7b7-6182085d435ahttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2021/lobe-sciences-enters-into-joint-ventureOn April 26, 2021, Lobe Sciences Ltd. entered into an agreement with VPI and certain industry-leading pioneers with respect to the joint design, development and commercialization of a new psychedelic/virtual experience pod – the KrysalisTM Pod.Mon, 26 Apr 2021 00:00:00 Z016ef9b9-6f8b-405d-9e6a-77562ef00bebhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2021/interpretation-of-csp-regulationsDans sa première décision portant sur le Règlement sur les certificats de protection supplémentaire et l’interprétation de sa portée, la Cour d’appel fédérale a jugé raisonnable le refus du ministre de délivrer un certificat de protection supplémentaire (« CPS ») pour un brevet couvrant le SHINGRIX® de GSK.Tue, 20 Apr 2021 00:00:00 Z0f63d17a-57c4-4f55-b0a0-b95813b7887chttps://gowlingwlg.com/fr-FR/insights-resources/reports/2021/business-as-unusualTo better understand the demographics, characteristics, needs and motivations of in-house teams we conducted a survey of GCs and in-house lawyers. Read our overview of the key findings from the survey as we review just how much priorities have shifted since the beginning of 2020.Tue, 20 Apr 2021 00:00:00 Z74206b27-71ec-4e4e-a7cf-6bc9e686f750https://gowlingwlg.com/fr-FR/insights-resources/client-work/2021/first-phase-of-new-homes-for-oxford-northGowling WLG advises on the first phase of new homes for Oxford's new global life sciences districtThu, 08 Apr 2021 00:00:00 Zdb22190b-3370-4db1-9942-3a6a86311b80https://gowlingwlg.com/fr-FR/insights-resources/podcasts/2021/patrick-duxbury-on-the-covid-19-vaccineLegally Vocal sits down with Patrick Duxbury to discuss his involvement in the landmark agreement between AstraZeneca and Oxford University.Mon, 15 Mar 2021 10:56:00 Z89b28e6a-7fdd-4961-a2fb-6f1d1da790f0https://gowlingwlg.com/fr-FR/insights-resources/articles/2021/takeda-wins-canadian-vyvanse-patent-appealThe Federal Court of Appeal has dismissed two appeals brought by Apotex in respect of the validity of certain claims of Takeda’s (as Shire) Canadian Patent No. 2,527,646 which cover, inter alia, lisdexamfetamine (LDX), the active ingredient in Takeda’s ADHD medication VYVANSE®.Fri, 12 Mar 2021 22:52:00 Z1ebe9931-1b70-4dba-a015-24c939a99473https://gowlingwlg.com/fr-FR/insights-resources/client-work/2021/appeals-dismissed-for-vyvanse-patentOn March 11, 2021, the Federal Court of Appeal dismissed two appeals brought by Apotex in respect of the validity of certain claims of Takeda's (as Shire) Canadian Patent No. 2,527,646 (the "646 Patent") which covers, inter alia, lisdexamfetamine (LDX), the active ingredient in Takeda's ADHD medication VYVANSE®.Thu, 11 Mar 2021 00:00:00 Z7d27e535-88fb-4eb5-9011-60068fa30a23https://gowlingwlg.com/fr-FR/insights-resources/articles/2021/federal-court-of-appeal-analysis-advantagesThe Federal Court of Appeal recently dismissed an appeal from Janssen v Apotex, 2019 FC 1355 (Phelan J.) in Apotex v Janssen, 2021 FCA 45.Wed, 10 Mar 2021 00:00:00 Z2c45b8c4-a20a-4cfd-ad8b-d8e70146a6b2https://gowlingwlg.com/fr-FR/insights-resources/articles/2021/statute-of-monopolies-action-dismissedThe Ontario Superior Court of Justice has dismissed a claim brought by Apotex for treble damages and an accounting of the innovative defendants’ profits brought under the Statute of Monopolies, the Trademarks Act, and at common law.Wed, 10 Mar 2021 00:00:00 Zddea8414-5e62-4705-8b55-4af3bb1040cehttps://gowlingwlg.com/fr-FR/insights-resources/articles/2021/eurasian-patent-office-launches-pharma-registerOn March 1, 2021, the Eurasian Patent Office launched the EAPO Pharmaceutical Register. The Register lists Eurasian patents that relate to the active pharmaceutical ingredients of the drugs according to their International Non-proprietary Names (INN).Mon, 08 Mar 2021 14:02:00 Ze0b2a9c2-2792-48f4-9002-bd887cd4512dhttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2021/lobe-sells-cannabis-assets-to-ionic-brandsOn March 8, 2021, Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF), a life sciences company focused on psychedelic medicines, announced that it had completed the previously announced sale to Ionic Brands Corp.Mon, 08 Mar 2021 00:00:00 Z0fa2eb6c-1dd6-4d3a-beae-54ab02ed6064https://gowlingwlg.com/fr-FR/insights-resources/client-work/2021/apotex-claim-dismissedOn March 8, 2021, the Ontario Superior Court of Justice dismissed a claim brought by Apotex for treble damages and an accounting of the innovative defendants' profits brought under the Statute of Monopolies, the Trademarks Act, and at common law. This is the first final decision issued in a series of similar cases currently before the Ontario and Quebec Superior Courts.Mon, 08 Mar 2021 00:00:00 Z30b44581-21fe-4bde-a5ae-05005c1a26d9https://gowlingwlg.com/fr-FR/insights-resources/client-work/2021/elastrin-receives-seed-funding-from-kizooOn March 4, 2021, Kizoo Technology Capital of Germany announced that it had provided seed funding for Elastrin Therapeutics.Thu, 04 Mar 2021 00:00:00 Z127bfef5-b69a-4a30-8207-8bffa160510fhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2021/update-on-pharma-regulatory-russia-2021This article provides an update on pharma regulatory issues in Russia for 2021Fri, 26 Feb 2021 00:00:00 Z8b2a51e5-e7e9-4853-9333-cd7f21516f5chttps://gowlingwlg.com/fr-FR/insights-resources/articles/2021/limitation-period-patented-medicine-regulationsIn the recently issued decision, Merck Sharp & Dohme Corp. v. Sandoz Canada Inc. (2020 FC 1180) Justice Southcott confirmed that a 45-day limitation period does not apply to actions commenced under s. 8.2 of the Patented Medicines (Notice of Compliance) Regulations (the "Regulations").Wed, 17 Feb 2021 00:00:00 Zffd36a6b-c664-4320-b593-fa389f7e6352https://gowlingwlg.com/fr-FR/insights-resources/client-work/2021/canada-contributes-to-precision-nanosystemsOn February 2, 2021, Precision NanoSystems, Inc. ("PNI") announced that it had received a contribution of $25.1 million through the Government of Canada's Strategic Innovation Fund (SIF).Tue, 02 Feb 2021 00:00:00 Z39245029-4526-422f-9ec1-24fe4fc5c5achttps://gowlingwlg.com/fr-FR/insights-resources/articles/2020/brexit-and-trade-secrets-6-key-things-to-knowOn 31 December 2020, the Brexit transition period comes to an end, and significant changes to the law in the UK will take effect.Thu, 28 Jan 2021 10:38:00 Zaa9c2555-b79c-45d9-a184-2f215e7e5d39https://gowlingwlg.com/fr-FR/insights-resources/articles/2021/brexit-and-copyright-6-key-things-to-knowOn 31 December 2020, the Brexit transition period comes to an end, and significant changes to the law in the UK will take effect. For copyright and neighbouring areas of the law, there are some important soundbites for businesses to be aware of – some of which you may already have heard about, while others may be news outside the UK (even for experienced copyright lawyers).Thu, 28 Jan 2021 10:38:00 Zd5a0788b-a14d-4384-98a4-3161188396f9https://gowlingwlg.com/fr-fr/insights-resources/articles/2020/brexit-and-designs-9-key-things-to-knowOn 31 December 2020, the Brexit transition period comes to an end. For designs and the law in relation to designs, there are some important soundbites for businesses to be aware of.Thu, 28 Jan 2021 10:37:00 Z9d8bb56f-169a-4813-af7a-58b363990eeahttps://gowlingwlg.com/fr-FR/insights-resources/articles/2020/brexit-and-patents-key-things-to-knowOn 31 December 2020, the Brexit transition period comes to an end and significant changes to the law in the UK will take effect.Thu, 28 Jan 2021 10:35:00 Z7ae26f73-6a01-47a0-92e6-d86ce7e4f1e7https://gowlingwlg.com/fr-FR/insights-resources/on-demand-webinars/2021/understanding-infringement-and-enforcementAs the scientific community continues to tackle some of the world's most challenging diseases, research and innovation has led to the discovery of new uses for previously known medicines. Patents that cover these new uses are often called "second medical use" patents.Fri, 22 Jan 2021 00:00:00 Zc36a0420-08d5-4997-af2f-21a2cb0c4a4fhttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2021/innodem-closes-series-a-financing-roundLe 19 janvier 2021, Innodem Neurosciences a annoncé qu'elle venait de conclure une ronde de série A dirigée par Morningside Ventures pour soutenir le développement et la commercialisation de sa technologie exclusive brevetée d'analyse numérique des biomarqueurs des maladies neurodégénératives.Tue, 19 Jan 2021 00:00:00 Zb178ed11-69a7-4ca5-98ce-5772d9e88513https://gowlingwlg.com/fr-FR/insights-resources/client-work/2021/gowling-wlg-advises-on-covid-19-projectsGowling WLG's international Life Sciences team has played an important part in the response to COVID-19 – advising on three key projects relating to potential vaccines.Fri, 08 Jan 2021 00:00:00 Zfab92d9f-528b-412b-8535-03243475daf1https://gowlingwlg.com/fr-fr/insights-resources/articles/2020/5g-well-connectedThe idea of connectivity has never been more important. Large parts of the global economy have been mothballed, families kept apart and businesses are operating with limited capacity and workforces scattered across multiple locations, making communication with our families, our places of work and our customers more crucial than ever.Thu, 07 Jan 2021 00:00:00 Zbcc4810b-0da5-4053-9a20-2a7a4fcb9230https://gowlingwlg.com/fr-FR/insights-resources/articles/2020/patented-medicines-regulations-amendmentThe coming-into-force date of the Regulations Amending the Patented Medicines Regulations (the Amendments) has been delayed by 6 months until July 1, 2021.Thu, 31 Dec 2020 00:00:00 Zb3b1ae91-a7c7-4d30-8eda-60b3c3631a5ahttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2020/sosei-heptares-advised-on-gsk-global-agreementGowling WLG's Life Sciences team has advised Sosei Heptares on its global collaboration and license agreement with GlaxoSmithKline to advance the treatment of immune disorders of the digestive system.Tue, 22 Dec 2020 00:00:00 Zf7f87c30-c09d-4f27-8c83-e1635d20e499https://gowlingwlg.com/fr-FR/insights-resources/articles/2020/the-corporate-human-rights-benchmark-key-pointsIn this article, we highlight ways in which the companies included in the Benchmark have been succeeding in their human rights commitments, whilst identifying gaps and challenges that remain.Fri, 18 Dec 2020 14:29:00 Z37c1d283-a356-4420-af50-96da742a3998https://gowlingwlg.com/fr-FR/insights-resources/articles/2020/covid-19-the-scientists-made-me-do-itRon Doering explores why, in the real world of regulatory practice, it's not possible or advisable to separate science, policy and politics.Mon, 14 Dec 2020 15:52:00 Z7ca0b3dd-8a03-4a3a-b455-eb8eaecc94a4https://gowlingwlg.com/fr-FR/insights-resources/client-work/2020/gowling-wlg-advises-on-rua-life-sciences-placingA team of life sciences and corporate finance experts from international law firm Gowling WLG has advised Cenkos Securities (as broker) and Shore Capital (as nominated adviser) on RUA Life Sciences PLC's £6 million fundraise.Mon, 14 Dec 2020 00:00:00 Z01fb590b-c82b-4de8-957d-af4b25a2a8eahttps://gowlingwlg.com/fr-fr/insights-resources/client-work/2020/gowling-wlg-advises-gyrus-capital-on-acquisitionGowling WLG has advised Gyrus Capital (Gyrus), an investment firm dedicated to investments in the healthcare and sustainability sectors, on its agreement to acquire the LivaNova heart valve (HV) business, part of market-leading medical technology and innovation company LivaNova PLC.Wed, 09 Dec 2020 00:00:00 Z9356b66a-d1c0-4ba5-9ce5-a8d7a3d5dd58https://gowlingwlg.com/fr-FR/insights-resources/articles/2020/patenting-antibody-based-biologics-in-canadaA summary of a number of important considerations when drafting claims for patent applications intended to be filed in Canada.Mon, 30 Nov 2020 00:00:00 Zb5506497-fe6e-459e-8715-f3e7afe2b0c8https://gowlingwlg.com/fr-fr/insights-resources/articles/2020/business-and-human-rights-mandatory-due-diligenceBusinesses must prepare for mandatory human rights due diligence requirements in an increasing number of countries. Our experts discuss the UN and EU's latest initiatives in this area.Fri, 27 Nov 2020 00:00:00 Zf28677ad-0b01-4a56-a151-88275b5d6f15https://gowlingwlg.com/fr-FR/insights-resources/client-work/2020/khiron-life-sciences-closes-bought-deal-financingOn November 26, 2020, Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, closed its previously announced "bought deal" short form prospectus offering of units, including the exercise in full of the over-allotment option.Thu, 26 Nov 2020 00:00:00 Z7d2014f2-4953-49e3-b1f0-1e8a116138f4https://gowlingwlg.com/fr-FR/insights-resources/client-work/2020/gowling-wlg-advises-getinge-on-quadralene-dealGowling WLG has acted for Getinge on its acquisition of 100% of the shares of Quadralene, a global manufacturer of decontamination products for the health care and dental sector for an initial £17 million, plus contingent deferred consideration up to £ 2.3 million.Tue, 17 Nov 2020 00:00:00 Zcdbc874d-c9ba-4c8c-98d7-44147e2587cbhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2020/working-with-known-materials-in-the-life-scienceLife science companies who are in the early stages of research often ask 'how will I know if I have something patentable'.Wed, 11 Nov 2020 00:00:00 Z000f4302-f9a6-4cc2-b78c-7e49fc2f408chttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2020/sosei-heptares-advised-on-tempero-bioGowling WLG's global Life Sciences team has advised Sosei Heptares on an agreement with new company Tempero Bio to advance treatments in neurological diseases.Mon, 09 Nov 2020 00:00:00 Z47d9fdcc-3ec2-4ef4-9e8b-66f014ac28f3https://gowlingwlg.com/fr-FR/insights-resources/client-work/2020/precision-nanosystems-to-develop-covid-19-vaccineOn October 22, 2020, Precision Nanosystems, Inc. ("PNI") announced that it had received a commitment of up to $18.2 million from the Government of Canada under the Innovation, Science and Economic Development's (ISED) Strategic Innovation Fund (SIF) to develop a COVID-19 vaccine.Thu, 22 Oct 2020 00:00:00 Zedd4911c-cbcb-4d45-baa3-c8d1a65b7347https://gowlingwlg.com/fr-FR/insights-resources/articles/2020/ten-highlights-of-china-s-new-patent-lawOn 17 October 2020, China approved the fourth amendment to the China Patent Law (CPL), which will take effect on 1 June 2021. It has been 12 years since the last amendment made in 2008, so there a number of notable changes.Wed, 21 Oct 2020 17:36:00 Za0198ccc-19c2-4d47-9277-cd2de32495f2https://gowlingwlg.com/fr-FR/insights-resources/client-work/2020/cenkos-securities-plc-advised-on-proposed-placingGowling WLG advises Cenkos Securities plc on SkinBioTherapeutics plc's proposed placing and open offer to raise up to £4.5 millionThu, 15 Oct 2020 00:00:00 Zf71c9087-2c4f-4e09-8417-50639eebb2d6https://gowlingwlg.com/fr-FR/insights-resources/articles/2020/ip-audits-what-s-in-your-ip-portfolioFundamental to the development of a robust IP strategy is a thorough understanding of the business' IP portfolio, which may include patents, trademarks, copyrights, trade secrets, domain names, and industrial designs. An IP audit provides just such an insight.Wed, 14 Oct 2020 20:42:00 Z1ef753e7-5a17-42d2-9ef9-1f019bd6a327https://gowlingwlg.com/fr-FR/insights-resources/articles/2020/getting-the-most-out-of-pharmaceutical-extensionsThe Russia Patent and Trademark Office (Rospatent) has tightened up its approach to allowing patent-term extensions to pharmaceutical and agrochemical patents. However, a strategic and far-sighted approach can still result in excellent protection.Thu, 10 Sep 2020 00:00:00 Zac29228a-6189-4327-975c-78dfa2b3651ehttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2020/northpond-ventures-co-leads-financing-roundOn August 27, 2020, Triumvira Immunologics Inc. successfully completed a US$55 million Series A financing round. The financing was co-led by Northpond Ventures, LLC and Leaps by Bayer, the impact investment unit of Bayer AG. Additional investors include Oceanpine Capital and Viva Biotech Holdings, and existing investors include Bloom Burton & Co. and the Centre for Commercialization of Cancer Immunotherapy (C3i).Thu, 27 Aug 2020 00:00:00 Zc8863cc3-7d81-4e79-b89b-6351210f8961https://gowlingwlg.com/fr-FR/insights-resources/articles/2020/reliance-on-innovative-drug-data-keyThe Federal Court recently issued its decision in Natco v Canada (Minister of Health), 2020 FC 788, providing useful guidance on the circumstances under which data protection under the Food and Drugs Regulations may be engaged. In particular, the Court commented on when the data protection provisions may be engaged in relation to subsequent products entering the market that contain the same medicinal ingredient as an innovative drug currently benefiting from active data protection.Thu, 13 Aug 2020 13:52:00 Z65d5e540-c054-4233-a2ea-d1b7ca40330ehttps://gowlingwlg.com/fr-FR/insights-resources/articles/2020/covid-19-impacts-on-ip-activity-in-the-courtsIn the UK, COVID-19 is leading to unprecedented adaption by the courts and the UK IPO to audio and video platforms, to enable normal business to continue as far as possible. New rules, guidance and practice seek to maintain access to justice for litigants and the public nature of hearings, including in intellectual property disputes, as Lydia Birch and Kate Hawkins explain.Mon, 10 Aug 2020 10:21:00 Za4c368d1-032e-4b28-97d0-11a20451d5cfhttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2020/astrazeneca-advised-on-collaboration-agreementGowling WLG advises AstraZeneca on collaboration to develop and commercialise a new antibody drug conjugate for treating multiple tumour types.Fri, 07 Aug 2020 00:00:00 Z91f5c0c5-3a02-40b5-9b3a-a0a8d90b60d2https://gowlingwlg.com/fr-fr/insights-resources/articles/2020/key-covid-19-considerations-for-your-businessThis document provides the latest updates on four key areas - contracts, employment, insolvency & director duties and government economic support - across multiple jurisdictions.Tue, 04 Aug 2020 17:52:00 Z43249bf6-7722-418e-904a-f36f81eeb356https://gowlingwlg.com/fr-FR/insights-resources/on-demand-webinars/2020/strategies-for-patent-litigation-claimants-viewIn the sixth and seventh episodes in our series, 'Lifecycle of a Smart Idea', Gowling WLG's IP professionals from around the world examine patent litigation strategy in the early stages.Mon, 27 Jul 2020 00:00:00 Z6e992730-5dd1-495e-8b2b-19dacec7bba5https://gowlingwlg.com/fr-FR/insights-resources/articles/2020/uk-merger-control-part-twoFurther to the UK government's recent addition of a new public interest criterion under the UK merger control regime, further revisions to the regime have now been enacted.Thu, 23 Jul 2020 00:00:00 Z83825a06-40b4-4c67-bc93-6a90b549966fhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2020/health-canada-s-interpretation-of-csp-rejectedIn April, the Federal Court issued its first decision interpreting the Certificate of Supplementary Protection Regulations in GlaxoSmithKline biologicals SA v Canada (Health), 2020 FC 397, where Justice Barnes stressed the importance of an interpretation that was consistent with the purpose and intent of the Canadian European Trade Agreement.Wed, 22 Jul 2020 15:46:00 Z3ef7f6cc-c720-4ad4-bf1b-64a5ae92dd74https://gowlingwlg.com/fr-FR/insights-resources/articles/2020/competition-bureau-role-in-regulating-food-claimsFood companies should pay attention to recent action by the Competition Bureau (the "Bureau"), as it may signal that the Bureau intends to take a more active role in regulating claims and advertising with respect to regulated products, such as foods.Tue, 21 Jul 2020 20:31:00 Ze0f77cd6-495c-4864-b1e8-151dd21d37b8https://gowlingwlg.com/fr-FR/insights-resources/articles/2020/covid-19-and-the-food-industryWhile I write this in early April, every industry is being profoundly affected by the global COVID-19 pandemic; our food and restaurant sectors are among those that have been hit the hardest. The media has concentrated on issues relating to our grocery stores and disruptions to the food supply chain. The current pandemic also raises many policy and legal questions that are not so obvious, some that require urgent attention and some that we will have to struggle with in the longer term after this crisis subsides.Tue, 21 Jul 2020 20:22:00 Z0a710758-3bae-4e97-be2a-0d6584fb691ehttps://gowlingwlg.com/fr-FR/insights-resources/articles/2020/proposed-changes-to-voluntary-canada-claimsThe government's recent proposal to update the guidelines for voluntary 'Product of Canada' and 'Made in Canada' claims could improve Canadian competitiveness and the clarity of information provided to consumers.Tue, 21 Jul 2020 20:21:00 Zb6f30d4e-6c94-4a57-9c47-a2a0d81b99fahttps://gowlingwlg.com/fr-FR/insights-resources/articles/2020/uk-merger-control-key-legal-considerationsWhen planning a transaction, it is increasingly important for parties to consider fully the potential application of merger control regimes worldwide.Tue, 14 Jul 2020 14:46:00 Za37ee858-2266-4a2d-a080-1e15ca8faaadhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2020/supply-contracts-under-the-new-cigaSupply contracts typically contain terms that allow suppliers to terminate their customer relationship on the customer's insolvency.Thu, 02 Jul 2020 08:44:00 Z15eea8da-d224-430e-949e-a74f1f3634a5https://gowlingwlg.com/fr-FR/insights-resources/client-work/2020/sosei-heptares-collaboration-with-abbvieGowling WLG advises Sosei Heptares on global collaboration with AbbVie.Wed, 01 Jul 2020 00:00:00 Z09a98ec8-3e10-4c61-b7a0-9660811e593chttps://gowlingwlg.com/fr-FR/insights-resources/articles/2020/uk-merger-control-and-government-interventionThe UK government recently made and proposed revisions to the UK merger control regime, which are intended to increase its ability to intervene in transactions and investments affecting certain aspects of the UK economy.Thu, 25 Jun 2020 00:00:00 Z1fa4472a-45a9-407e-b39f-daedcfe62236https://gowlingwlg.com/fr-FR/insights-resources/articles/2020/upheaval-for-patent-law-of-sufficiency-from-the-ukThe UK Supreme Court (UKSC) has handed down its judgment in patent dispute Regeneron Pharmaceuticals Inc v Kymab Ltd ([2020] UKSC 27 (24 June 2020), making key rulings for the law of 'sufficiency'.Thu, 25 Jun 2020 00:00:00 Z5b54c3db-93a6-406b-9063-549ed647a950https://gowlingwlg.com/fr-FR/insights-resources/on-demand-webinars/2020/patent-strategy-optimizing-life-sciences-patentsThird on-demand webinar in our 'Lifecycle of a Smart Idea' series exploring the scope of patent protection across jurisdictions.Tue, 23 Jun 2020 00:00:00 Zaa0ea6a6-f291-4cc2-8e75-b060cf404a82https://gowlingwlg.com/fr-FR/insights-resources/on-demand-webinars/2020/trade-secrets-international-protection2nd Webinar in our "Lifecycle of a Smart Idea" series with a closer look at protecting trade secrets.Mon, 08 Jun 2020 00:00:00 Z2e28018d-b0eb-4e84-825d-4a17a04cdf6ehttps://gowlingwlg.com/fr-FR/insights-resources/articles/2020/infringement-action-under-pm-noc-regulationsIn a recently released decision (2020 FC 635), Justice O’Reilly held that patent infringement actions taken under section 6(1) of the Patent Medicines (Notice of Compliance) Regulations do not become moot if the action is not heard or decided before the patent(s) at issue expires.Fri, 05 Jun 2020 00:00:00 Z3a334c0f-43ae-441a-8775-5680f726ce5chttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2020/astrazeneca-and-university-of-oxford-collaborationGowling WLG a conseillé AstraZeneca dans le cadre d'un accord de collaboration historique pour le développement et la distribution du vaccin potentiel COVID-19 de l'Université d'Oxford.Wed, 03 Jun 2020 00:00:00 Z99ae6923-915a-415d-903d-8080e121efcahttps://gowlingwlg.com/fr-FR/insights-resources/videos/2020/a-message-from-our-global-life-sciences-groupAs global efforts to contain COVID-19 are giving biotechnology and biopharmaceuticals a key role on the world stage, we understand that staying connected as a sector is more important than ever.Wed, 03 Jun 2020 00:00:00 Z97c2aafc-0c8b-4427-9020-e7c3a4e434d6https://gowlingwlg.com/fr-FR/insights-resources/articles/2020/protection-of-secrets-in-patent-infringementThe need to strengthen procedural protection of trade secrets in patent infringement proceedings has recently taken shape. Speech is silver, but silence is golden.Tue, 02 Jun 2020 00:00:00 Z3c7aa538-686d-44c4-a748-27e57f250851https://gowlingwlg.com/fr-FR/insights-resources/articles/2020/will-covid-19-usher-a-new-normal-for-pensionsWill COVID-19 usher in a 'new normal' in pensions? Or will it accelerate trends that were already evident before the crisis?Wed, 20 May 2020 00:00:00 Z66f3d7c3-ec25-4b24-8ba3-d4302879528ahttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2020/precision-cansino-co-develop-covid-19-vaccineOn May 20, 2020, CanSino Biologics Inc. and Precision NanoSystems, Inc. announced a co-development agreement of an mRNA lipid nanoparticle vaccine against COVID-19.Wed, 20 May 2020 00:00:00 Ze8c0c318-4b26-4ab2-9682-5f10c67a3e54https://gowlingwlg.com/fr-FR/insights-resources/on-demand-webinars/2020/to-patent-or-keep-secretGiven the frenetic pace of today's innovation lifecycle, do patents always afford the best protection of proprietary inventions?Thu, 14 May 2020 00:00:00 Z06659dbd-b5c6-4129-aca4-a509930c7c30https://gowlingwlg.com/fr-FR/insights-resources/articles/2020/six-months-to-claim-millions-in-duty-refundsThe COVID-19 pandemic is leading legal teams to consider innovative ways of delivering cost savings and increasing revenues. Free Trade Agreements ("FTAs") may be an unexpected source of cash for UK exporters.Tue, 12 May 2020 15:49:00 Z6c892683-92c6-400e-9bae-d7e796ae5c61https://gowlingwlg.com/fr-FR/insights-resources/articles/2020/manufacturing-face-masks-during-covid-19En dépit des changements apportés au régime réglementaire concernant les masques de protection, il est nécessaire que la clarté de l'étiquetage et la sécurité demeure une priorité pour les fabricants afin d'éviter des réclamations en responsabilité du fait des produits et des conséquences réglementaires.Tue, 05 May 2020 00:00:00 Z798f29ff-5d7c-49b6-93fb-a62186ecbb1bhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2020/pharma-regulatory-amendments-in-russia-covid-19The Law on the Introduction of Amendments to Certain RF Laws Concerning the Prevention and Liquidation of Emergency Situations has now come into force, amending several laws related to the circulation and registration of medicines and medical devices in Russia.Thu, 23 Apr 2020 00:00:00 Zb89ce5e2-a495-4b45-a8f3-1966705ce071https://gowlingwlg.com/fr-fr/insights-resources/articles/2020/federal-court-supports-broad-interpretation-cspThe Federal Court has released the first Judicial Review decision addressing the Certificate of Supplementary Protection Regulations, in a case pertaining to a refusal by the Minister of Health to award a CSP to Glaxosmithkline Biologicals for a patent covering its SHINGRIX® product.Thu, 09 Apr 2020 00:00:00 Z186d1479-0ac5-4097-845c-f5a3ef271c15https://gowlingwlg.com/fr-FR/insights-resources/articles/2020/developments-in-arrow-declarationsArrow relief continues to develop in the law of the UK, with the Court of Appeal recently refusing to strike out claims for a much broader declaration than has previously been granted.Thu, 09 Apr 2020 00:00:00 Z9c228651-ac14-4127-af43-ab5cb2ade0dchttps://gowlingwlg.com/fr-FR/insights-resources/articles/2020/amendments-affecting-pharmaceuticals-in-russiaRussia's Law on the Circulation of Medicines is probably one of the country's most frequently amended laws - and certainly one of its most debated. However, new amendments introduced in December concerning obligatory marking have been largely welcomed by the local pharmaceutical community.Fri, 03 Apr 2020 14:28:00 Z306385dc-9736-4f48-b3ad-9f1ca56d6fb3https://gowlingwlg.com/fr-fr/insights-resources/articles/2020/trade-secrets-directive-has-not-changedSince the implementation of the Trade Secrets Directive in 2018, there has been a question in the UK about the extent to which the protection for confidential information provided by the common law has been impacted.Fri, 03 Apr 2020 13:42:00 Z6a4c13e5-f188-4cee-a4dd-fbb5c84f7a61https://gowlingwlg.com/fr-fr/insights-resources/articles/2020/covid-19-processing-personal-dataGovernment, public, and private organisations are urgently taking measures to contain and mitigate the virus, some of which have implications on the processing of personal data.Fri, 03 Apr 2020 00:00:00 Zd5788024-9233-48e4-b8c5-6f9abcc88a47https://gowlingwlg.com/fr-fr/insights-resources/articles/2020/covid-19-and-uk-merger-controlAlthough many companies have put their 'pre-crisis' acquisition plans on hold, the fallout from the current outbreak is likely to present certain companies with opportunities to acquire distressed firms, or the assets of such firms.Wed, 01 Apr 2020 10:01:00 Z82201270-0dc1-4db7-9617-a8daf029db90https://gowlingwlg.com/fr-fr/insights-resources/articles/2020/covid-19-coronavirus-job-retention-scheme-detailWhen reading the HMRC Guidance it is important to remember that the guidance is for what employers can claim via the Scheme not guidance on employee rights. Here we look at the key points of guidance and highlight some of the employment law issues raised as a result.Mon, 30 Mar 2020 12:42:00 Z6eba90ce-f819-407d-a0f2-48c28ff90de1https://gowlingwlg.com/fr-FR/insights-resources/articles/2020/pay-the-correct-spc-fee-or-risk-expiryInga Pietsch and Huw Evans explain the need for fully informed and careful compliance with administrative requirements for SPCs, which are national in nature.Fri, 27 Mar 2020 10:22:00 Zc0acf6e5-0a6e-4906-ab95-23b0231cc174https://gowlingwlg.com/fr-FR/insights-resources/articles/2020/covid-19-uk-holiday-leave-permissible-carry-overOn 27 March the Government amended the Working Time Regulations 1998 (WTR) to allow carry forward of up to four weeks accrued holiday leave.Fri, 27 Mar 2020 00:00:00 Zf0901477-6eda-4f1e-af42-5580b9ba8716https://gowlingwlg.com/fr-fr/insights-resources/articles/2020/covid-19-amendments-to-the-patent-actAprès de longues délibérations, le gouvernement fédéral a adopté une loi d'aide en réponse à la pandémie de la COVID-19 (Loi concernant certaines mesures en réponse à la COVID-19). Cette loi a obtenu la sanction royale à 13 h 30 environ, le 25 mars dernier.Thu, 26 Mar 2020 00:00:00 Zaca6c2c5-02e3-4d09-91ac-40f9872aab96https://gowlingwlg.com/fr-fr/insights-resources/articles/2020/covid-19-coronavirus-job-retention-schemeWe look at how the 'Job Retention Scheme' proposed by Chancellor, Rishi Sunak, will affect employers and employees.Mon, 23 Mar 2020 14:10:00 Z67781ece-1488-4fca-b480-d9a85b10cf02https://gowlingwlg.com/fr-FR/insights-resources/articles/2020/german-constitutional-court-delays-upcIn Germany, the Federal Constitutional Court (Bundesverfassungsgericht) has held that the statute by which the German Parliament (Bundestag) sought to ratify the UPC Agreement (the 'Act of Approval') is void.Fri, 20 Mar 2020 00:00:00 Zb5a56512-93fe-4950-aaa1-e8184b76a21chttps://gowlingwlg.com/fr-FR/insights-resources/articles/2020/covid-19-virtual-health-care-services-canadaDans le sillage de la maladie à coronavirus (COVID-19), les professionnels de la santé multiplient les efforts afin d'éviter toute interruption de service ou toute détérioration dans la qualité des soins offerts aux patients. Le ministère de la Santé de l'Ontario a publié un document d'orientation à l'intention du secteur de la santé en vue d'aider les établissements concernés à minimiser le risque d'infection au sein de leurs pratiques respectives.Mon, 16 Mar 2020 00:00:00 Z018b0ee9-4703-4dd4-8a1c-755fcea97445https://gowlingwlg.com/fr-fr/insights-resources/articles/2020/how-to-restart-business-operations-china-covid-19Depuis la fin janvier 2020, l'éclosion rapide de COVID-19 et les mesures drastiques prises par les autorités chinoises pour endiguer l'épidémie ont causé d'importantes perturbations touchant la vie quotidienne, les dépenses des consommateurs, l'activité commerciale et manufacturière, les chaînes d'approvisionnement et la logistique. Cette situation a entraîné un bouleversement de l'économie de la Chine qui, par effet d'entraînement, a eu des répercussions ressenties dans le monde entier.Thu, 27 Feb 2020 12:32:00 Zd4271043-a66b-4ef9-be82-2d7d2a751500https://gowlingwlg.com/fr-FR/insights-resources/articles/2020/canadian-patent-law-2019-year-in-reviewThere were various developments in Canadian patent law in 2019. Numerous decisions of the Federal Court of Appeal and Federal Court will have a notable impact on patent law in Canada going forward. In addition, the Patent Rules were the subject of significant amendments that will impact both prosecution and enforcement of patent rights in Canada for years to come.Wed, 26 Feb 2020 00:00:00 Ze747b832-6549-4ab5-a6a1-508af21209fdhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2020/ir35-review-announced-but-date-unchangedThe existing public sector restrictions and rules on off-payroll working (IR35) will be extended to medium and large private sector employers from 6th April 2020.Thu, 09 Jan 2020 11:20:00 Z23ff5c2e-c0e5-4fbe-9cef-2104197ba5e5https://gowlingwlg.com/fr-FR/insights-resources/client-work/2020/canadian-hospital-specialties-acquires-carestreamOn Jan. 6, 2020, Canadian Hospital Specialties Limited ("CHS") announced the acquisition of Canadian operations of CAREstream Medical, the leader in the field of respiratory and anesthesia solutions and supplies.Mon, 06 Jan 2020 00:00:00 Z37733f1a-1b83-4b73-8c5b-e4119f0d2a79https://gowlingwlg.com/fr-FR/insights-resources/client-work/2019/gowling-wlg-advises-sosei-heptares-on-strategic-paGowling WLG's award-winning Life Sciences team has advised long-standing client Sosei Heptares on its strategic multi-target partnership with Takeda Pharmaceutical Company Limited (Takeda).Fri, 06 Dec 2019 00:00:00 Z749f2898-08cf-49b5-a639-77d5b8eda8f5https://gowlingwlg.com/fr-FR/insights-resources/articles/2019/dismissing-an-employee-maternity-payOur employment and equalities experts consider the SMP tricky issues including 'bonus babies', 'offsetting' and 'exit packages'.Tue, 26 Nov 2019 11:29:00 Z3980d350-26a8-4616-8034-950181130ef4https://gowlingwlg.com/fr-FR/insights-resources/articles/2019/precast-concrete-cartel-and-the-cmaThe UK CMA has imposed fines of more than £36 million upon three suppliers of precast concrete drainage products for an infringement of UK and EU competition law.Wed, 06 Nov 2019 00:00:00 Zc4ea666b-0fe1-4935-a006-bc864a1adf0ehttps://gowlingwlg.com/fr-FR/insights-resources/articles/2019/shanks-v-unileverThe UK Supreme Court has awarded an employee (Mr Shanks), whose inventions led to patents that were of 'outstanding benefit' to his employer (Unilever), compensation of £2 million as a 'fair share' of that benefit.Fri, 25 Oct 2019 14:24:00 Z24dfa7f4-70d5-4aac-a600-6fad171da87chttps://gowlingwlg.com/fr-FR/insights-resources/articles/2019/how-to-ensure-your-supply-chain-is-brexit-readyThis article is intended to help you identify where your key risks are and what you should do.Wed, 09 Oct 2019 14:22:00 Z450dae5e-8414-46bc-867b-9dde04bec225https://gowlingwlg.com/fr-fr/insights-resources/articles/2019/drug-manufacturers-challenge-pmprb-legislationTwo recent legal challenges have been launched attacking the federal government's system of price regulation of patented medicines. The stakes could not be higher.  Recent amendments to the regulations have fundamentally changed the system in ways that we believe will be damaging to manufacturers, Canada's health care system, and to Canadians.Tue, 24 Sep 2019 00:00:00 Z96da5f73-815e-4326-b843-997a2bc4425ahttps://gowlingwlg.com/fr-FR/insights-resources/articles/2019/ip-strategy-the-4-signs-you-re-nailing-itCompare your company's IP strategy against your competitors with Gowling WLG's online benchmarking tool.Tue, 17 Sep 2019 10:17:00 Z8d48ecfd-194c-40eb-8c46-af5c9ddfbbb3https://gowlingwlg.com/fr-FR/insights-resources/articles/2019/dazed-and-confused-a-closer-look-at-the-amended-pSi l'annonce, vendredi dernier, des modifications apportées au Règlement sur les médicaments brevetés (le « RMB ») n'a pas causé de véritable surprise, elle a cependant mis en évidence la profonde incertitude avec laquelle doivent composer les brevetés qui commercialisent des médicaments au Canada.Thu, 15 Aug 2019 00:00:00 Zb103ea2f-dcfb-42b5-a3bf-508ceaa8143dhttps://gowlingwlg.com/fr-fr/insights-resources/client-work/2019/sosei-heptares-strategic-partnership-with-takedaGowling WLG's Life Sciences team has advised long-standing client Sosei Heptares on its strategic multi-target partnership with Takeda Pharmaceutical Company Limited.Fri, 09 Aug 2019 00:00:00 Z1f073425-95d9-4e4f-873f-cc6df7310bb8https://gowlingwlg.com/fr-FR/insights-resources/articles/2019/pmprb-shakeup-united-states-and-switzerland-no-lThe federal government has announced the long-awaited changes to the Patented Medicines Regulations, which are set to come into force on July 1, 2020.Fri, 09 Aug 2019 00:00:00 Zd16544c0-bab7-4598-b0fd-23aff3455e0fhttps://gowlingwlg.com/fr-fr/insights-resources/articles/2019/the-importance-of-ip-rights-in-technologyOur intellectual property experts consider the importance of IP rights in technology during disruptive times.Thu, 25 Jul 2019 00:00:00 Zc004103a-d123-4fab-844d-77d1f8aad86bhttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2019/gowling-wlg-advises-sosei-heptaresGowling WLG's award-winning Life Sciences team has advised long-standing client Sosei Heptares on a drug research collaboration and license agreement with Genentech.Fri, 19 Jul 2019 13:40:00 Ze0a3d6ab-ba85-4028-a4c2-d4e1a9df3514https://gowlingwlg.com/fr-FR/insights-resources/articles/2019/why-the-c-suite-and-ip-team-should-talkIntellectual property is growing in importance and should no longer be seen as just a legal issue by the C-suite.Tue, 02 Jul 2019 14:48:00 Zd49700e5-ad46-413d-b1e5-3d52a2393c4ehttps://gowlingwlg.com/fr-FR/insights-resources/articles/2019/disruptive-technology-examplesOur experts explore the different disruptive technology examples that are set to bring change to business as we know it.Thu, 16 May 2019 11:56:00 Z8f6b32dc-03fd-4776-a3b7-35dd2465b30ehttps://gowlingwlg.com/fr-FR/insights-resources/articles/2019/ai-driven-products-require-new-regulationAlors que les entreprises privées et les organismes gouvernementaux continuent d’envisager les perspectives prometteuses et les défis liés aux produits dotés d’intelligence artificielle (IA) qui prolifèrent sur le marché, il n’est pas étonnant que la réglementation de ces produits suscite de plus en plus d'inquiétudeTue, 14 May 2019 00:00:00 Zb0d2a92f-f651-4658-8e7a-ce9081b5c9c4https://gowlingwlg.com/fr-FR/insights-resources/podcasts/2019/international-data-breach-strategiesThe introduction of the GDPR has seen a surge in breaches being notified to regulators and many further breaches being reported in the media.Thu, 02 May 2019 11:45:00 Zab801b3e-7a32-44de-97da-1c9d88522b6fhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2019/health-canada-medical-device-regulationsIn late 2018, a series of news articles took aim at Canada's regulation of medical devices, alleging that Health Canada's medical device approval and adverse event monitoring systems were severely lacking. This article will provide an update regarding steps Health Canada has now taken to tighten up regulation of medical devices.Wed, 24 Apr 2019 00:00:00 Z0d5c323e-e461-4774-87b1-1969c99e453ahttps://gowlingwlg.com/fr-FR/insights-resources/articles/2019/innovative-drugs-data-protection-in-canadaInnovative drugs in Canada are granted data protection, preventing generic competition for a period of eight years following their initial approval.Tue, 16 Apr 2019 12:00:00 Z3e6e3c6a-f302-4db3-90e4-8288b2411a0dhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2019/law-improve-accessibility-to-marketing-authorizeTue, 16 Apr 2019 00:00:00 Zcd44ebed-f211-49a3-a243-96df9a49de25https://gowlingwlg.com/fr-FR/insights-resources/client-work/2019/gowling-wlg-advises-astrazeneca-on-collaborationGowling WLG's life sciences experts have advised long-standing client AstraZeneca on a $6.9 billion cancer drug collaboration agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo).Fri, 05 Apr 2019 00:00:00 Z53a2a91b-e82f-4de9-ade4-c239e72c2fbahttps://gowlingwlg.com/fr-FR/insights-resources/articles/2019/uk-supreme-court-explains-the-law-of-obviousnessThe UK Supreme Court has delivered an important judgment on the test of 'obviousness' in patent law, and in particular for dosing regimen patents.Tue, 02 Apr 2019 00:00:00 Z55b847d8-9d9d-4548-b493-f1712c4d984chttps://gowlingwlg.com/fr-FR/insights-resources/articles/2019/should-your-business-invest-in-blockchainShould businesses invest in blockchain technology to benefit their operations and processes? We explore how it is making an impact across industries.Thu, 21 Mar 2019 13:20:00 Ze2f2dcfe-9f36-4c84-810b-ec5be00be60bhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2019/risks-facing-acquiring-companiesOn 14 March 2019, the Court of Justice delivered a landmark judgment regarding the liability of acquiring companies to compensate third parties for infringements of EU competition law committed by acquired companies.Mon, 18 Mar 2019 00:00:00 Z707048cc-98f0-44bb-a886-dd0bf61485c6https://gowlingwlg.com/fr-FR/insights-resources/client-work/2019/gowling-wlg-aid-argenx-and-halozyme-collaborationGowling WLG's life sciences team has acted for clinical-stage biotechnology company argenx in its global collaboration and license agreement with Halozyme.Fri, 15 Feb 2019 00:00:00 Z4a0e9a81-66c8-41c9-a65a-2a4cef5e0dd3https://gowlingwlg.com/fr-FR/insights-resources/articles/2019/how-to-avoid-a-fine-when-a-data-breach-occursHow can companies avoid paying large fines when they have a data breach? Sheena Jacob explores a recent case in Singapore.Thu, 24 Jan 2019 10:30:00 Z69c7ba52-e15a-4abb-94be-2368d0fb85f0https://gowlingwlg.com/fr-FR/insights-resources/articles/2019/gdpr-challenges-of-using-aiGowling WLG's experts look at how the current laws on data protection laws already impact the way that organisations can harness the power of AI.Mon, 21 Jan 2019 11:54:00 Zc99ea383-59fe-4120-8376-edcc99851823https://gowlingwlg.com/fr-FR/insights-resources/articles/2019/changes-to-the-uk-s-trademarks-lawThe EU Trademarks Directive 2015 comes into force in the UK; bringing with it some key changes to the UK's legal system governing the application, registration, enforcement and licensing of trademarks.Mon, 14 Jan 2019 00:00:00 Z62515acc-a0f5-431e-b85b-fdb198049b22https://gowlingwlg.com/fr-FR/insights-resources/articles/2019/brexit-cross-border-trade-challengesThe customs and trade perspectives have never been more important to consider, as the potentail for a no-deal Brexit intensifies.Fri, 11 Jan 2019 00:00:00 Z85950000-fd40-40e0-a420-8438e5bc9119https://gowlingwlg.com/fr-FR/insights-resources/podcasts/2018/digital-protectionism-trade-and-the-wtoGowling WLG discusses the modernisation needed in order to tackle the challenges presented to free trade by both traditional and digital protectionism.Wed, 19 Dec 2018 00:00:00 Z1460da15-d74d-4225-a921-13749147208fhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2018/gsk-awarded-arrow-declaration-in-patent-disputeGowling WLG's IP experts discuss GSK's High Court patent dispute with Vectura.Thu, 13 Dec 2018 00:00:00 Z8dfbbf03-f175-4780-8012-8803ec818ae6https://gowlingwlg.com/fr-FR/insights-resources/on-demand-webinars/2018/it-masterclass-gdpr-updateGowling WLG's IT Masterclass webinar gives a legal update on GDPR six months on.Fri, 30 Nov 2018 00:00:00 Ze94ea64a-fab4-471d-b50e-90952be171efhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2018/uk-supreme-court-ruling-in-warner-lambert-caseThe UK Supreme Court's judgment in Warner-Lambert v Generics has, sadly, unsettled areas of patent law in the UK, while confirming the invalidity of key claims of Warner-Lambert's patent.Wed, 21 Nov 2018 00:00:00 Z8147aa36-c7c8-47cf-a076-26eaf12e6e70https://gowlingwlg.com/fr-FR/insights-resources/client-work/2018/life-sciences-team-acts-for-immunocoreInternational law firm Gowling WLG has acted for leading T Cell Receptor (TCR) biotechnology company, Immunocore, on its transaction with Genentech relating to Immunocore's developmental cancer drug IMC-C103C.Tue, 20 Nov 2018 09:22:00 Zcbcc8bee-08fb-47bd-b52d-7a8d1e468ef3https://gowlingwlg.com/fr-FR/insights-resources/articles/2018/warner-lambert-pregabalin-patent-caseGowling WLG's IP team provides a snap-shot commentary on the Supreme Court's reasoning in the Warner-Lambert case.Wed, 14 Nov 2018 00:00:00 Zd2b2b3f3-bb10-4e37-918d-9555d92f673fhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2018/new-at-gowling-wlg-customs-tradeIn five months, the UK is due to leave the EU and the 145,000 VAT-registered UK businesses that currently trade only with the EU will become importers and exporters.Tue, 06 Nov 2018 15:15:00 Z36bb9fbf-3053-4a03-9648-355458940a4ahttps://gowlingwlg.com/fr-FR/insights-resources/podcasts/2018/understanding-electronic-signaturesWhat are E-signatures, how do they work and what does best practice look like? David Lowe shares his insight into this important topic and provides practical guidance on using E-signatures to manage your day-to-day commercial contracts.Mon, 05 Nov 2018 15:57:00 Z6479f0e0-0c3f-497f-aa65-e43e5bc23224https://gowlingwlg.com/fr-FR/insights-resources/podcasts/2018/customs-trade-compliance-brexit-preparationIn this session we strip back the debate to identify the challenges business will face, and provide practical guidance on how to navigate the post Brexit customs landscape.Wed, 10 Oct 2018 00:00:00 Zff25bc78-a1b7-498a-b413-13f32f988285https://gowlingwlg.com/fr-FR/insights-resources/podcasts/2018/blockchain-the-ultimate-disruptorBlockchain technology is changing the landscape in a major way. However, this innovative technology comes with highly complex laws and processes that require sophisticated legal and technical expertise, and an insider's understanding of the ever-evolving regulatory space.Wed, 10 Oct 2018 00:00:00 Z78a1bf15-e891-4940-b2c3-6298d1865555https://gowlingwlg.com/fr-FR/insights-resources/articles/2018/usmca-what-it-means-for-patents-and-pharmaceuticalIn a joint statement on Sept. 30, 2018, the United States and Canadian Governments announced that they reached an agreement, alongside Mexico, on a new, modernized trade agreement for the 21st century. The pending trilateral deal, called the United States-Mexico-Canada Agreement (USMCA), is intended to replace the North American Free Trade Agreement (NAFTA) currently in force.Fri, 05 Oct 2018 00:00:00 Z5477c5cb-b757-453e-a362-29914c7853a5https://gowlingwlg.com/fr-FR/insights-resources/articles/2018/brexit-and-state-aidThis guide looks at what the post-Brexit state aid regime may look like and what this means for business.Wed, 26 Sep 2018 00:00:00 Zfdccc7d2-561a-4015-9fd8-a863a1b043c8https://gowlingwlg.com/fr-FR/insights-resources/articles/2018/uk-government-no-deal-brexit-guidance-for-ipThe UK Government has released guidance on the Brexit process for intellectual property in a no deal scenario. UK legislation will extract UK rights from existing EU-wide trademark and design registrations. The UK will continue to recognise existing unregistered Community design right and will create a new unregistered design right of equivalent scope. For the "immediate" term, the UK will also continue to recognise regional exhaustion (but the European Economic Area (EEA) will not recognise the UK within that system). The existing patent systems will largely be unaffected by Brexit. Please read on for our fuller summary of the highlights of the 24 September 2018 guidance.Tue, 25 Sep 2018 00:00:00 Z70c5671c-9f55-4201-a29d-b1d00141c8bchttps://gowlingwlg.com/fr-FR/insights-resources/articles/2018/brexit-what-will-it-mean-for-dispute-resolutionGowling WLG's Brexit Taskforce look at what the UK Government's Brexit white paper, the future relationship between the United Kingdom and the European Union, means for dispute resolution.Tue, 28 Aug 2018 09:04:00 Z31db5058-2f73-43a6-b54a-5fc611d47ff7https://gowlingwlg.com/fr-FR/insights-resources/articles/2018/competition-law-director-disqualificationThe UK competition authority is consulting on proposed changes to its current guidance on director disqualification in competition law cases.Fri, 10 Aug 2018 00:00:00 Z9a3e2fee-f6df-4bfa-8758-ec13728a6d0fhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2018/liable-for-violations-by-overseas-subsidiariesWhen will a parent company in the UK be held accountable for human rights failings by its subsidiaries in other countries? Will having a global human rights policy leave the parent company more exposed?Thu, 09 Aug 2018 10:59:00 Zada648f6-a986-4c01-b699-2c9605ea4fb2https://gowlingwlg.com/fr-FR/insights-resources/articles/2018/shorter-trials-schemeIP partner John Coldham looks back at the aims and achievements of the Shorter Trials Scheme pilot, which has been running in the High Court since October 2015, and considers how litigants may successfully make the most of the scheme.Wed, 08 Aug 2018 14:24:00 Zcf385d55-73b5-4a8d-8920-2c227504025ehttps://gowlingwlg.com/fr-FR/insights-resources/podcasts/2018/the-contract-law-lifecycleAt our most recent ThinkHouse Foundations event, Associate, Alex Wrixon, from our Commercial Litigation team gave an update on the latest developments in contracts law, looking at how key cases have a bearing on the 'contract lifecycle'.Mon, 06 Aug 2018 14:42:00 Z4e1bd83f-021d-45a0-9883-df696cbd005ahttps://gowlingwlg.com/fr-FR/insights-resources/articles/2018/uk-merger-control-requests-for-informationThe UK competition authority (the CMA) has recently imposed fines for procedural breaches of the UK merger control regime. Given the risks of non-compliance (including fines, and possible criminal sanctions), this update outlines key issues to be considered when engaging with the CMA.Thu, 02 Aug 2018 00:00:00 Z7c0bde74-44ac-459a-b752-bec33221e576https://gowlingwlg.com/fr-FR/insights-resources/articles/2018/employment-essentials-july-2018What issues will affect your business in July 2018? Our employment, labour & equalities experts bring you the latest legal developments.Wed, 01 Aug 2018 00:00:00 Zc993461c-ae06-4b25-992e-cd1ca4637a15https://gowlingwlg.com/fr-FR/insights-resources/articles/2018/the-eu-withdrawal-act-what-you-need-to-knowLe 26 juin, la loi sur le retrait de l’Union Européenne soit la EU (Withdrawal) Act 2018 ou EUWA (la « Loi ») a reçu la sanction royale. Cette nouvelle loi vise à éviter un vide juridique lorsque les lois qui s’appliquent actuellement au Royaume-Uni en raison de son adhésion à l’Union Européenne (l’« UE ») disparaîtront après le Brexit.Thu, 05 Jul 2018 00:00:00 Ze3cb35e4-70d3-4801-aeab-8ee4bb33b420https://gowlingwlg.com/fr-FR/insights-resources/articles/2018/shire-successfully-defends-canadian-vyvanse-patenApotex's invalidity allegations regarding Shire's Canadian Patent 2,527,646 covering the active ingredient in Shire's ADHD medication VYVANSE® have been rejected following a 17-day trial before Justice Fothergill of the Federal Court.Tue, 03 Jul 2018 00:00:00 Z6367a1a0-2a56-4f86-9980-e2e7ed7bbc43https://gowlingwlg.com/fr-FR/insights-resources/articles/2018/how-to-shoot-for-arrow-reliefThe Court of Appeal has ruled that the discretion as to whether or not to award Arrow relief lies with the trial judge, for exercise in light of the facts and circumstances at the date of the trial.Thu, 28 Jun 2018 00:00:00 Z57dfa4fd-73f2-4bae-b773-094e8154fdfbhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2018/is-international-arbitration-the-futureWhy are disputes in the life sciences sector increasingly being resolved by way of international arbitration?Tue, 12 Jun 2018 08:51:00 Z3a095ceb-ff5f-40ac-8c2a-5c5350472c8fhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2018/trade-secrets-directive-becomes-directly-effectiveOn 9 June 2018, the deadline expires for EU Member States to implement the necessary legislation to give effect to the 'Trade Secrets Directive'.Thu, 07 Jun 2018 00:00:00 Z440617a4-489d-4f20-85da-2810b2d044e0https://gowlingwlg.com/fr-FR/insights-resources/articles/2018/distributing-pharmaceuticals-in-the-uaeThe healthcare industry is a priority sector for the UAE government, which continues to increase its spending in the development of high standard healthcare services in the country, notwithstanding the bearish oil market.Thu, 31 May 2018 10:08:00 Z65706061-e2c7-4475-8311-9a07d9bc66f1https://gowlingwlg.com/fr-FR/insights-resources/client-work/2018/cardiol-therapeutics-closes-private-placementLe 24 mai 2018, Cardiol Therapeutics inc. (« Cardiol ») a annoncé la clôture fructueuse d'un placement privé réalisé par l'entremise d'un courtier dont le montant en capital s'élève à environ 10,5 millions de dollars en débentures convertibles non garanties de la société. AltaCorp Capital inc. a agi à titre de conseiller financier exclusif de Cardiol et d'unique placeur pour compte dans le cadre du placement privé.Thu, 24 May 2018 12:00:00 Zf348cc0e-9754-4c7d-8e3b-bdf9140be2efhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2018/parallel-import-guidance-clarified-by-cjeuThe CJEU has issued a ruling clarifying what you can, and cannot, do if you wish to import goods from one Member State of the EU to another.Thu, 24 May 2018 09:58:00 Z1cb55448-74a9-4016-92a3-55162583cd43https://gowlingwlg.com/fr-FR/insights-resources/client-work/2018/gowling-wlg-acts-for-astrazeneca-on-drug-collaboraIn July 2017, AstraZeneca completed a transaction on a cancer drug collaboration with Merck. Merck will pay AstraZeneca up to $8.5 billion in total consideration, including $1.6 billion upfront, $750 million for certain license options and up to $6.15 billion contingent upon successful achievement of future regulatory and sales milestones.Fri, 18 May 2018 00:00:00 Z519c0436-0c29-46bc-ae2c-f975489a2673https://gowlingwlg.com/fr-FR/insights-resources/client-work/2018/canadian-pharmacists-association-invests-in-pharmaOn May 3, 2018, the Canadian Pharmacists Association announced an investment in Pharmapod Ltd., a company based in Dublin, Ireland.Thu, 03 May 2018 00:00:00 Z6f88356f-2228-49e1-a634-ef7addb1e365https://gowlingwlg.com/fr-FR/insights-resources/articles/2018/uk-ratifies-the-upc-agreementOn 26 April 2018 the UK completed its ratification of the UPC Agreement by depositing its instrument of ratification with the European Council.Fri, 27 Apr 2018 00:00:00 Z5a37bcdc-9d3f-4a6b-ab6f-adf680f2ba23https://gowlingwlg.com/fr-FR/insights-resources/client-work/2018/aleafia-completes-combination-with-canabo-medicalOn March 26, 2018, Aleafia Inc. completed its business combination with Canabo Medical Inc. to form Aleafia Health Inc.Mon, 26 Mar 2018 00:00:00 Zee0dc78a-37ee-4a25-9cbc-7751d366c7fdhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2018/uk-ratifies-hague-agreement-on-industrial-designsIn an important step for design right owners, the United Kingdom has completed its ratification of the 'Hague Agreement' concerning the registration of industrial designs.Wed, 14 Mar 2018 12:22:00 Z4e2785b1-c03f-49f5-9325-5d13c564b512https://gowlingwlg.com/fr-FR/insights-resources/articles/2018/implications-of-the-actavis-v-eli-lilly-judgmentIn a landmark judgment in July 2017, the UK Supreme Court introduced a doctrine of equivalents into modern UK patent law.Thu, 01 Mar 2018 00:00:00 Z4e1fbdc7-ba9c-44b6-9a7d-afeeca75c675https://gowlingwlg.com/fr-FR/insights-resources/articles/2018/uk-supreme-court-introduces-doctrine-of-equivalentIn a landmark decision, Actavis v Eli Lilly [2017] UKSC 48, the UK Supreme Court has re‐steered the law of patent infringement in the UK, stating that there is a doctrine of equivalents, and expressly permiting recourse by the courts to the prosecution file in appropriate limited circumstances.Mon, 22 Jan 2018 00:00:00 Z8f39a4c7-9e20-48be-b417-6a39b3219d3ehttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2018/mpx-bioceutical-closes-private-placement-offeringLe 15 janvier 2018, MPX Bioceutical Corporation (CSE : MPX) (OTC : MPXEF), une société multinationale de produits de cannabis diversifiés, a conclu avec succès la seconde et dernière tranche de son placement privé d'unités annoncé précédemment, pour un produit brut total d'environ 28,8 millions de dollars.Mon, 15 Jan 2018 12:00:00 Zdb6f463b-2f3e-4135-a8a8-743c72779351https://gowlingwlg.com/fr-FR/insights-resources/articles/2018/canadian-patent-law-2017-year-in-reviewL’année 2017 a été très chargée en ce qui a trait au droit canadien sur les brevets. La controversée doctrine de la promesse a été rejetée par la Cour suprême du Canada dans l’affaire AstraZeneca Canada Inc. c. Apotex Inc.; le plus important jugement pécuniaire au Canada a été accordé au titre de la contrefaçon de brevet dans l’affaire The Dow Chemical Company v Nova Chemical; le Règlement sur les médicaments brevetés (avis de conformité) et les Règles sur les brevets ont fait l’objet d’importantes modifications et le Projet de loi C-30 a introduit la possibilité de demander la restauration de la durée d’un brevet au moyen d’un « certificat de protection supplémentaire » dans certaines circonstances.Wed, 03 Jan 2018 00:00:00 Zf03768ef-b2dc-4612-9795-ba4d7146038bhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2017/the-skinny-on-skinny-labelsIn a recent decision of Federal Court (Bristol-Myers Squibb Canada v Apotex Inc., 2017 FC 1061), Justice Lafrenière dismissed the prohibition proceeding brought by Bristol-Myers Squibb Canada (BMS) against Apotex Inc. (Apotex) for a generic version of ABILIFY®, which is indicated for several uses.Thu, 21 Dec 2017 00:00:00 Z7f373e27-f0f7-4543-87d6-5c44e12e67eahttps://gowlingwlg.com/fr-FR/insights-resources/articles/2017/russian-federal-antimonopoly-service-threatens-renParallel importation has been a hot topic in Russia for some time.Mon, 23 Oct 2017 00:00:00 Z032cf7cb-52bd-4075-83b2-c2f716265d8fhttps://gowlingwlg.com/fr-fr/insights-resources/articles/2017/defects-in-pre-patent-issue-process-do-not-renderIn Apotex Inc. v Pfizer Inc. et al, 2017 FCA 201, the Federal Court of Appeal refused to void a patent based on an administrative error made during the prosecution of the patent application.Wed, 18 Oct 2017 10:57:00 Z0de7c23d-a16a-469f-bfe7-89651cb56012https://gowlingwlg.com/fr-FR/insights-resources/articles/2017/actavis-v-eli-lilly-what-is-normal-interpretatiIn a landmark decision (Actavis v Eli Lilly), the UK Supreme Court has re-steered the law of patent infringement in the UK, stating that there is a doctrine of equivalents. But the doctrine need not be invoked if a variant infringes a claim "as a matter of normal interpretation".Tue, 26 Sep 2017 11:40:00 Z5f7dff19-0c13-4210-bce1-f57995ac0502https://gowlingwlg.com/fr-FR/insights-resources/articles/2017/government-of-canada-finalizes-amended-noc-regulatThe Government of Canada has finalized the Certificate of Supplementary Protection Regulations (the CSP Regulations) and the amended Patented Medicines (Notice of Compliance) Regulations (the NOC Regulations).Mon, 11 Sep 2017 00:00:00 Zf567c55e-68d3-4e63-b5dd-c15f78f71a7chttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2017/aegerion-pharmaceuticals-and-amryt-pharma-in-agreeGowling WLG's Life Sciences team, led by partner Patrick Duxbury and including Mathilda Davidson, Alice Stagg, James Barr and Bernardine Adkins, have assisted Aegerion Pharmaceuticals in its licensing agreement with Amryt Pharma.Mon, 04 Sep 2017 04:18:00 Z9f8a314e-5ba7-41ae-be29-e3b92743fc3dhttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2017/gowling-wlg-assists-astrazeneca-in-establishing-coLegal experts at the international law firm, Gowling WLG, have played a key role in assisting AstraZeneca in formulating a collaborative agreement with Takeda Pharmaceutical Company Limited to jointly develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson's disease (PD).Fri, 01 Sep 2017 04:00:00 Zf8322f44-870f-43c6-9337-12fc61356ceehttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2017/life-sciences-team-advises-astrazeneca-on-key-tranGowling WLG's life sciences team, led by partner Patrick Duxbury, acted for the global pharmaceutical company AstraZeneca on its collaboration with Sanofi Pasteur to jointly develop and commercialise MEDI8897.Fri, 01 Sep 2017 00:00:00 Z33332db8-5e78-438d-83f8-107aef352f88https://gowlingwlg.com/fr-FR/insights-resources/client-work/2017/aztrazeneca-and-pieris-pharmaceuticals-collaborateGowling WLG's life sciences team has been instrumental in assisting longstanding client AstraZeneca on its collaboration with Pieris Pharmaceuticals.Fri, 18 Aug 2017 00:00:00 Z2ab47058-1e18-43ff-b368-703e29ae4adfhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2017/curtain-lifted-on-proposed-amended-pm-noc-regulatThe curtain has been lifted to reveal the proposed amendments to the Patented Medicines (Notice of Compliance) Regulations (the Amended Regulations) that have been a long-awaited result of CETA.Mon, 17 Jul 2017 00:00:00 Z946f2e77-8336-43c1-b9a2-1a95b92986e0https://gowlingwlg.com/fr-FR/insights-resources/articles/2017/uk-supreme-court-introduces-doctrine-of-equivalentIn a landmark decision (Actavis v Eli Lilly), the UK Supreme Court has re-steered the law of patent infringement in the UK, stating that there is a doctrine of equivalents.Thu, 13 Jul 2017 00:00:00 Zd5b6f3b0-5c26-4993-a6d0-144aba4a9c26https://gowlingwlg.com/fr-FR/insights-resources/guides/2017/universe-of-pharmaceutical-trademarks-in-russiaWith a population of more than 140 million people, Russia has one of fastest-growing pharmaceutical industries in the world, increasing at a rate of more than 10% annually.Wed, 31 May 2017 00:00:00 Zc851152d-397f-422d-ab8d-4f6e092244c8https://gowlingwlg.com/fr-FR/insights-resources/articles/2017/the-fight-against-counterfeit-pharmaceuticalAccording to the World Health Organization (WHO) definition, a counterfeit medicine is a medicine, which is deliberately and fraudulently mislabelled with respect to identity and/or source.Mon, 15 May 2017 03:56:00 Z4a80a64b-0ef7-4330-aa23-28083cbd04f4https://gowlingwlg.com/fr-FR/insights-resources/client-work/2017/gowling-wlg-advises-astrazeneca-on-transaction-forGowling WLG's Life Sciences team has assisted global pharmaceutical company, AstraZeneca on its collaboration with Pieris Pharmaceuticals.Fri, 05 May 2017 04:00:00 Zb91f5893-387f-4a71-8758-556779932f73https://gowlingwlg.com/fr-fr/insights-resources/articles/2017/combatting-cyber-crime-critical-for-life-sciencesBiotech and pharmaceutical firms hold vast amounts of valuable data and information making them prime targets for cyber-attacks - so how are they protecting themselves?Thu, 27 Apr 2017 10:26:00 Z465029cc-1d62-4639-bb81-dcd6ff55eaf2https://gowlingwlg.com/fr-FR/insights-resources/articles/2017/evidence-for-establishing-sound-prediction-and-theThe Federal Court of Appeal's (FCA) recent decision in Teva v. Leo Pharma addresses important issues related to the doctrines of sound prediction and sufficiency.Thu, 30 Mar 2017 00:00:00 Z77f843a3-a5ff-4e97-a817-5b7e51287b86https://gowlingwlg.com/fr-FR/insights-resources/client-work/2017/gowling-wlg-advises-astrazeneca-on-key-transactionExperts from the firm's life sciences group have assisted the global pharmaceutical company, AstraZeneca on a significant transaction.Thu, 09 Mar 2017 05:00:00 Z799c7139-63c9-488f-be4f-029ab623d89fhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2017/l-accord-economique-et-commercial-global-aecg-entrLe 15 février 2017, le Parlement européen a approuvé l'Accord économique et commercial global (AECG) entre le Canada et l’Union européenne. Cette étape précède l’entrée en vigueur provisoire de l’accord, laquelle est prévue pour ce printemps.Wed, 08 Mar 2017 11:09:00 Zd6447c24-d4a7-406a-9395-477493f03a8dhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2017/route-to-market-for-humira-biosimilar-clearedIn a landmark judgment, the High Court has granted a novel type of declaratory relief to clear the route to market for a product facing a raft of pending patent applications incapable of challenge in the UK court: If the declaration serves a useful purpose, and upon considering the justice to the parties and any special reasons, the court can grant declarations that effectively offer an invisibility cloak against infringement actions based on patent applications which are later granted.Mon, 06 Mar 2017 00:00:00 Z28e99031-d20e-4b9c-adad-673c427a4c69https://gowlingwlg.com/fr-FR/insights-resources/client-work/2017/high-court-gives-ground-breaking-declaratory-relieThe March 2017 High Court judgment granted declaratory relief to FKB, which was attempting to launch a product and protect it against later, as yet ungranted, patent applications by AbbVie Technology.Sat, 04 Mar 2017 04:17:00 Zbefd4ca9-e32e-42c5-9537-2695019ae162https://gowlingwlg.com/fr-FR/insights-resources/articles/2017/canada-eu-comprehensive-economic-and-trade-agreemeOn February 15, 2017, the European Parliament approved the Canada-EU Comprehensive Economic and Trade Agreement (CETA), paving the way for entry into force of the agreement on a provisional basis, which is expected later this spring.Thu, 16 Feb 2017 00:00:00 Ze6941d1c-0c63-4a39-96d6-4ee1c8cd53d0https://gowlingwlg.com/fr-FR/insights-resources/articles/2017/what-brexit-means-for-life-sciencesIt has been an active year for the UK life sciences sector, with the EU referendum seemingly having no immediate impact on deal activity.Wed, 11 Jan 2017 03:45:00 Z2600f646-fab8-4725-a262-f2b2c3feecd1https://gowlingwlg.com/fr-FR/insights-resources/articles/2017/canadian-patent-law-2016-year-in-reviewThis article summarizes noteworthy Canadian patent law decisions and developments from 2016.Wed, 04 Jan 2017 00:00:00 Z628c46e8-5647-4da4-b5f2-3a70eea89705https://gowlingwlg.com/fr-FR/insights-resources/client-work/2016/life-sciences-team-aids-astellas-pharma-in-transfeGowling WLG's Life Sciences experts advised client Astellas Pharma Europe in a December 2016 deal to transfer the exclusive rights for Qutenza, a pain management therapy, to Grünenthal. Grünenthal's rights to the drug will only apply for Europe, the Middle East and Africa.Fri, 30 Dec 2016 00:00:00 Z581b0f7c-9bfa-4448-ba9f-15ad4cde6355https://gowlingwlg.com/fr-FR/insights-resources/client-work/2016/gowling-wlg-advises-astellas-pharma-over-the-transGowling WLG's Life Sciences team has advised Astellas Pharma Europe in an agreement to transfer the exclusive rights for Qutenza™ (capsaicin 8% patch) in Europe, Middle East and Africa to Grünenthal.Tue, 20 Dec 2016 05:00:00 Z2b7bff2f-20ed-4405-8483-59dcf6b4b950https://gowlingwlg.com/fr-FR/insights-resources/articles/2016/uk-signals-intent-to-remain-in-the-new-upc-systemThe United Kingdom's Minister for Intellectual Property, Baroness Neville-Rolfe, has announced that the government is proceeding with preparations to ratify the Unified Patent Court Agreement (UPC Agreement).Wed, 30 Nov 2016 00:00:00 Z29462da1-4b8d-4e5c-b3ea-785d5117246fhttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2016/gowling-wlg-advises-aegerion-pharmaceuticals-on-qlGowling WLG a agi à titre de conseiller canadien pour Aegerion Pharmaceuticals, Inc. (cotée à l’indice NASDAQ), laquelle entreprise a fusionné avec QLT Inc. (cotée aux indices NASDAQ et TSX) en vue de former Novelion Therapeutics Inc.Tue, 29 Nov 2016 00:00:00 Z664dee91-1cc6-4b19-89b9-9abaa0a176bahttps://gowlingwlg.com/fr-FR/insights-resources/articles/2016/challenge-to-patentee-s-right-to-elect-between-damWhich party has the right to choose the patentee's remedy after a successful action for patent infringement?Thu, 10 Nov 2016 16:26:00 Zf91947db-60d9-4430-b0b5-16d9f760836dhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2016/changes-to-ip-rights-on-the-horizon-canada-introdWe previously reported on important changes the recently signed Comprehensive Economic and Trade Agreement between Canada and the European Union (CETA) requires Canada to make to its Patent Act and Trade-marks Act.Fri, 04 Nov 2016 00:00:00 Zfcc5cb84-3552-4d07-ba40-449658600427https://gowlingwlg.com/fr-fr/insights-resources/client-work/2016/life-sciences-team-advises-crescendo-biologics-onCrescendo Biologics turned to Gowling WLG's Life Sciences team, led by partner Patrick Duxbury, for assistance on its collaboration with Takeda Pharmaceutical Company with the aim of discovering, developing and commercialising Humabody®-based therapeutics aimed at cancer indications with a high unmet medical need.Mon, 31 Oct 2016 00:00:00 Zd10ddd60-6bb9-4b12-a8e0-e1fcf7116465https://gowlingwlg.com/fr-FR/insights-resources/articles/2016/federal-court-of-appeal-grants-minister-of-healthIn a decision dated October 12, 2016, the Federal Court of Appeal upheld two decisions of the minister of health to issue Notice of Compliances to generic drug manufacturers without addressing the requirements of the Patented Medicines (Notice of Compliance) Regulations.Mon, 24 Oct 2016 00:00:00 Z6eac4742-88d8-4b9f-9998-5eb0d004b68chttps://gowlingwlg.com/fr-fr/insights-resources/client-work/2016/gowling-wlg-advises-infrastructure-ontario-and-macLe 21 octobre 2016, Infrastructure Ontario (IO) et Mackenzie Health (MH) ont annoncé la clôture financière du nouvel Hôpital Mackenzie Vaughan dans la région de York en Ontario.Fri, 21 Oct 2016 00:00:00 Z195b5a78-5324-400e-baaa-76590e8b8007https://gowlingwlg.com/fr-fr/insights-resources/client-work/2016/gowling-wlg-advises-crescendo-biologics-on-collaboGowling WLG's Life Sciences team, led by partner Patrick Duxbury and including associate Kathryn Charles, have advised client Crescendo Biologics on its collaboration with Takeda Pharmaceutical Company Limited.Tue, 11 Oct 2016 04:00:00 Z43752122-9b28-45d8-afeb-82c4e6f3bfa1https://gowlingwlg.com/fr-FR/insights-resources/client-work/2016/gowling-wlg-provides-canadian-transactional-supporLe 23 septembre 2016, Xiwang Foodstuffs Company Ltd. (« Xiwang Food ») a annoncé qu’elle avait complété son acquisition précédemment annoncée de Iovate Health Sciences International, Inc. (« Iovate »), par l’intermédiaire de l’acquisition de la société mère de Iovate, Kerr Investment Holding Corporation (« Kerr »), du Toronto Oak Trust pour une contrepartie totale de 730 millions $ CA.Fri, 23 Sep 2016 00:00:00 Z3695930a-0112-43b2-93bc-ac039e3e9b0fhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2016/patent-survives-anticipation-attack-based-on-use-iOn September 7, 2016, the Federal Court found that Apotex and Cobalt infringed three claims of Bayer's Canadian Letters Patent No. 2,382,426. The Court also found those claims to be valid.Thu, 22 Sep 2016 11:28:00 Z48c9625c-d685-4358-9915-27f66615ee46https://gowlingwlg.com/fr-FR/insights-resources/articles/2016/russian-bill-on-telemedicine-to-remove-legal-uncerThe advent of high speed internet and telecommunications has made telemedicine possible in Russia. Aiming to overcome geographical barriers and increase access to healthcare services, more medical institutions are using telemedicine.Tue, 06 Sep 2016 00:00:00 Z76d146e1-717b-4839-b03a-683b6d33aa40https://gowlingwlg.com/fr-FR/insights-resources/articles/2016/eli-lilly-s-erectile-dysfunction-patent-stands-upThe English High Court (Patents Court) has ruled in a patent dispute concerned with the treatment of erectile dysfunction. Actavis and Mylan had commenced "clear the way" litigation by seeking to revoke Eli Lilly's patent in order to launch generic versions of its CIALIS medicine upon expiry of the relevant SPC protection (November 2017).Thu, 01 Sep 2016 00:00:00 Ze9c81a5f-b37f-4387-a8e3-cb74723c11a5https://gowlingwlg.com/fr-FR/insights-resources/articles/2016/genentech-herceptin-formulation-patents-invalidThe Court of Appeal has confirmed that two Genentech patents concerning lyophilised formulations of trastuzumab (the active ingredient in Herceptin) are invalid for obviousness.Tue, 30 Aug 2016 08:28:00 Z92639be3-2d3b-401e-b616-7f7831efc4f3https://gowlingwlg.com/fr-FR/insights-resources/client-work/2016/working-with-heptares-to-develop-partnerships-to-tIn April 2016, Gowling WLG advised Heptares, a wholly-owned subsidiary of Sosei Group Corporation, on a $3.375 billion global R&D and commercialisation partnership with Allergan Pharmaceuticals to license a broad portfolio of compounds targeting neurological disorders, including Alzheimer's disease.Tue, 30 Aug 2016 00:00:00 Z23cdce78-6f6d-4037-9f21-7100d20f73a9https://gowlingwlg.com/fr-FR/insights-resources/articles/2016/portions-of-apotex-s-requested-relief-for-being-keIn an Aug. 8, 2016 Ontario Superior Court of Justice decision Lederman J. ruled on a motion brought by the defendant Pfizer seeking to strike claims to multiple forms of relief sought by the plaintiff Apotex. Apotex pled that it was entitled to various relief by virtue of being kept off of the Viagra® market by reason of Pfizer’s ultimately invalid “446 Patent”.Thu, 25 Aug 2016 10:32:00 Z51b1ed66-ea22-4be8-adf6-99fc2d0f5bb5https://gowlingwlg.com/fr-FR/insights-resources/articles/2016/english-patents-court-rules-patent-not-infringed-fThe English High Court (Patents Court) is a world-leading forum for efficient, high quality resolution of patent disputes. Demonstrating again the benefits of the court's flexible and adaptable procedure, Mr Justice Arnold has delivered a full first instance judgment in a patent infringement case regarding therapeutic patches less than four and a half months after the claim was filed. This is less time than is needed to obtain preliminary relief in many jurisdictions.Thu, 14 Jul 2016 00:00:00 Zc8bf5ac5-a10f-48ef-98b6-7c58b15bb9eahttps://gowlingwlg.com/fr-FR/insights-resources/articles/2016/changes-to-the-profession-patent-and-trademark-agOn June 24, 2016, by way of statutory amendment, the age-old common law concept of privilege between lawyers and their clients was extended to certain communications between patent and trademark agents (collectively 'agents') and their clients.Mon, 04 Jul 2016 14:54:00 Z78306408-7108-47ca-b0bd-d7642410a1c3https://gowlingwlg.com/fr-FR/insights-resources/articles/2016/brexit-what-vote-leave-means-for-uk-life-scienceOn 23 June 2016, in a national referendum, the population of the UK voted by a narrow majority (52%) to leave the European Union (EU). What does this mean for the life sciences sector?Mon, 04 Jul 2016 00:00:00 Zd9dd2117-fb78-4b7c-8f8d-8b6218403f94https://gowlingwlg.com/fr-FR/insights-resources/articles/2016/patentability-of-methods-of-medical-treatment-in-cA method of medical treatment is not patentable in Canada. This rule arises out of a concern that granting a monopoly over a method of medically treating a patient could interfere with physicians’ skill and judgment when treating patients.Fri, 17 Jun 2016 09:39:00 Z621d220c-d2d1-482c-9eed-d958ae24f397https://gowlingwlg.com/fr-FR/insights-resources/articles/2016/federal-court-of-appeal-affirms-application-of-priMon, 06 Jun 2016 00:00:00 Za259ad96-4568-4dec-8e8a-c0ecc8c6258fhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2016/what-other-products-federal-court-orders-generiUnlike other actions, fulsome particulars of generic pharmaceutical damages claims (under section 8 of the Patented Medicines (Notice of Compliance) Regulations) have not always been thought to be necessary. It had been suggested that information in the possession of defendants might define the scope of such claims.Wed, 25 May 2016 00:00:00 Z02a3991f-0422-4006-a04f-3c57108578b3https://gowlingwlg.com/fr-FR/insights-resources/articles/2016/federal-court-releases-updated-guidelines-to-goverWed, 25 May 2016 00:00:00 Z2e728de2-4a2f-4f14-bc5f-e15a2b24c03bhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2016/wyeth-s-meningitis-b-vaccine-patent-valid-and-infrWyeth's Meningitis B (Men B) vaccine patent (the Patent) has been held valid by the English Patents Court, following a challenge by GlaxoSmithKline (GSK). GSK's Bexsero vaccine was found to infringe the Patent, but Wyeth has indicated that in light of the public health requirement for effective vaccines against Men B, it will not seek injunctive relief.Tue, 24 May 2016 00:00:00 Z7f2953bb-56e1-443a-88fa-70ca6891e760https://gowlingwlg.com/fr-FR/insights-resources/articles/2016/eli-lilly-s-cialis-patent-withstands-double-patenThe Federal Court of Appeal has provided guidance on the law of obviousness-type double patenting in dismissing Mylan’s appeal pertaining to Eli Lilly’s Canadian Patent.Tue, 26 Apr 2016 00:00:00 Z52619130-4588-4f07-a3d8-d8bf5ad3a62ahttps://gowlingwlg.com/fr-fr/insights-resources/client-work/2016/gowling-wlg-advises-argenx-on-625-million-collaboGowling WLG's Life Sciences team has advised argenx on its collaboration with global biopharmaceutical company AbbVie to develop ARGX-115, a potential treatment for cancer.Thu, 21 Apr 2016 04:00:00 Z9d3c5929-a5d9-4582-92cc-cc61735f68a6https://gowlingwlg.com/fr-fr/insights-resources/client-work/2016/gowling-wlg-advises-heptares-on-3-375-billionGowling WLG's life sciences experts have advised long-standing client (Heptares Therapeutics (Heptares) on a definitive $3.375 billion agreement with Allergan Pharmaceuticals International Limited, a wholly-owned subsidiary of Allergan plc, a leading global pharmaceutical company.Thu, 07 Apr 2016 04:00:00 Z6366f05b-1d1d-40f2-ae75-a59096a378cfhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2016/approvability-of-generic-noc-satisfies-imminence-cThe Federal Court in Gilead Sciences Inc v Teva Canada Limited, 2016 FC 336 has clarified the law with respect to the imminence requirement of future patent infringement claims.Thu, 07 Apr 2016 00:00:00 Za2506831-4055-4348-a11e-ca01d94e89bbhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2016/the-final-word-on-the-claim-for-innovator-profitsGeneric pharmaceutical companies have long sought the disgorgement of innovator profits following litigation under the Patented Medicines (Notice of Compliance) Regulations (the “Regulations”). On January 14, 2016 the Supreme Court of Canada (SCC), once again, denied leave after Apotex appealed a decision of the Court of Appeal for Ontario (OCA) which upheld Eli Lilly’s motion to strike these claims.Thu, 31 Mar 2016 00:00:00 Z473d5c1d-afb4-41fa-a45a-1ee0822ced78https://gowlingwlg.com/fr-FR/insights-resources/articles/2016/technology-commercialization-forecast-heavy-clouLe Conference Board du Canada publie régulièrement un rapport intitulé Les performances du Canada : Bilan comparatif, lequel porte sur divers secteurs, notamment l’économie, l’environnement, l’innovation et la santé. Malheureusement, le rendement du Canada en ce qui a trait à l’innovation a reçu la cote « D » pendant plus de deux décennies et, en moyenne, a été classé au 14e rang sur les 17 pays du groupe de comparaison depuis les années 1980. Le Conference Board du Canada définit l’innovation comme suit : (i) la création de connaissances, (ii) la transformation de nouvelles connaissances en produits et services et (iii) la diffusion de nouveaux produits et services dans les marchés.Mon, 28 Mar 2016 00:00:00 Ze14f3905-82c5-4f8c-aefd-62cede2b16aahttps://gowlingwlg.com/fr-FR/insights-resources/articles/2016/federal-court-deviates-from-established-tests-forIn the decision summarized below, Apotex successfully obtained a dismissal of Gilead’s application for a prohibition order in respect of Canadian Patent 2,261,619 on the basis of improper listing on the Patent Register.Tue, 22 Mar 2016 00:00:00 Z374d7a90-d386-4ce7-8110-f5c23d3b5f4chttps://gowlingwlg.com/fr-FR/insights-resources/articles/2016/what-does-the-budget-2016-mean-for-the-uk-s-mid-maGeorge Osborne's eighth budget was positioned to a significant extent as 'a budget for business' and there was certainly a number of eye-catching measures.Tue, 22 Mar 2016 00:00:00 Z1b607669-fa9d-4070-b5eb-47017bfdc453https://gowlingwlg.com/fr-FR/insights-resources/articles/2016/high-court-considers-factors-for-transfer-to-ipecThe High Court has considered the factors to be taken into account for transfer to the Intellectual Property Enterprise Court (IPEC).Thu, 03 Mar 2016 00:00:00 Z944c183a-bd02-4304-9d13-e1fdbd2e6e2chttps://gowlingwlg.com/fr-FR/insights-resources/articles/2016/changes-at-pmprb-to-safeguard-against-excessivelyOver the course of the next three years, PMPRB is seeking to change to its operations with the aim of becoming a more effective and stronger consumer protection agency. According to its recently released Strategic Plan for 2015-2018, the PMPRB identified a number of challenges facing the PMPRB and Canadian consumers of pharmaceuticals. These include:  the emergence of extrinsic bodies engaging in price review, absence of publically funded universal drug coverage, and non-transparent, fragmented drug purchasing across the country.Thu, 04 Feb 2016 00:00:00 Zf4fcc091-fb72-4096-b96b-333889d35428https://gowlingwlg.com/fr-FR/insights-resources/articles/2016/drug-advertising-in-the-context-of-social-mediaThu, 21 Jan 2016 00:00:00 Z536c4eb3-127d-42db-8ae0-64861453e6c2https://gowlingwlg.com/fr-FR/insights-resources/articles/2016/health-canada-seeks-comment-on-revised-seb-guidancOn Dec. 7, 2015, Health Canada released a revised Guidance Document for sponsors of Subsequent Entry Biologics (SEB).Tue, 19 Jan 2016 00:00:00 Za27728be-2de4-4032-8f47-7f7a313e4eb9https://gowlingwlg.com/fr-FR/insights-resources/articles/2016/duty-of-fairness-the-responsibility-of-businessDo the size, resources and degree of sophistication of a regulated business affect what a regulator is required to do in order to ensure that it is treated fairly? This was a key issue considered by the Court of Appeal in <em>R (Roche Registration Ltd) v the Secretary of State for Health</em>.Wed, 13 Jan 2016 00:00:00 Ze0616d3c-16cf-4936-9737-c5abe50be21fhttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2016/alltech-acquires-masterfeedsReprésentation d’Alltech dans le cadre de son acquisition de Masterfeeds, ce qui en fait l’une des plus importantes entreprises de nutrition animale du Canada.Fri, 08 Jan 2016 00:00:00 Z1624d386-ee30-4182-9f81-e5006fcc9151https://gowlingwlg.com/fr-fr/insights-resources/articles/2015/bc-court-of-appeal-dismisses-proposed-consumer-claOn Dec. 8, 2015, the British Columbia Court of Appeal dismissed a proposed class action by consumers against Pfizer Canada Inc. in connection with Pfizer’s now invalid patent which covered its VIAGRA® product.Tue, 01 Dec 2015 00:00:00 Z92da0c16-c714-4beb-9099-f1828c08248ahttps://gowlingwlg.com/fr-FR/insights-resources/articles/2015/pharmaceutical-data-protection-in-canada-the-lateIn the recent Photocure decision the Federal Court has once again sided with Canada's Minister of Health in denying data protection for a new medicinal ingredient.Tue, 01 Dec 2015 00:00:00 Z46f0c8cb-2c26-484e-aaa2-f0aba02e6c28https://gowlingwlg.com/fr-fr/insights-resources/articles/2015/tests-for-obviousness-and-insufficiencyNew Patents Court judge Mr Justice Henry Carr has explained the tests for inventive step and insufficiency in his decision in a 'clearing the way' action brought by Actavis.Thu, 26 Nov 2015 00:00:00 Z58e91178-e24e-44d9-95c6-eefbb7a01f3ahttps://gowlingwlg.com/fr-fr/insights-resources/articles/2015/data-protection-periods-for-medicinal-productsThe Court of Justice of the European Union (CJEU) recently gave judgments in Novartis Europharm v European Commission (Cases T-472/12 and T-67/13) The CJEU held that where a marketing authorisation holder has developed its medicinal product (e.g. by developing a different strength, pharmaceutical form, administrative route or presentation), the developed product will share the regulatory data protection period of the original product, even where the developed product holds a separate marketing authorisation. Generics manufacturers may use the data once that period has expired.Tue, 17 Nov 2015 00:00:00 Z3716453e-1e9a-4dca-b549-8438851c507dhttps://gowlingwlg.com/fr-fr/insights-resources/articles/2015/ono-s-cancer-immunotherapy-patent-found-validIn Merck Sharp & Dohme v Ono Pharmaceutical & Anr, Birss J found that Ono's cancer immunotherapy patent was valid.Thu, 12 Nov 2015 00:00:00 Zeb74f67f-ab0e-432d-a06e-2af11cbaaf95https://gowlingwlg.com/fr-FR/insights-resources/articles/2015/hot-topic-life-sciences-licensing-trends-and-isThis seminar looks at current trends in life sciences licensing and collaborations.Thu, 12 Nov 2015 00:00:00 Z9102b964-7cdc-48cb-a0bb-0c6f24b99a33https://gowlingwlg.com/fr-fr/insights-resources/articles/2015/modern-slavery-and-supply-chains-updatedThe Modern Slavery Act 2015 (MSA) is ultimately designed to tackle slavery and human trafficking, but a key provision introduced a requirement on organisations with a turnover of more than £36 million to produce an annual transparency statement.Tue, 03 Nov 2015 00:00:00 Z6acc3fcf-7838-4838-b0d7-9ad513268199https://gowlingwlg.com/fr-fr/insights-resources/articles/2015/federal-court-of-appeal-finds-that-pmprb-extends-tOn Nov. 6, 2015, the Federal Court of Appeal issued a rare decision relating to Canada's pricing control regime for patented medicines administered by the Patented Medicine Prices Review Board ("PMPRB").Sun, 01 Nov 2015 00:00:00 Zca36af67-fbab-4cd7-aaa8-633fc55a0059https://gowlingwlg.com/fr-fr/insights-resources/articles/2015/federal-court-issues-first-biologics-decision-undeAmgen Canada Inc v Apotex Inc (2015 FC 1261) is the first decision of the Federal Court under the Patented Medicines (Notice of Compliance) Regulations relating to a subsequent entry biologic.Sun, 01 Nov 2015 00:00:00 Z208fb197-b9b5-46e0-8332-0873b0ca496fhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2015/federal-court-grants-leo-pharma-s-application-forOn Nov. 18, 2015, Justice Locke granted Leo Pharma’s application to prohibit the minister of health from approving Teva’s version of Leo Pharma’s patented DOVOBET® product until after expiry of Canadian Patent 2,370,565 (the “565 Patent”).Sun, 01 Nov 2015 00:00:00 Z549a4140-0be2-4dfe-921c-47aeacf93117https://gowlingwlg.com/fr-FR/insights-resources/articles/2015/federal-court-holds-that-post-filing-amendments-arIn Hospira Healthcare Corporation v Canada (Minister of Health) (2015 FC 1205), Justice Gagné of the Federal Court dismissed Hospira’s application for judicial review of the Minister’s refusal to issue a Notice of Compliance (NOC) to Hospira for its oxaliplatin product until the expiry of the data exclusivity period for Sanofi-Aventis’ oxaliplatin product (ELOXATIN®).Sun, 01 Nov 2015 00:00:00 Zdbcab09a-2713-4d01-8884-59ffa496f3dehttps://gowlingwlg.com/fr-FR/insights-resources/articles/2015/amgen-s-cinacalcet-application-dismissed-based-onSun, 01 Nov 2015 00:00:00 Z966626b7-2ed4-4cf4-9884-ddd7fdef7eb8https://gowlingwlg.com/fr-fr/insights-resources/client-work/2015/novera-therapeutics-announces-collaboration-with-jOn October 14, 2015, The Ontario Institute for Cancer Research ("OICR") and Novera Therapeutics Inc. announced a collaboration with Janssen Biotech, LLC, a pharmaceutical company of Johnson & Johnson, to accelerate the development of promising small molecule drug candidates for haematological cancers.Wed, 14 Oct 2015 00:00:00 Z4769e6ac-a17d-4fbf-b9d7-186606c9c5ddhttps://gowlingwlg.com/fr-fr/insights-resources/articles/2015/the-trans-pacific-partnership-changes-for-patentsChanges may be on the horizon for Canada's legal and regulatory regime for patents and pharmaceuticals.Thu, 01 Oct 2015 00:00:00 Z8b593d7a-6fa2-4976-a809-3823be872f10https://gowlingwlg.com/fr-fr/insights-resources/articles/2015/warner-lambert-v-actavis-the-end-of-the-beginningIn the English Patents Court, Mr Justice Arnold has ruled that key claims of Warner-Lambert's "second medical use" patent to pregabalin for the treatment of pain are invalid for insufficiency, and that the patent is not infringed by Actavis' activities involving its generic pregabalin medicine.Tue, 22 Sep 2015 00:00:00 Z11619c71-ff6d-489c-bb93-55d804f98debhttps://gowlingwlg.com/fr-fr/insights-resources/articles/2015/rules-recommendations-and-clear-distinctionsShortly before the summer recess, the High Court gave judgment in R (Richmond Pharmacology Ltd) v Health Research Authority.Thu, 17 Sep 2015 00:00:00 Z1fd47ccb-8b3a-4f78-83c1-049f99fc12bdhttps://gowlingwlg.com/fr-fr/insights-resources/articles/2015/modern-slavery-and-supply-chains-october-2015This alert explains the outcome of the government consultation relating to requirements on certain businesses to publish an annual slavery and human trafficking statement regarding their supply chain as part of the Modern Slavery Act 2015. The new supply chain requirements are expected to come into force in October 2015.Wed, 16 Sep 2015 00:00:00 Z09dc2e4c-8ac3-4d3a-892e-c5b37e7a0043https://gowlingwlg.com/fr-fr/insights-resources/articles/2015/ontario-superior-court-refuses-to-strike-generic-sTue, 01 Sep 2015 00:00:00 Zdb7b3e5b-3cfd-4657-b35f-55be6c2ca7cchttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2015/rfq-issued-for-mount-sinai-hospital-redevelopmentOn August 13, 2015, Infrastructure Ontario and Sinai Health System announced that they had issued a request for qualifications to build and finance Mount Sinai Hospital's Phase 3A redevelopment project.Thu, 13 Aug 2015 00:00:00 Ze861f9d0-76f9-4fe2-8f4b-0b217e3fa9bdhttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2015/federal-court-of-appeal-reinterprets-product-speciOn July 17, 2015, the Federal Court of Appeal set aside a judgment of the Federal Court that upheld Health Canada’s refusal to list Canadian Patent 2,379,329 owned by Eli Lilly Canada Inc. on the Patent Register maintained under the PM(NOC) Regulations.Fri, 17 Jul 2015 00:00:00 Z800ce024-7227-4f2f-9af7-4393bdc3c6abhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2015/court-of-appeal-rules-in-smith-nephew-v-convatecIn a dispute between Smith & Nephew and ConvaTec, the Court of Appeal has ruled that "between 1% and 25%" extends to all values ≥ 0.5% and <25.5%. overturning the first instance decision of mr justice birss, court appeal rejected a construction based on significant figures, which would have born no result to distribution random error in practice.Fri, 03 Jul 2015 00:00:00 Z479eaea0-efb5-4cf6-a3df-3b0505cb43e0https://gowlingwlg.com/fr-FR/insights-resources/articles/2015/hospira-v-genentech-iii-swiss-form-claim-obviousIn a judgment dated 24 June 2015, Arnold J has delivered the latest blow in the ongoing saga surrounding trastuzumab (the monoclonal antibody in Herceptin) and Hospira's continued efforts to knock out Genentech's patents and clear the way for the launch of a generic version of the medicine.Fri, 03 Jul 2015 00:00:00 Z349edad2-5b3d-47b7-9609-987744276521https://gowlingwlg.com/fr-fr/insights-resources/articles/2015/fca-does-not-address-trial-judge-s-finding-that-thWed, 01 Jul 2015 00:00:00 Zaa34c578-ee8b-4ab9-b7c9-f95b20071eechttps://gowlingwlg.com/fr-FR/insights-resources/articles/2015/federal-court-of-appeal-reinterprets-product-speciOn July 17, 2015, the Federal Court of Appeal set aside a judgment of the Federal Court that upheld Health Canada’s refusal to list Canadian Patent 2,379,329 (the ‘329 patent) owned by Eli Lilly Canada Inc. on the Patent Register maintained under the PM(NOC) Regulations.Wed, 01 Jul 2015 00:00:00 Zcbe6e35b-cb7e-4476-8575-987e45e80c08https://gowlingwlg.com/fr-FR/insights-resources/articles/2015/federal-court-grants-accounting-of-profits-and-addThe Federal Court recently released a decision accounting for an infringer's profits in a pharmaceutical matter.Wed, 01 Jul 2015 00:00:00 Zf01c7f1d-8aa4-4937-a832-27ffba1c772bhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2015/federal-court-grants-interlocutory-stay-in-ip-dispOn June 12, 2015, the Federal Court issued an interlocutory stay in the context of a data protection application in Horizon Pharma plc v The Minister of Health et al, 2015 FC 744.Wed, 01 Jul 2015 00:00:00 Z1b859013-58dc-4a82-9472-b606b70ac5e9https://gowlingwlg.com/fr-FR/insights-resources/articles/2015/russian-tax-authorities-impose-tax-on-foreign-compForeign companies setting up sales networks in Russia should be aware of the decision summarized below, which creates a potential increased tax exposure.Wed, 01 Jul 2015 00:00:00 Zfe8f8652-e0b9-4693-bbac-1575834ae85bhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2015/fca-imposes-could-and-would-test-to-assess-non-iLa Cour d’appel fédérale (CAF) a publié ses motifs dans le cadre de l’appel de la décision de la juge Snider en matière de dommages-intérêts concernant le médicament lovastatine. La juge Snider a accordé à Merck 119 millions de dollars, plus des intérêts, à titre de dommages-intérêts en raison de la violation par Apotex du brevet de Merck pour son produit lovastatine. La CAF a rejeté l’appel d’Apotex (copie disponible ici).Wed, 01 Jul 2015 00:00:00 Z149df97e-360a-4a25-a909-b9aa92ba2322https://gowlingwlg.com/fr-FR/insights-resources/articles/2015/eli-lilly-succeeds-in-overturning-award-of-dnisThe Court of Appeal has delivered its long-awaited judgment in the Actavis v Eli Lilly dispute, ruling that Actavis is not entitled to a declaration of non-infringement (DNI) of Eli Lilly's European patent.Tue, 30 Jun 2015 00:00:00 Zeaacb1dd-1217-459f-a5c6-ffca790ace4fhttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2015/rfp-issued-for-new-mackenzie-vaughan-hospitalOn June 29, 2015, Infrastructure Ontario and Mackenzie Health issued a request for proposals to three teams shortlisted to design, build, finance and maintain a new state-of-the-art hospital that will be constructed in Vaughan: Plenary Health, Mackenzie Vaughan Health Partnership and Hospital Infrastructure Partners.Mon, 29 Jun 2015 00:00:00 Z0decafe4-fb81-4e07-83fe-0e8e7808010chttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2015/federal-court-affirms-principle-of-claim-differentNovartis Pharmaceuticals Canada Inc. v. Teva Canada Ltd. and Minister of Health and Novartis AG, 2015 FC 770Fri, 19 Jun 2015 00:00:00 Zf01d2d13-8619-476d-bd58-a8d43e9bc33chttps://gowlingwlg.com/fr-fr/insights-resources/articles/2015/ip-ownership-for-r-d-companies-cautionary-tales-aIn this presentation, Selena Kim discusses how companies engaged in R&D can successfully secure title to their intellectual property.Mon, 01 Jun 2015 00:00:00 Z4a7534dc-bbc2-4995-b4fe-4dd7e21fa8eehttps://gowlingwlg.com/fr-FR/insights-resources/articles/2015/swiss-form-patent-claims-do-not-need-subjectiveAfter three decades of "fall-out" from the decision of the European Patent Office's Enlarged Board of Appeal in Eisai (Second medical indication) [1985] OJ EPO 64, the English Court of Appeal has issued considered, well-reasoned guidance on the construction of patent claims in "Swiss" form. The decision is likely to have impact well beyond British shores.Mon, 01 Jun 2015 00:00:00 Z5a990cd2-3e4c-4d93-8921-bf9ad6eb2c00https://gowlingwlg.com/fr-FR/insights-resources/articles/2015/fca-confirms-that-no-disclosure-of-factual-basis-oMon, 01 Jun 2015 00:00:00 Z2a778558-2254-4828-880c-2b1a6543e1d4https://gowlingwlg.com/fr-FR/insights-resources/articles/2015/federal-court-affirms-principle-of-claim-differentJustice O'Reilly of the Federal Court has rejected Teva's allegations of invalidity regarding Novartis’s patent covering its iron chelator product EXJADE (deferasirox) (2015 FC 770).Mon, 01 Jun 2015 00:00:00 Zc0cc928a-8909-422b-9371-b4806794cc5ahttps://gowlingwlg.com/fr-FR/insights-resources/articles/2015/pm-noc-regulation-amendments-now-in-forceIndustry Canada has now enacted the amendments to the Patented Medicines (Notice of Compliance) Regulations (Regulations) in order to permit claims to compounds to be listed against multiple drug combination products. The regulation is dated June 18, 2015, and we understand that it is to be published July 1, 2015. We attach a copy of the regulation and royal assent.Mon, 01 Jun 2015 00:00:00 Z585beca9-7a1f-4beb-84d5-1b1585b1a16fhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2015/high-court-refuses-to-refer-questions-on-the-interThe High Court has refused to refer to the Court of Justice of the European Union (CJEU), at a preliminary stage, questions on the interpretation of the Supplementary Protection Certificate (SPC) Regulation, in a dispute between ViiV Healthcare UK Ltd and Teva UK Ltd regarding HIV medicine Kivexa.Wed, 13 May 2015 00:00:00 Z8b44665b-ad2b-46cc-b77f-713fade8cae0https://gowlingwlg.com/fr-FR/insights-resources/articles/2015/spain-s-challenge-to-the-unitary-patent-rejectedAs we predicted in November last year, the Court of Justice of the European Union (CJEU) has dismissed Spain's challenge to the legality of the regulations establishing the Unitary Patent.Thu, 07 May 2015 00:00:00 Zddb201e2-61ac-474f-88c2-2876e4b5bc55https://gowlingwlg.com/fr-fr/insights-resources/articles/2015/industry-canada-seeks-comment-on-proposed-changesOn May 2, 2015, the Governor in Council issued proposed amendments to sections 2, 3, and 4 of the Patented Medicines (Notice of Compliance) Regulations. These amendments specifically address the eligibility of listing patent claims that may not include all medicinal ingredients referred to in the approved drug product for which listing was sought on the Patent Register.Fri, 01 May 2015 00:00:00 Zdd8f7146-e404-4e60-bb93-a43099f592dahttps://gowlingwlg.com/fr-FR/insights-resources/articles/2015/federal-court-of-appeal-suggests-need-for-supremeThe FCA in Cobalt v. Bayer has explicitly called into question two central principles of Canadian patent law: the standard of review for claim construction and the patentability of methods of medical treatment.Fri, 01 May 2015 00:00:00 Z7f828ec1-6b62-49b7-93e4-96bbaa043501https://gowlingwlg.com/fr-FR/insights-resources/articles/2015/apotex-denied-claim-for-innovator-s-profits-followFri, 01 May 2015 00:00:00 Zd0855129-30ee-481b-a929-cfc2b856a1abhttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2015/ontario-court-of-appeal-denies-generic-pharmaceutiLe 5 mai 2015, la Cour d’appel de l’Ontario a rejeté la demande du fabricant de médicaments génériques fondée sur l’enrichissement injustifié.Fri, 01 May 2015 00:00:00 Z262dbfae-f5f5-46bc-998f-753be0170462https://gowlingwlg.com/fr-FR/insights-resources/articles/2015/supreme-court-of-canada-dismisses-first-section-8Le 20 avril 2015, la Cour suprême du Canada a rejeté l’appel de Sanofi-Aventis à l’égard d’une action intentée par Apotex en vue de réclamer des dommages-intérêts en vertu de l’article 8 du Règlement sur les médicaments brevetés (avis de conformité). Apotex avait intenté l’action suite à des procédures d’interdiction concernant sa version générique du ramipril, médicament commercialisé par Sanofi sous le nom ALTACE®. Il s’agissait du premier appel entendu par la Cour suprême en lien avec une réclamation en dommages-intérêts au titre de l’article 8.Wed, 01 Apr 2015 00:00:00 Z81ae0898-4156-4103-8b03-b30b2d5711c9https://gowlingwlg.com/fr-FR/insights-resources/articles/2015/implementing-vanessa-s-law-and-new-powers-under-thAs a followup to the recent amendments to Canada's Food & and Drugs Act that came into force on Nov. 6, 2014, Protecting Canadians from Unsafe Drugs Act or “Vanessa's Law,” Health Canada has now posted interpretive guidelines for comment. The deadline for comments is June 8, 2015.Wed, 01 Apr 2015 00:00:00 Z76eb587f-0377-4b56-9f3d-572c440d4295https://gowlingwlg.com/fr-FR/insights-resources/client-work/2015/mirexus-announces-investment-from-goddard-enterpriOn April 10, 2015, Mirexus Biotechnologies Inc. announced a new investment from Goddard Enterprises Ltd. (“GEL”) of Barbados.Wed, 01 Apr 2015 00:00:00 Z2ca55ed9-c937-468a-ad0e-78b92f11796chttps://gowlingwlg.com/fr-fr/insights-resources/articles/2015/spcs-and-combination-productsOn 12 March 2015 the CJEU gave its ruling in Actavis v Boehringer Ingelheim, yet another reference from the UK courts regarding the interpretation of the SPC Regulation 469/2009.Tue, 24 Mar 2015 00:00:00 Zfead9c89-4dce-4869-a05e-914f72f2c606https://gowlingwlg.com/fr-fr/insights-resources/articles/2015/how-transparent-is-your-supply-chainOur Commercial IT and Outsourcing team looks at the transparency measure in the Modern Slavery Bill, the effect this may have on businesses and how businesses can prepare themselves...Wed, 18 Mar 2015 00:00:00 Z38998b37-bee6-4ee4-a9cc-6596e07e54eahttps://gowlingwlg.com/fr-fr/insights-resources/articles/2015/prescribing-pregabalin-in-warner-lambert-v-actavisIn a judgment published on 2 March 2015, the fascinating saga between Warner-Lambert and Actavis takes yet another turn.Thu, 05 Mar 2015 00:00:00 Z727c22b8-c0a6-4435-add3-e24b6dca00d4https://gowlingwlg.com/fr-fr/insights-resources/articles/2015/cipo-revised-guidance-on-methods-of-treatmentL’Office de la propriété intellectuelle du Canada (OPIC) a récemment publié l’Avis de pratique PN 2015-01, lequel traite de l’examen de revendications d'utilisation médicale. L’Avis de pratique assouplit certaines des pratiques d’examen actuelles quant à la brevetabilité des régimes posologiques. Dans ces nouvelles directives, les éléments essentiels de la revendication qui ont trait à un dosage fixe, à un régime posologique fixe, à une sous-population de patients ou à un site d'administration particulier ne sont pas considérés comme limitant l'exercice des compétences professionnelles ou du jugement d'un médecin, un facteur important dans la détermination de la brevetabilité de l'objet de la revendication.Sun, 01 Mar 2015 00:00:00 Z3bf0d6f1-c904-4ed2-807a-a6dfa919ebafhttps://gowlingwlg.com/fr-fr/insights-resources/client-work/2015/shortlisted-companies-invited-to-bid-on-st-thomasOn March 10, 2015, Infrastructure Ontario and St. Thomas Elgin General Hospital announced that they had released a request for proposals to companies shortlisted to build and finance the hospital’s Emergency, Ambulatory and Mental Health Redevelopment Project.Sun, 01 Mar 2015 00:00:00 Z7900b526-2d25-4bfb-b0c0-784991cbe5c2https://gowlingwlg.com/fr-FR/insights-resources/client-work/2015/casey-house-redevelopment-project-reaches-financiaOn March 6, 2015, Infrastructure Ontario and Casey House announced that the facility had signed a fixed-price contract with Bird Construction to build and finance their redevelopment project.Sun, 01 Mar 2015 00:00:00 Z4594aafb-193c-4ae2-9377-2b5458e545aehttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2015/milton-district-hospital-expansion-project-reachesOn March 30, 2015, Infrastructure Ontario and Halton Healthcare Services announced that they had awarded a fixed price contract to the Plenary Health Milton consortium to design, build, finance and maintain the Milton District Hospital expansion project in Milton, Ontario.Sun, 01 Mar 2015 00:00:00 Z5ef14cdd-1ed9-4522-b82b-d928801cea84https://gowlingwlg.com/fr-FR/insights-resources/client-work/2015/theralase-technologies-completes-public-offering-oOn March 3, 2015, Theralase Technologies Inc. (TSXV: TLT) (PINKSHEETS: TLTFF) announced that it had closed its previously announced public offering of units, having issued an aggregate of 18,181,817 units at a price of $0.44 per unit for aggregate gross proceeds of approximately $8,000,000.Sun, 01 Mar 2015 00:00:00 Zc497b273-778d-42bf-bf3f-f1d16803dde6https://gowlingwlg.com/fr-FR/insights-resources/articles/2015/parallel-imports-when-it-is-permissible-to-rebranThe Court of Appeal has returned its judgment in parallel imports case Speciality European Pharma v Doncaster Pharmaceuticals. Antony Craggs, Principal Associate in our IP team, explains how the Court of Appeal's guidance develops the test of objective necessity laid down by the CJEU.Wed, 25 Feb 2015 00:00:00 Z7e3ffb92-cd01-470b-958e-40f7a371ed1chttps://gowlingwlg.com/fr-fr/insights-resources/articles/2015/arnold-j-refuses-to-strike-out-warner-lambert-s-clArnold J has handed down a second decision in the dispute between Warner-Lambert and Actavis. He refused, on 21 January 2015, to grant Warner-Lambert an interim injunction relating to infringement of its European patent EP (UK) 09434061.Fri, 13 Feb 2015 00:00:00 Z5a30c39d-27ea-4707-bb3c-f2ae94bfae72https://gowlingwlg.com/fr-fr/insights-resources/articles/2015/trastuzumab-dosage-regimen-patent-is-invalidThe Court of Appeal has confirmed Birss J's finding that Genentech's dosage regimen patent, concerning the monoclonal antibody which is the active ingredient in Herceptin, was obvious. The appeal concerns the first of Birss J's judgments between Hospira and Genentech last year.Fri, 13 Feb 2015 00:00:00 Z7e5ad54f-2320-4775-afe5-031e5d264effhttps://gowlingwlg.com/fr-fr/insights-resources/articles/2015/russia-criminalizes-counterfeit-medicinesOn Dec. 25, 2014, the Russian Parliament adopted new legislation on counterfeiting which became effective on Jan. 23, 2015.Sun, 01 Feb 2015 00:00:00 Ze1feddc0-78fe-411b-b7ba-b01287ff946fhttps://gowlingwlg.com/fr-fr/insights-resources/client-work/2015/federal-court-awards-eli-lilly-106-million-in-patOn January 23, 2015, the Federal Court released its decision regarding the quantum of damages recoverable by Eli Lilly in an action relating to Apotex’s infringement of patents related to the manufacture of the antibiotic cefaclor.Fri, 23 Jan 2015 00:00:00 Zb53537a1-4431-4716-8571-ed5fe450fc18https://gowlingwlg.com/fr-FR/insights-resources/articles/2015/prohibition-notices-if-it-ain-t-broke-don-t-fixProhibition notices are serious enforcement measures that form part of the recipient’s criminal record and can be costly in terms of achieving compliance with their terms, which can be highly prescriptive, and due to the impact they can have upon reputation and tender opportunities.Wed, 21 Jan 2015 00:00:00 Z8b7e81ce-2cb5-475d-9fbb-957a1f68d5bahttps://gowlingwlg.com/fr-fr/insights-resources/articles/2015/federal-court-determines-minister-s-decisions-granOn Dec. 19, 2014, the Federal Court set aside a decision of the Minister of Health granting a Notice of Compliance (NOC) to Teva authorizing the sale of its product that referred to Pfizer’s Aromasin®.Thu, 01 Jan 2015 00:00:00 Z0b76e0a3-999a-48e6-80a5-14b4e5cde625https://gowlingwlg.com/fr-fr/insights-resources/client-work/2015/tvm-capital-life-science-leads-series-c-investmentOn January 13, 2015, CoLucid Pharmaceuticals, Inc., announced that it had completed a $37.1 million Series C preferred stock offering.Thu, 01 Jan 2015 00:00:00 Zb30ead23-9582-4fd4-b44a-2c9caf52a0b3https://gowlingwlg.com/fr-FR/insights-resources/articles/2015/federal-court-rejects-nia-defence-and-awards-compoLe 23 janvier 2015, la Cour fédérale a publié une décision portant sur le montant des dommages-intérêts recouvrable par Eli Lilly (« Lilly ») dans le cadre d’une action concernant la contrefaçon, par Apotex, de brevets visant la fabrication de l’antibiotique céfaclor. Lilly a obtenu des dommages-intérêts y compris ceux qu’elle réclamait en lien avec la perte de profits liés à la perte de ventes et les indemnisations d’intérêts avant jugement calculés au taux moyen correspondant au taux de profit global de Lilly, composé annuellement pour la période de 17 ans s’étant écoulée entre l’introduction de la procédure et l’adjudication définitive du montant des dommages-intérêts.Thu, 01 Jan 2015 00:00:00 Z0e89d75b-e16d-4fdc-8061-4b221cdff76chttps://gowlingwlg.com/fr-FR/insights-resources/client-work/2015/precision-nanosystems-and-arcturus-therapeutics-anOn January 9, 2015, Precision NanoSystems, a leader in the development and application of microfluidics for the manufacture of nanomedicines; and, Arcturus Therapeutics, a leading small interfering RNA (siRNA) and messenger RNA (mRNA) drug discovery and development company, announced a partnership for the manufacture of RNA medicines.Thu, 01 Jan 2015 00:00:00 Zcc7010f9-3df9-42b0-97cf-47d8f9e8584dhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2014/obviousness-could-the-skilled-person-make-it-withBirss J. rules on product by process claim construction, extension of scope, added matter and obviousness in Hospira v Genentech.Tue, 16 Dec 2014 00:00:00 Z43352a7c-a1d8-4cf8-8a2e-1a70cb3a5a57https://gowlingwlg.com/fr-FR/insights-resources/articles/2014/teva-v-leo-a-novel-test-for-inventive-stepIn Teva v Leo Birss J. chose not to follow the test in Pozzoli v BDMO when holding the claims of two patents relating to a combination formulation for treating psoriasis invalid as lacking inventive step.Fri, 07 Nov 2014 00:00:00 Z01df98da-6460-412d-af43-f1552d987f05https://gowlingwlg.com/fr-FR/insights-resources/articles/2014/the-comptroller-of-patents-has-been-given-extra-poThe Comptroller of Patents has been given extra powers to revoke patents based on lack of novelty or inventive step.Wed, 08 Oct 2014 00:00:00 Z57667228-a3c1-4712-9a58-91ee29ec7bf7https://gowlingwlg.com/fr-FR/insights-resources/articles/2014/permanent-injunction-granted-despite-patentee-notOn May 22, 2014, the Federal Court of Canada issued an injunction curtailing Janssen Inc.’s marketing of its drug ustekinumab (STELARA®) in ongoing patent litigation with AbbVie Corporation and related companies. The Court had previously found that certain claims of the patent in issue were both valid and infringed.Wed, 18 Jun 2014 00:00:00 Z002e1306-3e0a-4ab3-b5f2-a7e2a79991afhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2014/subject-matter-scope-and-second-medical-use-defIn a recent Technical Board of Appeal decision, the European Patent Office (EPO) has shed some light upon the boundaries of the prohibition against double-patenting.Wed, 21 May 2014 00:00:00 Z4017b9d5-1457-42c4-80eb-afe1c9e18601https://gowlingwlg.com/fr-FR/insights-resources/articles/2014/patent-law-proposals-to-bring-clinical-trials-backNew patent law proposals laid in Parliament earlier this week could result in clinical trials being brought back to the UK. Our experts address some of the key points and take a look at what they could mean for businesses within the industry.Fri, 09 May 2014 00:00:00 Za96ede96-46f7-4857-9646-3ee6b2031bb3https://gowlingwlg.com/fr-FR/insights-resources/articles/2014/independent-providers-and-nhs-pension-schemeWe look at the provisions and restrictions for Independent Providers in more detail and the new financial controls placed on all employers in the NHS Pension Scheme.Thu, 10 Apr 2014 00:00:00 Zba6249dd-c153-4cc5-8570-2b4071861b83https://gowlingwlg.com/fr-FR/insights-resources/articles/2014/private-health-market-competition-commission-makeIn the last 18 months, competition has been at the forefront of debate in the healthcare sector. NHS mergers, the Competition Commission's private health investigation, the interaction of both public and private sectors in private patient units and the consideration of competition law in relation to integrated care have all been hot topics.Mon, 27 Jan 2014 00:00:00 Z66331d31-2fbd-4003-bcba-cd40250a6b4chttps://gowlingwlg.com/fr-FR/insights-resources/videos/2013/modernising-the-eu-procurement-rulesChristopher Brennan looks at the modernising of the EU procurement rules, what the changes are, why are the changes being made, when will they come into force and ... will they work?Thu, 21 Nov 2013 00:00:00 Z04a9a7f9-0d0c-4531-8720-bea95c4b75bfhttps://gowlingwlg.com/fr-FR/insights-resources/articles/2013/utility-sound-prediction-and-promise-of-the-patenIn recent years, attacks on the lack of sound prediction and failure to meet the promise of the patent have proven to be a crushing hammer in the hands of those who challenge patents. This article considers the Canadian patent utility requirements that extend beyond mere usefulness.Mon, 01 Apr 2013 00:00:00 Z038a3832-301a-4370-98c4-0eb697cce9e8https://gowlingwlg.com/fr-FR/insights-resources/client-work/2013/stem-cell-therapeutics-closes-unit-offeringOn March 15, 2013, Stem Cell Therapeutics Corp. (TSXV: SSS), a life sciences company developing stem cell-related technologies, announced that it had closed its previously announced prospectus offering of units for the aggregate gross proceeds of $3,078,750. Euro Pacific Canada Inc. acted as the agent for the offering.Fri, 15 Mar 2013 00:00:00 Z